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ATP binding cassette transporters 
The ATP binding cassette (ABC) transporter family forms one of the largest membrane-
bound protein families encoded by the human genome and a total of 49 genes of human 
ABC protein have been identified and sequenced.1,2 Based on the arrangement of molecular 
structural components, i.e., nucleotide binding domains and topologies of transmembrane 
domains, human ABC transporters are classified into seven different subfamilies (A to G).3,4 
Before the first transporter genes were cloned, it was long known that resistant sublines were 
formed after incubating cancer cell lines with chemotherapeutic agents.5,6 In 1976, Juliano 
and Ling7 were the first to report that this resistance was associated with a particular 170 kD 
glycoprotein, which was later named P-glycoprotein (P-gp). Its gene was cloned for the first 
time in 1986 and called multidrug resistance gene 1 (mdr1).8 Nowadays, the eukaryotic ABC 
transporters are well characterized and are known to transport a variety of molecules, against 
steep concentration gradients at the expense of ATP, across the plasma membrane as well as 
across intracellular membranes of the endoplasmic reticulum, peroxisomes, lysosomes, and 
mitochondria. Nearly all ABC proteins are efflux transporters, except for the cystic fibrosis 
transmembrane conductance regulator (CFTR/ABCC7), which acts as a chloride ion channel, 
and the sulfonylurea receptors SUR1/ABCC8 and SUR2/ABCC9 that regulate K+ channels.9,10
Efflux transporters have an important role in tissue defense through the removal of harmful 
molecules. Collectively, ABC proteins are capable of transporting a wide variety of substrates 
including hydrophilic, lipophilic, cationic, anionic, and neutrally charged molecules as well 
as their conjugated metabolites, as reviewed by Leslie et al.11 Transporters that have been 
extensively studied in the context of tissue defense and drug resistance include P-gp, 
multidrug resistance-associated proteins (MRPs) and breast cancer resistance protein (BCRP) 
(table 1).1,3,11 These transporters are found in many organs and tissues in the body, including 
epithelia of e.g. the intestine, liver and kidney, as well as tissues with a tight barrier function 
like the blood-brain barrier (BBB), blood-placenta barrier, blood-testis barrier (BTB) and the 
choroid plexus as part of the blood-cerebrospinal fluid (CSF) barrier, however, expression 
levels differ per organ. For example, P-gp and BCRP are most abundant in the BBB while in the 
liver MRP2 is most abundantly expressed and in the kidney proximal tubule cells, MRP4 and 
P-gp are highly expressed.11-13 The efflux transporters are expressed either at the basolateral 
(MRP1 and -3) or apical (P-gp, BCRP, and MRP2) cell membrane, except for MRP4, the 
localization of which is dependent on the cell type either in the apical (renal proximal tubule 
cells and BBB) and basolateral membranes (hepatocytes and choroid plexus epithelium).14
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General introduction
1
In renal proximal tubule cells, hepatocytes and enterocytes, basolaterally-located ABC 
transporters pump molecules from the cells towards the blood stream and in the apical 
membrane, they drive urinary and biliary excretion and prevent intestinal uptake of their 
substrates. Transporters located on the apical or luminal membrane of endothelial cells 
which form a tight barrier, e.g. BBB, blood-CSF barrier and blood-placenta barrier, prevent 
molecules from entering specific tissues by pumping them into the blood stream. Membranes 
from other endothelial cells contain pores via which small molecules can freely diffuse into 
and out of cells. Still, transporters are present in the membranes of these cells which can 
pump molecules against a steep concentration gradient. By this, transporters often provide 
protection against harmful molecules, nevertheless, their role can be disadvantageous 
when eliciting drug resistance. Transporter-mediated treatment failure is a major clinical 
complication in cancer therapy. Their role in drug resistance is reinforced by the fact that 
expression levels of transporters are tightly regulated and reduced intracellular drug 
accumulation is often attributed to an overexpression of efflux proteins. This thesis focusses 
on BCRP, a member of the G subfamily of ABC transporters.
Breast cancer resistance protein (BCRP)
The human ABCG subfamily (as well as the murine and rat Abcg subfamily) contains five 
members, i.e. ABCG1, ABCG2, ABCG4, ABCG5, and ABCG8. Most of the ABC transporters are 
full transporters, containing two nucleotide binding domains (NBDs) and two transmembrane 
domains (TMDs) on one polypeptide. Family members of the human ABCG subfamily, 
however, are so-called half transporters that have one NBD at the N-terminus and one 
TMD, which possesses six transmembrane helices, at the C-terminus (figure 1): a reverse 
orientation compared to all other ABC genes. These half transporters require dimerization to 
form a functional transporter.17 
In 1998, Doyle et al.18 were the first to report a gene, responsible for the novel resistance 
phenotype found in mitoxantrone-treated human MCF-7 breast cancer cells. They named the 
gene BCRP since it was cloned from a subline of breast cancer cells. Soon thereafter, Allikmets 
et al.19 described a nearly identical transporter, termed ABCP as this ABC transporter was 
found to be highly expressed in placenta. Then, another group cloned a gene responsible for 
the high degree of resistance to mitoxantrone observed in the colon carcinoma cell line S1-
M1-80 and named it mitoxantrone resistance gene, or MXR.20 The genes described proved to 
be nearly identical when their sequences became available and the BCRP/ABCP/MXR gene 
was placed in the G subfamily of ABC transporters and was assigned the name ABCG2.9
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Chapter 1
In two ways BCRP is a misfit between its fellow subfamily members. Firstly, the other four 
members, the intracellularly located ABCG1 and ABCG4, and the plasma membrane located 
ABCG5 and ABCG8, are involved in transmembrane transport of phospholipids and sterols 
(like cholesterol)21-24, while BCRP is a nonsterol transporter.25 Secondly, BCRP functions solely 
as a homodimer, whereas ABCG5 and ABCG8 are known to form a functional heterodimer, 
which promotes the efflux of cholesterol and sitosterol.21,26,27 Also, ABCG1 has been described 
to heterodimerize with ABCG4 to form a functional transporter.25,28 
Dimerization of two adjacent BCRP molecules is realized via disulfide bonds, which are 
formed in the lumen of the endoplasmic reticulum. The extracellular cysteine- (Cys-) 603 is 
important for dimer formation as an interpeptide disulfide bond links both Cys-603 residues 
of two monomeric BCRP molecules (figure 1). Because of the high homology of amino acid 
sequences in the extracellular loop between the human ABCG2 gene and its orthologues 
in monkey, pig, cow, dog, rat, mouse, and fowl, it is assumed that the cysteine residue 
corresponding to Cys-603 is critically involved in Bcrp homodimer formation in those species 
as well.27 Removal of Cys-603 abolishes dimerization without affecting expression and plasma 
membrane-targeting of the transporter. Two other cysteine residues in the extracellular loop, 
i.e. Cys-592 and Cys-608, appear to be essential for protein stability as well as for plasma 
membrane-targeting of BCRP.29,30 These cysteine residues are considered to form an intra-
molecular disulfide bond, as illustrated in figure 1. 
Figure 1. Schematic illustration of the molecular structure of BCRP. A BCRP-molecule contains six 
transmembrane helices and a nucleotide binding domain.31 Dimerization of two BCRP-molecules 
is required to form a functional transporter, accomplished by the disulfide bond at Cys-603. An 
intra-molecular disulfide bond is formed between Cys-592 and Cys-608, which is important for 
protein stability. 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
13
General introduction
1
Other posttranslational modifications of BCRP include N-glycosylation and phosphorylation. 
BCRP is often present in polarized cells, which are characterized by their asymmetric cell 
surface organization (the apical and the basolateral surface). The delivery mechanism for 
membrane bound-proteins in these cells is more complex than those of non-polarized cells. 
It has been demonstrated that N-glycosylation of BCRP plays an important role in protein 
folding, maintenance of protein stability and the translocation of a BCRP dimer to the apical 
plasma membrane.32,33 Besides, N-glycosylation of BCRP appears to enhance ubiquitin-
mediated proteasomal degradation.34 Sequence analyses revealed three potential N-linked 
glycosylation sites in human BCRP35 and two in rat Bcrp36. Moreover, BCRP is phosphorylated 
at threonine 362, which promotes BCRP dimerization and ultimately its plasma membrane 
localization.37 
BCRP in blood-organ barriers 
The majority of BCRP is localized to the plasma membrane where it can export molecules 
out of the cell. Many epithelia in the body express BCRP, e.g. ovary, prostate, intestine, liver, 
kidney, and lactating mammary gland, as well as tissues with a tight barrier function like the 
blood-organ barriers.15,16,38,39 These barriers consist of capillary endothelial cells whose tight 
junctions between adjacent cells are highly developed, which prevent small molecules to 
easily reach the organ (figure 2). By this tight barrier as well as by efflux transporters, which 
are present in the endothelial cells and remove those molecules that were able to pass the 
barrier, the particular organ is protected from harmful molecules. The BBB is the blood-organ 
barrier that separates the circulating blood from the brain interstitial fluid. Schinkel et al.40 
were the first to show the importance of efflux transporters in the BBB when they found an 
unusual high mortality in Mdr1a-/- knockout mice after treatment with the centrally neurotoxic 
antiparasitic agent, ivermectin. Next to P-gp, BCRP is abundantly expressed in the BBB (figure 
2A).41 Many drugs are BCRP substrates and BBB transporter function is advantageous when 
the particular drug is aimed to target peripherally located receptors because BCRP limits 
brain drug exposure and potentially coincided side effects. However, anti-epileptics, anti-
depressants, and anti-psychotics target receptors in the brain and, therefore, BCRP-mediated 
limitation of brain exposure can obviously be disadvantageous. BCRP is also present in the 
choroid plexus, the so-called blood-CSF barrier, where it facilitates transport of substrates 
from the blood towards the CSF (figure 2B). The CSF provides a highly controlled and stable 
environment for the central nervous system and allows for homeostatic regulation by 
distribution of neuroendocrine factors, electrolytes and nutrients, and removal of metabolic 
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Chapter 1
waste. CSF is formed as plasma is filtered from the blood through the epithelial cells of the 
choroid plexus, which is located in the major cisternae of the third and fourth ventricles of 
the brain. Obviously, it is difficult to measure drug concentrations at the target site of drugs 
that act on the central nervous system. Therefore, often drug concentration in the CSF was 
used as a surrogate.42 
Figure 2. Schematic illustration of BCRP localization in the blood-brain barrier (A), blood-CSF barrier 
(B), blood-placenta barrier, and blood-testis barrier (D). Due to tight junctions the cells form a tight 
barrier, which prevents molecules to freely diffuse into the organ. Efflux transporters, like BCRP, 
regulate the transport of potentially harmful molecules. (Figure was created using images from 
Servier Medical Art; http://www.servier.com/Powerpoint-image-bank)
Another blood-organ barrier is the blood-placenta barrier. The placenta is an organ that 
brings maternal and fetal blood circulations into proximity, allowing mutual interchange of 
nutrients and waste products. In the placenta, BCRP is highly expressed at the membrane of 
syncytiotrophoblasts and helps to prevent potentially harmful molecules from entering the 
fetal compartment. BCRP expression was also found on the luminal (fetal-facing) surface of 
fetal blood vessels of the villous core (figure 2C) and is thought to regulate the transfer of 
various endogenous compounds to the fetus.43 Though, syncytial BCRP expression is much 
higher as compared to BCRP expression in fetal blood vessels. Studies using a dually perfused 
human placenta model and Bcrp-deficient animal models showed that fetal exposure to 
topotecan, genistein, nitrofurantoin, and glyburide was limited by BCRP.44-47 Its expression 
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1
levels have been shown to decrease throughout pregnancy, leaving the fetus susceptible 
to drugs that are administered to pregnant women (i.e. synthetic glucocorticoids, selective 
serotonin reuptake inhibitors, glyburide, antiretrovirals) at later stages of the pregnancy.48,49 In 
this respect, the regulation of BCRP is intensively studied.50-52 Steroid hormones are thought 
to play an important role in this, as explained further in this chapter. 
In the testis, the blood-testis barrier (BTB) physically divides the seminiferous epithelium into 
the basal and the apical compartment, thereby creating a testicular microenvironment that 
is pivotal for mammalian steroidogenesis and spermatogenesis.53 Unlike other blood-organ 
barriers, the BTB consists of several cell types that together protect the developing germ 
cells. Tight junctions, adherens junctions and gap junctions between the Sertoli cells, which 
nourish and support the developing germ cells throughout the stages of spermatogenesis, 
prevent molecules to easily reach the adluminal compartment of the seminiferous epithelium. 
The active part of the BTB consists of efflux transporters. P-gp, BCRP, MRP1 and MRP4 are 
most abundantly expressed and are located in the Sertoli cells, steroid producing Leydig 
cells or capillary endothelium.15,54-56 BCRP is only expressed in the luminal membranes of 
testicular capillary endothelium (figure 2D). The positioning of the efflux transporters in the 
BTB suggests that their substrates are transported out of the seminiferous tubules to prevent 
entry and accumulation of harmful molecules in the testes and to protect the developing 
germ cells. 
Role of BCRP in physiology and pathology
Nowadays, BCRP is recognized as a xenobiotic transporter that plays a major role in multidrug 
resistance and a myriad of BCRP substrates have been described, among them xenobiotics 
like chemotherapeutic agents, tyrosine kinase inhibitors, antivirals, HMG-CoA reductase 
inhibitors, and flavonoids.9 Besides the protective role of BCRP against xenobiotic compounds, 
accumulating evidence shows that BCRP also transports endogenous compounds. 
Uric acid is such an endogenous substrate for BCRP. It is a weak organic acid and the end 
product of purine nucleotides degradation in humans. Elevated plasma uric acid levels, i.e. 
hyperuricemia, are related to a variety of pathologies, including gout, cardiovascular disease 
and chronic kidney disease. Gout is the most common form of inflammatory arthritis caused 
by sodium uric acid crystal precipitation.57 Formation of these crystals is also the cause of 
nephrolithiasis.58 Hyperuricemia is caused by either an increase in uric acid production or by 
a decrease in its excretion. Efflux transporters, like BCRP, located on the apical membrane of 
the kidney proximal tubule cells play an important role in the elimination of uric acid.16,59 The 
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Chapter 1
vital role of BCRP in uric acid homeostasis can clearly be observed in patients suffering from 
hyperuricemia due to single nucleotide polymorphisms (SNPs) that render the transporter 
inactive, such as the common SNP C421A encoding the Q141K mutation.60-62 
BCRP is also involved in the elimination of several porphyrins, like protoporphyrin IX, 
hematoporphyrin and heme. Heme is the functional group of hemoproteins and crucial 
for many cellular processes. However, excess of free heme can be detrimental to tissues by 
mediating oxidative and inflammatory injury. Heme scavengers act as the first line of defense 
against the injurious actions of heme 63-65, however, they may be saturated when exposed to 
large amounts of heme. Downstream, several putative defense systems against intracellular 
heme are known, such as heme oxygenase-1 (HO-1), but also the efflux transporter BCRP.66-68 
HO-1 degrades heme into biliverdin, iron, and carbon monoxide. A possible interplay between 
the two proteins has not yet been described. 
Furthermore, BCRP was also found to be a highly conserved feature in a wide variety of 
stem cells. At first it was noticed that a distinct subpopulation of cells, side-population cells, 
accumulated less dye when using the fluorescent DNA dye Hoechst33342 to stain mouse 
bone marrow cells. Later, Zhou et al.69 identified Bcrp as being responsible for preservation 
of the side-population and its potential role in the regulation of hematopoietic development 
has been suggested. However, the transporter does not appear to be necessary for normal 
hematopoiesis as Bcrp-deficient mice are viable with normal numbers of stem cells, despite 
the complete absence of side-population cells.46 BCRP has been shown to provide protection 
to the hematopoietic stem cells against cytotoxic substrates.70 Nowadays, it is known that side-
population cells not only reside within the bone marrow but just as well in non-hematopoietic 
organs. These non-hematopoietic side-population cells can differentiate into many cell types 
and thereby contribute to tissue repair.71,72 In side-population cells, BCRP/Bcrp expression 
falls dramatically with the differentiation of pluripotent stem cells.69 Krishnamurthy et al.66 
studied the role of BCRP in these cells and they suggested that the transporter provides 
protection against intracellular accumulation of heme-related molecules (e.g. porphyrins) to 
enable cell survival under conditions of hypoxia.
Furthermore, it has been demonstrated that BCRP is expressed in alveolar epithelial cells of 
the mammary gland during pregnancy and lactation, where it actively secretes a variety of 
drugs, carcinogens, and toxins into milk.73 In apparent contradiction with its detoxifying role 
elsewhere in the body, this BCRP-mediated contamination of milk exposes suckling infants 
to potentially harmful molecules. Yet, the evolutionarily conserved expression and induction 
of BCRP in the lactating mammary gland suggests an important physiological function. 
Therefore, van Herwaarden et al.74 proposed that BCRP might function to provide the milk 
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1
with essential nutrients such as riboflavin (vitamin B2) and possibly also biotin (vitamin B7), 
offsetting the coincidental risk of contaminating milk with harmful molecules. Interestingly, 
the endogenous BCRP substrates folic acid and vitamin B12 were not actively secreted into 
milk by murine Bcrp. 
BCRP and steroid hormones
The localization of BCRP in the plasma membrane is shown to be sex specific. The sex steroids 
estradiol, progesterone and testosterone have been shown to impact BCRP expression. In 
estrogen-responsive cells, estradiol down-regulates mRNA expression of BCRP and BCRP 
function is impeded as estradiol initiates its internalization and stimulates proteosomal 
degradation. Estradiol signals through the estrogen receptors ERα and ERβ.51,75-78 Progesterone 
upregulates BCRP expression via a progesterone response element in the promoter, as shown 
in a cancer cell line derived from human placental choriocarcinoma.79 The inductive effects of 
testosterone on BCRP mRNA expression were shown by Tanaka et al.78 in kidneys and liver of 
castrated rats and mice in combination with sex steroid treatment. 
Besides regulatory properties, steroids are also linked with transport activity. BCRP transports 
conjugated steroids, such as dehydroepiandrosterone sulfate (DHEAS), estrone sulfate 
(E1S) and, to a lesser extent, estradiol glucuronide (E217βG).
80-83 Moreover, a role for BCRP 
in transport of androgens in prostate stem cells84 and transport of estradiol in membrane 
vesicles from Lactococcus lactis containing functional human BCRP85 was suggested. 
Attempts to confirm a similar role for BCRP expressed in mammalian cells have failed until 
now, suggesting that the membrane micro-environment is of importance in transporting 
the highly lipophilic hormones. A steroid binding site in BCRP has been proposed by two 
independent groups using an in silico docking approach.86,87 These findings suggest a role 
for BCRP in hormone metabolism and regulation, however, the molecular bases of protein-
steroid interactions are yet unclear.50
In vitro and in vivo models to study BCRP and related ABC transporters
Methods to study ABC transporter function vary from organ perfusion systems, tissue cultures, 
isolated subcellular fractions (e.g. microsomes) to cloned and expressed single proteins. With 
these methods transport processes can be studied at various levels of complexity. Most of 
the in vitro methods make use of transporter-overexpression cell models, generated either 
by stable transfection or by transient transfection or transduction. A common and fast assay 
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that allows for the rapid screening and identification of potential substrates and inhibitors is 
the ATPase assay. In this assay, membranes of transporter-overexpressing cells are incubated 
with potential substrates. Since transporter-mediated efflux requires ATP hydrolysis, 
hence, stimulation of ATPase activity suggests that the compound is a possible substrate or 
inhibitor.88 Another high-speed method is the membrane vesicle transport assay (also called 
uptake assay). Membrane vesicles are prepared from transporter-overexpressing cells. Both 
right-side-out and inside-out oriented vesicles are generated, however, only transport of 
molecules into the cavity of inside-out oriented vesicles can be measured (figure 3). 
Figure 3. A schematic illustration of a rapid screening method of human BCRP-molecule interactions 
using inside-out membrane vesicles isolated from BCRP-overexpressing HEK293 cells. Using the 
energy derived from ATP hydrolysis, substrate molecules (green) are transported into the vesicle 
by BCRP that can be inhibited by specific inhibitors (orange). (Figure was created using images from 
Servier Medical Art; http://www.servier.com/Powerpoint-image-bank)
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In this thesis, we used membrane vesicles prepared from transporter-overexpressing 
human embryonic kidney (HEK293) cells, established using baculovirus transductions that 
were produced using the Bac-to-Bac system (Invitrogen).89,90 Using this assay, substrates 
and transport inhibitors can be identified, as well as their kinetic characteristics (Km or Ki). 
Furthermore, the model is useful in predicting drug-drug interactions. However, the assay 
is only suitable for assessing the transport of hydrophilic (polar) compounds as lipophilic 
(non-polar) compounds often diffuse out of the vesicles after the incubation period, hence, 
transporter-mediated uptake is difficult to determine. 
Besides, these compounds easily stick to the filters and therefor high background signals 
disturb transport measurements. For determining transport of non-polar compounds, 
often cell assays are used. In this thesis, we used Madin-Darby canine kidney (MDCKII) 
cells stably overexpressing BCRP and P-gp.91 Transport of molecules can be studied using 
MDCK cell monolayers in normal well plates or transwells. Both assays highly depend on 
passive diffusion of the test compound over the cell membrane, as efflux can be determined 
only after the compound has entered the cell. In the accumulation assay, cell monolayers 
are loaded with the compound of interest together with a transport inhibitor. Since active 
transport out of cells is much faster than passive diffusion back into cells, and transporters 
mediate the efflux of molecules against concentration gradients, a difference in accumulation 
in transporter-overexpressing cells compared to control cells demonstrates the involvement 
of the transporter in the efflux of the test compound. In transwell transport assays, polarized 
cells, grown on a semi-permeable membrane, form a barrier between the apical compartment 
and the basolateral compartment of the well. By adding the compound to either the apical 
or the basolateral compartment, apical-to-basolateral transport or basolateral-to-apical 
transport can be determined to delineate the bidirectional transport of the compounds.92 
If the substrate is available in radioactively labeled form, the accumulation assay is often 
the method of choice because it is faster and less laborious than the transwell transport 
assay. However, when analyzing substrates by analytical methods like high-pressure liquid 
chromatography (HPLC), which is often combined with tandem mass spectrometry (LC-MS/
MS), it is much easier to extract the target molecules out of media (transwell assay) than out 
of cellular matrices (accumulation assay). These in vitro methods are able to identify novel 
substrates and transporter inhibitors. Besides, transport kinetics and drug-drug interactions 
can be studied. Nevertheless, the relevance of a transporter in the disposition of a certain 
compound is usually studied in vivo. 
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The development of transporter knockout animals has provided us with more insight into the 
function and characteristics of ABC transporters, however, these models are not devoid of 
limitations. Compensatory gene expression and protein synthesis of other transporters may 
countervail the lack of the specific gene.93 Yet, short-term exposure to transporter inhibitors 
is often not that straightforward. Inhibitors not always affect the transporters completely 
or they are not specific for one transporter. Furthermore, some inhibitors only affect the 
transporter at cytotoxic concentrations and are, therefore, not suitable for in vivo utilization. 
For BCRP/Bcrp, fumitremorgin C (FTC) is an effective and specific inhibitor but neurotoxic 
effects disqualify its use in vivo. Its derivative Ko143 appeared to be more potent than FTC in 
vitro and has been used in in vivo experiments.94,95 Also GF120918 (elacridar), which potently 
inhibits both P-gp and BCRP, is used in animals and is shown to be extremely well tolerated in 
mice as well as in human.95-97 Using these in vivo models, the effect of BCRP on the disposition 
of certain molecules can be studied by comparing accumulation of substrates in plasma and 
organs of wild type and Bcrp-deficient or Bcrp-inhibited animals. When analyzing the role 
of BCRP in a specific organ, in situ or ex vivo perfusion models are often used, i.e. kidney 
(urinary elimination), intestine (absorption), BBB (brain penetration), liver (biliary excretion) 
and placenta (transplacental passage) perfusion models. Furthermore, combining confocal 
microscopy with quantitative digital image analysis, isolated brain capillaries from rats 
and mice can be studied and visualized ex vivo. With this state-of-the-art technique, it is 
not only possible to study the transport route of a certain molecule but allows to identify 
Bcrp expression modulators as well. Ultimately, combining the results of different molecular, 
cellular and in vivo studies are required to identify the exact role of individual transporters in 
the distribution of certain compounds. 
Aim and outline of this thesis
Research on the role of BCRP in most organs has until now been focused predominantly on 
the restriction of drug penetration and its protective function against the toxic effects of 
exogenous compounds. Yet, accumulating evidence shows that BCRP transports endogenous 
molecules just as well. Most of these substrates are transported out of organs into the blood, 
however, in some tissues the direction of transport is the opposite, like in the mammary 
gland, liver, kidneys and choroid plexus. Together with its broad range of substrates, this 
emphasizes the efficiency of BCRP as a transporter and suggests that, while there are 
redundant mechanisms of xenobiotic protection, the protein is also very important in 
physiology. The aim of this thesis was to investigate the role of the efflux transporter BCRP in 
endocrine and metabolic processes.
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Chapters 2, 3 and 4 focus on BCRP/Bcrp in endocrine organs. In chapter 2, the presence 
and localization of Bcrp was investigated in endocrine organs of wild type mice. Moreover, 
the interaction of various steroid hormones with BCRP activity was studied. Chapters 3 and 
4 describe the interaction between several endocrine disrupting chemicals that, in males, 
predominantly target the testis, and several efflux transporters present in the BTB using in 
vitro methods (chapter 3). Furthermore, the role of BCRP in the disposition of one of these 
endocrine disruptors, bisphenol A, was examined in vivo in mice. The results of this study are 
described in chapter 4. 
The role of BCRP in important metabolic processes is described in chapters 5, 6 and 7. 
The protection against heme, which induces oxidative stress, by two significant protective 
proteins, HO-1 and BCRP is described in chapter 5. Furthermore, the role of BCRP and 
MRP4 in the regulation of kynurenic acid levels in the brain (chapter 6) and in the kidneys of 
hyperuricemic mice (chapter 7) was investigated. The thesis concludes with chapter 8, where 
the implications of this research and future perspectives are discussed. 
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Abstract
Breast cancer resistance protein (BCRP) is known for its protective function against the 
toxic effects of exogenous compounds. In addition to this, a role in the transport of 
endogenous compounds has also been described. Since BCRP in the plasma membrane 
was shown to be regulated by sex steroids, we investigated the presence and possible role 
of BCRP in steroid hormone producing organs. Therefore, the presence and localization of 
Bcrp was investigated in endocrine organs of wild type mice. Furthermore, the interaction 
of various steroid hormones with human BCRP activity was studied. Quantitative PCR 
revealed Bcrp mRNA in the pituitary and adrenal glands, pancreas, ovary, testis and 
adipose tissue. Immunohistochemistry revealed the presence of Bcrp in the cortex of the 
adrenal gland and in plasma membranes of adipocytes. In the pituitary gland, pancreas, 
ovary and testis, Bcrp was mainly located in the capillaries. The interaction between BCRP 
and twelve steroid hormones was studied using membrane vesicles of HEK293-BCRP cells. 
Estradiol, testosterone, progesterone and androstenedione inhibited BCRP-mediated 
uptake of 3H-estrone sulfate (E1S) most potently, with calculated inhibitory constant 
(Ki) values of 5.0 ± 0.2 µM, 36 ± 14 µM, 14.7 ± 1.3 µM and 217 ± 13 µM, respectively. 
BCRP function was attenuated non-competitively, which implies an allosteric inhibition 
of BCRP-mediated E1S transport by these steroids. In conclusion, localization of Bcrp in 
endocrine organs together with the efficient allosteric inhibition of the efflux pump by 
steroid hormones are suggestive for a role for BCRP in steroid hormone regulation.
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Introduction 
Breast Cancer Resistance Protein (BCRP; ABCG2) is a member of the ATP Binding Cassette 
(ABC) superfamily of transmembrane proteins involved in the transport of a variety of 
molecules against steep concentration gradients at the expense of ATP. BCRP is a half 
transporter that requires dimerization to become a fully active efflux pump and was originally 
discovered in a breast cancer cell line resistant to chemotherapeutics.1-3 Nowadays, BCRP 
is recognized as a xenobiotic transporter that plays a major role in multidrug resistance.2,4,5 
The efflux pump is present in various tissues with a barrier function, including the placenta, 
prostate, small intestine, brain, colon, liver, mammary gland and kidney.4,6-9 Besides the 
protective role of BCRP against accumulating xenobiotic compounds, a role in the transport 
of endogenous compounds has also been described, such as the transport of folic acid10, 
heme11-13, urate14,15 and uremic toxins16. Moreover, BCRP transports conjugated steroids, such 
as dehydroepiandrosterone sulfate (DHEAS)17, estrone sulfate (E1S) and estradiol glucuronide 
(E217βG)
10,18,19.
The localization of BCRP in the plasma membrane is shown to be sex specific, which is 
suggested to be due to the suppressive effect of estradiol and the inductive effect of 
testosterone.20-23 Also, progesterone has been shown to regulate BCRP transcription in cancer 
cell lines, including BeWo cells, a cell line derived from human placental choriocarcinoma.24 
Moreover, a role for BCRP in transport of androgens was suggested in prostate stem cells25 
and transport of estradiol was demonstrated in membrane vesicles from Lactococcus lactis 
containing functional human BCRP26, indicating that the efflux pump might also play a role 
in steroid action. In this respect, the presence of BCRP was described for some hormone 
producing organs7,23,27, but for some organs, only BCRP mRNA content or presence of the 
protein by Western blot was shown. In the present study, we investigated murine organs, 
including the pituitary and adrenal glands, pancreas, kidney, ovary, testis and adipose 
tissue for the presence and localization of Bcrp. Furthermore, we evaluated the effects of 
several sex steroids on BCRP-mediated substrate transport using membrane vesicles of 
baculovirus transduced HEK293 cells. Our results show presence of the efflux pump in steroid 
producing organs. In addition, the sex steroids estradiol, testosterone, progesterone and 
androstenedione inhibited BCRP function in a concentration-dependent manner. 
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Materials and methods
RNA isolation and quantitative PCR
All procedures involving animals were approved by the Animal Experimental Committee of 
the Radboudumc. Bcrp mRNA was assessed in the adrenal gland, pituitary gland, epididymal 
fat pad, abdominal fat pad, pancreas, testis, ovary and the kidney of Friend leukemia virus 
B (FVB) mice (Charles River Laboratories, Germany). Isolated organs were immediately snap 
frozen in liquid nitrogen until further analysis. Fat pads, adrenal glands and pituitaries were 
homogenized using micropestles. Other organs were homogenized in frozen state using a 
Mikro-dismembrator U (Sartorius B. Braun Biotech Int., Melsungen, Germany). To avoid RNA 
degradation, the metal cylinders were washed with 0.5 M NaOH prior to use. Subsequently, 
total RNA was isolated using a NucleoSpin® RNA II kit (Macherey-Nagel, Düren, Germany) 
according to manufacturer’s instructions. Immediately, a reverse transcriptase reaction was 
performed with 250 ng RNA using random primers (Invitrogen, Breda, the Netherlands) and an 
Omniscript® RT kit (Qiagen, Hilden, Germany), following manufacturer’s recommendations. 
Synthesized cDNA was used for quantitative PCR, performed in a StepOnePlus™ Real-Time 
PCR system by means of the TaqMan® protocol (Applied Biosystems, Warrington, UK). Bcrp 
mRNA concentration was normalized to the mRNA concentration of the housekeeping gene 
β-actin. The primer-probe sets were obtained from Applied Biosystems (β-actin; 4352933E, 
Bcrp; Mm00496364_m1). 
 
Immunohistochemistry
The localization of Bcrp was assessed by immunohistochemistry. Organs from Bcrp-/- mice 
were used as negative controls. The knockout mice were kindly provided by Dr. A. Schinkel 
(Netherlands Cancer Institute, Amsterdam, the Netherlands) and were bred and housed 
at the Central Animal Laboratory of the Radboudumc. The organs were fixed by cardiac 
perfusion. Briefly, the mice were anesthetized with a single, lethal i.p. injection of 100 mg/
kg pentobarbital (Nembutal, 60 mg/ml). The hearts of anesthetized mice were exposed and 
the right atrium was clipped with surgical scissors. A 23-gauge needle was inserted into 
the left ventricle and phosphate buffered saline (PBS) containing heparin (300 ml/h) was 
administered. Subsequently, the mice were perfused with a 4% w/v formaldehyde solution, 
freshly prepared from paraformaldehyde. The organs were removed and fixed in a 4% w/v 
formaldehyde solution for 24 h and embedded in paraffin, except for fat pads, which were 
fixed in Bouin’s fixative immediately after the perfusion fixation. Sections of 5 µm were 
mounted on 3-aminopropyltriethoxysilane (APES) coated slides and dried for 2 h at 57 °C. 
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After deparaffinization with xylene and rehydration, the slides were heated in sodium citrate 
buffer (pH 6) at 100 °C for 15 min. Endogenous peroxidase was blocked with 1.5% v/v H2O2 
for 30 min. After blocking with nonimmune rabbit serum, the slides were incubated with 
primary antibody against mouse Bcrp (BXP-9, 1:20; Kamiya Biomedical Company, Seattle, 
WA, USA) overnight at 4 °C. The biotinylated secondary antibody (rabbit-anti-rat, 1:500; 
Acris Antibodies GmbH, Herford, Germany) was incubated for 30 min followed by a 30 min 
incubation with standard avidin-biotin complex (ABC; Brunschwig Chemie, Amsterdam, the 
Netherlands). Next, DAB chromogene was used for visualization. Slides were counterstained 
with Mayer’s hematoxylin, dehydrated, and mounted with DPX. Sections were evaluated by 
means of a light microscope (Leica DM 6000 B) and digitized using a Leica DFC480 digital 
camera (Leica Microsystems, Wetzlar, Germany). 
Transduction of Human Embryonic Kidney (HEK293) cells and isolation of membrane vesicles
Increased synthesis of human BCRP and MRP3 in HEK293 cells was established using 
baculoviruses, which were produced using the Bac-to-Bac system (Invitrogen, Breda, the 
Netherlands) with BacMamVSV-EX-hBCRP (pENTR221-hBCRP; HsCD00044371; Harvard 
Institute of Proteomics, Harvard Medical School, Boston, MA, USA) and BacMamVSV-EX-
hMRP3 (sequence of MRP3 was equal to GenBank accession number NM_003786), as 
described previously by Wittgen et al.28. As a control, the enhanced yellow fluorescent protein 
(eYFP) was introduced into the baculoviruses as well. 
Crude membranes of HEK293-BCRP, -MRP3, -eYFP cells were isolated, resuspended in TS buffer 
(10 mM Tris-HEPES and 250 mM sucrose, pH 7.4) and membrane vesicles were prepared 
according to a previously described method.29 Total protein concentration was determined 
by a Bio-Rad protein assay kit (Bio-Rad Laboratories, Veenendaal, the Netherlands). Crude 
membrane vesicles were dispensed in aliquots, snap frozen in liquid nitrogen, and stored at 
-80 °C until further use.
Western blot analysis
Membrane vesicles were prepared for gel electrophoresis by incubation with Laemmli 
sample buffer (consisting of 0.5 M tris-HCl pH 6.8, 8% w/v sodium dodecyl sulfate (SDS), 40% 
w/v glycerol, 0.08% w/v bromophenol blue and 0.4 M β-mercapto-ethanol) for 10 min at 
65 °C. Proteins (15 µg total protein per sample) were separated by SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) using a 10% gel and blotted onto a nitrocellulose membrane using 
a dry blot system (iBlot; Invitrogen, Breda, the Netherlands). The membrane was incubated 
overnight at 4 °C with mouse-anti-hBCRP antibody (BXP-21, 1:200; Kamiya Biomedical 
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Company, Seattle, WA, USA) or mouse-anti-hMRP3 antibody (M3II-21, 1:200; Abcam, 
Cambridge, UK). Primary antibodies were detected using fluorescently labelled goat-anti-
mouse secondary antibody (IRdye800; 1:10,000 Rockland Immunochemicals, Boyertown, PA, 
USA). Signals were visualized using the Odyssey imaging system (Li-Cor Biosciences, Lincoln, 
NE, USA).
BCRP-mediated estrone sulfate (E
1
S) uptake and inhibition by steroids
Uptake of [3H]-E1S into HEK293-BCRP and -eYFP membrane vesicles was performed using 
an assay which was well established in our lab.16,28,29 A reaction mix consisting of TS buffer 
supplemented with 4 mM ATP/AMP, 10 mM MgCl2 and various concentrations of [
3H]-E1S at 
pH 7.4 was added to 7.5 µg of membrane vesicles (based on total protein content). After an 
incubation of 60 sec at 37 ºC to enable ATP-dependent uptake, the reaction was stopped by 
placing the samples on ice and by addition of ice-cold TS buffer. Reaction mix was removed 
and the vesicles were washed by means of a rapid filtration technique using glass fiber filter 
plates (Millipore, Etten-Leur, the Netherlands). Scintillation fluid was added to the filters and 
the amount of radioactivity was determined using a scintillation counter (Tri-Carb® 2900TR; 
Perkin Elmer, Waltham, MA, USA). Reference samples were measured to calculate the amount 
of transported E1S. ATP-dependent transport was calculated by subtracting values measured 
in the presence of AMP from those measured in the presence of ATP. Net BCRP-mediated E1S 
transport was calculated by subtracting ATP-dependent E1S uptake in HEK293-eYFP vesicles 
from that of HEK293-BCRP vesicles. Linearity of E1S uptake in time was determined using 250 
nM E1S. 
The effects of several androgens, estrogens and progestagens (all obtained from Sigma-
Aldrich, St. Louis, MO, USA or Steraloids Inc., Newport, RI, USA) on vesicular E1S uptake were 
assessed by performing the above-mentioned transport assay in the presence of 50 µM of the 
steroid. All steroid hormones were dissolved in ethanol. Maximum ethanol concentrations of 
1.3% v/v were used in uptake experiments and solvent controls were included to exclude non-
specific effects. The inhibition by the steroid hormones estradiol, testosterone, progesterone 
and androstenedione on vesicular E1S uptake were studied in more detail. Therefore, the 
membrane vesicles were incubated in the presence of increasing concentrations of the 
steroid at three different concentrations of [3H]-E1S (50, 100, and 250 nM). In studies with 
androstenedione, the glass fiber filter plate was pre-incubated with 50 mg/ml BSA for one 
hour at 37 °C and the reaction mix was supplemented with 0.2 mg/ml BSA, to reduce the 
background which is caused by adhesion to the filter plate. The sidedness of the membrane 
vesicles was not determined as ATP-dependent uptake can occur only in inside-out vesicles. 
The relative inhibition by steroids was expressed as percentage of maximum uptake.
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Inhibition of MRP3-mediated estradiol glucuronide (E217βG) uptake by steroids
The effects of estradiol, testosterone, progesterone and androstenedione on MRP3 activity 
was determined by the same method as described above, using E217βG as a substrate. 
HEK293-eYFP and -MRP3 membrane vesicles were incubated with 80 nM [3H]-E217βG with 
or without the steroids, for 3 min at 37 °C. The washing steps were performed using PVDF 
filter plates (Millipore, Etten-Leur, the Netherlands). These parameters were adapted from 
Wittgen et al.28. Unlabeled E217βG (100 µM) was used as a positive control for inhibition of 
MRP3 activity. 
Data analysis
Relative Bcrp mRNA concentration was normalized for the cycle threshold (Ct) value of the 
endogenous reference gene β-actin (delta Ct; dCt) and depicted as the reciprocal of dCt 
(mean ± SEM). Differences in mRNA concentration between male and female organs were 
assessed by means of a Student’s t-test, considering P < 0.05 significant. Fold differences 
in Bcrp mRNA levels between the organs were calculated using 2(dCt organ1-dCt organ2). Uptake 
experiments were performed in triplicate in three independent batch isolations. Michaelis-
Menten analysis was used to study transport kinetics. Inhibition curves are depicted as 
mean ± SEM of three independent experiments. Curve fitting was performed by non-linear 
regression analysis. The mode of inhibition was determined using Dixon’s method combined 
with linear regression analysis to estimate the inhibitory constant (Ki). A representative of 
one experiment is depicted. Differences in MRP3-mediated E217βG uptake were assessed 
by means of a one-way ANOVA test followed by Dunnett’s post hoc test. All analyses were 
performed with GraphPad Prism software (version 5.02, GraphPad Software Inc., San Diego, 
CA, USA).
Results
Bcrp mRNA analysis in murine organs 
Bcrp mRNA levels in murine endocrine organs were determined by means of quantitative PCR 
(figure 1). For comparison, mRNA levels in kidneys were evaluated, which are known to be 
very high.8 The relative Bcrp mRNA concentration was normalized to the mRNA concentration 
of the endogenous reference gene β-actin. The variation in cycle threshold (Ct) values of 
β-actin indicated that the qPCR reactions were reproducible (SEM ≤ 0.92). Bcrp mRNA was 
present in all organs tested. The relative mRNA concentration in the adrenal gland, pituitary 
gland, epididymal and abdominal fat, the pancreas and in the ovary was comparable and 
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found to be more than 30 times lower as compared to mRNA levels in the kidney. Bcrp mRNA 
levels in the testis was about four times higher than in the other organs, but 9-fold lower as 
compared to the kidney. Interestingly, mRNA levels of Bcrp in male mice were slightly higher 
than in female mice (P < 0.01 for the kidney and P < 0.05 for other organs), while there was 
no difference in β-actin mRNA concentration between samples from males and females.
Figure 1. Relative Bcrp mRNA concentration in wild type mouse organs, normalized for the cycle 
threshold (Ct) value of the endogenous reference gene β-actin (delta Ct; dCt). For all experiments, 
tissues from six mice were individually analyzed, except for the adrenal gland and the pituitary 
gland. For those, three samples of two pooled organs were analyzed. Bars represent the reciprocal 
of mean dCt ± SEM of independent experiments (N=3-6). * P < 0.05; ** P < 0.01 compared to 
Bcrp mRNA concentration in males by Student’s t-test. There was no difference in β-actin mRNA 
concentration between males and females. The SEM of β-actin Ct values was ≤ 0.92. 
Localization of Bcrp in murine organs
Immunohistochemical analysis revealed localization of Bcrp protein in numerous murine 
organs. Organ sections of Bcrp-/- mice were used to determine nonspecific staining. Both male 
and female organ sections were evaluated, but no differences in localization of the protein 
between male and female were found (data not shown). Therefore, only organs from female 
mice are shown here, except for the testis. Figure 2 depicts Bcrp localization in organs with a 
barrier function, viz. kidney, brain and liver. In the kidney, Bcrp staining was most prominently 
observed in the proximal tubular lumen, the brush border. Also in Bowman’s capsule brush 
border, which is present in murine nephrons, Bcrp was localized. The distal tubular lumen did 
not contain Bcrp. No Bcrp staining was found in the negative control sections (Bcrp-/-). 
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Figure 2. Representative immunohistochemical images of Bcrp distribution in wild type (left 
panels) and Bcrp-/- (negative control; right panels) mouse kidney, brain tissue and liver. Because of 
an absence of gender difference in localization, only organs from female mice are shown. Perfusion 
fixed, paraffin embedded organ-sections were incubated with a primary antibody against mouse 
Bcrp (BXP-9). DAB chromogene staining (brown) visualizes Bcrp localization. The sections were 
counterstained with Mayer’s hematoxylin. Bars 100 µm. Inserts represent details of Bcrp positivity 
and corresponding negative controls. Bcrp was present in the brush border of proximal tubule and 
in the brush border of Bowman’s capsules (arrow) of the kidney and in the capillaries of the brain 
and liver. 
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Furthermore, Bcrp was localized in the capillaries of the brain and liver. Besides presence 
of Bcrp in organs with a barrier function, the protein was found in endocrine organs (figure 
3 and 4). In the sinusoidal capillaries in adrenal gland cortex, Bcrp was clearly localized. In 
addition to this, some cells showed intracellular Bcrp staining in the zona glomerulosa and 
zona reticularis, but neither in the zona fasciculata nor in the medulla of the adrenal gland 
intracellular Bcrp staining was found. In the capillaries of the anterior pituitary gland, Bcrp 
was localized at the apical surface of the endothelial cells. The hormone producing cells of 
the pituitary gland showed no Bcrp-specific staining. The adipocytes in both epididymal 
and abdominal fat pads showed Bcrp positivity, which was absent in Bcrp-/- sections. No 
differences in localization of the pump were found between epididymal and abdominal fat 
pads, therefore, only micrographs of epididymal fat pads were shown in figure 3. Bcrp was 
not located in the endocrine and exocrine cells of the pancreas (figure 4), but endothelial 
cells lining the lumen of the capillaries in the pancreas showed a very subtle Bcrp staining, 
when comparing wild type organs with the negative control organs. Blood vessels of the 
testis, located between the seminiferous tubules, were Bcrp positive. On the other hand, the 
interstitial cells of Leydig and the Sertoli cells, which were located within the seminiferous 
tubules, did not show Bcrp staining. Furthermore, the transport protein was localized in 
endothelial cells lining the lumen of ovarian blood vessels. Interestingly, not all vessels were 
Bcrp positive, but Bcrp was present in all small capillaries. 
Presence and activity of BCRP in isolated membrane vesicles
Increased synthesis of human BCRP in HEK293 cells was established by transduction with 
baculovirus containing the recombinant bacmide DNA. Western blot analysis performed on 
isolated membrane vesicles demonstrated that the transduction was successful, as indicated 
by the band at ~75 kD (figure 5a). The negative control, consisting of membrane vesicles 
isolated from HEK293-eYFP cells, showed no presence of BCRP. Transport activity was 
determined by incubating the membrane vesicles with [3H]-E1S at 37 °C. Time-dependent 
uptake showed linearity up to 120 s (data not shown). Michaelis-Menten analysis (figure 
5b) revealed a Km of 4.5 ± 0.4 µM and a Vmax of 332 ± 12 pmol/mg*min-1, after incubating 
the vesicles for 60 s at 37 °C. In control (eYFP) vesicles, a maximum uptake rate of 6 pmol/
mg*min-1 was found.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
39
Localization of Bcrp in endocrine organs and inhibition of its transport activity by steroid hormones
2
Figure 3. Representative immunohistochemical images of Bcrp distribution in wild type (left panels) 
and Bcrp-/- (negative control; right panels) mouse adrenal gland, pituitary gland and epididymal 
fat. Because of an absence of gender difference in localization, only organs from female mice are 
shown. Perfusion fixed, paraffin embedded organ-sections were incubated with a primary antibody 
against mouse Bcrp (BXP-9). DAB chromogene staining (brown) visualizes Bcrp localization. The 
sections were counterstained with Mayer’s hematoxylin. Bars 100 µm for adrenal gland and 50 µm 
for pituitary gland and epididymal fat. (a) zona glomerulosa, (b) zona fasciculata, (c) zona reticularis 
of the adrenal gland are indicated. Inserts represent details of Bcrp positivity and corresponding 
negative controls. Bcrp was located in the sinusoidal capillaries in adrenal gland cortex, in the 
capillaries of the pituitary gland and in adipocytes. 
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Figure 4. Representative immunohistochemical images of Bcrp distribution in wild type (left panels) 
and Bcrp-/- (negative control; right panels) mouse pancreas (female), testis and ovary. Perfusion 
fixed, paraffin embedded organ-sections were incubated with a primary antibody against mouse 
Bcrp (BXP-9). DAB chromogene staining (brown) visualizes Bcrp localization. The sections were 
counterstained with Mayer’s hematoxylin. Bars 100 µm. Inserts represent details of Bcrp positivity 
and corresponding negative controls. Blood vessels in the testis and ovary showed distinct Bcrp 
positivity, whereas in the pancreas, they showed very subtle Bcrp staining.
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Figure 5. (a) Western blot analysis of HEK293-eYFP- and -BCRP membrane vesicles. BCRP was 
detected using mouse-anti-BCRP antibody (BXP-21). A Michaelis-Menten plot (b) revealed net 
BCRP-mediated uptake of E1S. Vesicles were incubated with increasing concentrations of [
3H]-E1S 
for 60 s at 37 °C in the presence of AMP or ATP. Net ATP-dependent uptake was calculated by 
subtraction of AMP values. Control (eYFP) vesicles showed maximum uptake of 6 pmol/mg*min-1. 
Graph represents means ± SEM of triplicate measurements in a representative experiment. 
Inhibition of transport activity of BCRP and MRP3 by steroids
The effects of several androgens, estrogens and progestagens on BCRP-mediated E1S 
uptake was assessed by incubating the membrane vesicles with [3H]-E1S in the presence of 
50 µM of the steroid for 60 s at 37 °C. A substrate concentration of 250 nM E1S was used 
(figure 5B, which was well below the Km of E1S uptake to ascertain initial uptake kinetics. 
Estradiol, testosterone, progesterone and androstenedione inhibited the efflux pump most 
potently (Table 1) and were, therefore, selected to be studied in more detail. Concentration-
dependent inhibition of BCRP-mediated uptake of E1S was found for all four steroids (figure 
6a-d). Progesterone was able to inhibit BCRP activity for >90% within the concentration-
range tested. Estradiol, testosterone and androstenedione inhibited the efflux pump for 
80%, 86% and 70%, respectively, at the highest possible concentrations tested. We were 
not able to assess whether the steroids were able to fully inhibit the efflux pump using our 
vesicular transport system because this was limited by the maximum solubility of the steroids 
in ethanol.
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Table 1. Effect of steroids (50 µM) on BCRP-mediated vesicular E1S uptake 
Steroid Vesicular E1S uptake (%)
Cholesterol 71.9 ± 5.2
Pregnenolone ND
17α-hydroxypregnonolone 77.2 ± 17.1
Dehydroepiandrosterone 58.7 ± 7.8
Androstenediol 70.2 ± 18.7
Progesterone 28.7 ± 14.4a
17α-hydroxyprogesterone 108.0 ± 18.7
Androstenedione 42.4 ± 9.4a
Testosterone 20.1 ± 12.2a
Dihydrotestosterone 48.4 ± 24.6
Estrone ND
Estradiol 40.4 ± 8.4a
Estriol 53.1 ± 22.5
Values are shown as mean ± SEM of one experiment performed in triplicate. Vesicular E1S uptake 
is expressed as a percentage of maximum uptake after incubation with 250 nM [3H]-E1S with or 
without 50 µM of the steroid for 60 s at 37 °C. ND, Not determined.
a The most potent inhibitors of BCRP-mediated E1S uptake were selected to be studied in more 
detail
Figure 6. Concentration-dependent inhibition of net BCRP-mediated E1S uptake by estradiol (a), 
testosterone (b), progesterone (c), and androstenedione (d). Vesicles were incubated with 250 nM 
[3H]-E1S and increasing concentrations of the steroid, for 60 s at 37 °C in the presence of AMP or 
ATP. AMP values were subtracted from ATP values. Net BCRP-mediated E1S uptake was calculated 
by subtraction of corresponding eYFP values and expressed as a percentage of maximum uptake. 
Curve fitting was performed by non-linear regression analysis. Graphs represent means ± SEM of 
three independent experiments.
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Because of their lipophilicity, steroids move readily through the plasma membrane and 
potentially might interfere with other membrane transporters. To exclude the possibility that 
the inhibitory effects on BCRP activity resulted from such a nonspecific phenomenon, the 
steroids were tested for their inhibitory effects on the activity of another ABC transporter, viz. 
MRP3. Unlike substrates for other ABC transporters, such as MRP1, MRP2 and P-glycoprotein, 
MRP3 substrates do not overlap with the ones known to be transported by BCRP. Because of 
this, we did not expect steroids to interact with MRP3. Increased synthesis of human MRP3 
in HEK293 membranes was confirmed using Western blot analysis (figure 7a). Concentrations 
of the steroids which were able to inhibit BCRP activity for more than 50% were used to 
determine their effects on MRP3 activity, using [3H]-E217βG as a substrate. Under these 
conditions, none of the steroids inhibited MRP3-mediated [3H]-E217βG uptake (figure 7b). 
Instead, testosterone and progesterone even stimulated MRP3 activity. Moreover, the 
positive control, unlabeled E217βG (100 µM), did inhibit [
3H]-E217βG uptake significantly, to 
19.4 ± 0.6 % of maximum uptake (P < 0.001). 
Figure 7. (a) Western blot analysis of HEK293-eYFP- and -MRP3 membrane vesicles. MRP3 was 
detected using mouse-anti-MRP3 antibody (M3II-21). (b) Effects of estradiol, testosterone, 
progesterone and androstenedione on MRP3 activity. Membrane vesicles were incubated with 80 
nM [3H]-E217βG (substrate) and indicated concentrations of the steroids, for three min at 37 °C. The 
effect of the steroids on net MRP3-mediated E217βG uptake is expressed as a percentage of uptake 
in negative control samples. Bars represent means ± SEM of three independent experiments. 
Differences in MRP3-mediated E217βG uptake were assessed by means of a one-way ANOVA test 
followed by Dunnett’s post hoc test.
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Dixon plot analysis
To determine the mode of interaction, we measured concentration-dependent effects of the 
steroids on BCRP activity at three different E1S concentrations. Figure 8 depicts Dixon plots 
of the data, which were analyzed by linear regression. The three lines representing steroid 
inhibition at different E1S concentrations of the four steroids intersected all at the x-axis, 
indicating a non-competitive inhibitory effect. The apparent inhibitory constant (Ki) values 
were 5.0 ± 0.2 µM for estradiol, 36 ± 14 µM for testosterone, 14.7 ± 1.3 µM for progesterone, 
and 217 ± 13 µM for androstenedione.
Figure 8. Dixon plots of inhibitory effects of estradiol (a), testosterone (b), progesterone (c), and 
androstenedione (d) on BCRP-mediated E1S uptake. Membrane vesicles were incubated with 
indicated concentrations of [3H]-E1S and increasing concentrations of the steroid. The reciprocal of 
transport velocity (1/V) was calculated and the mode of inhibition was determined using Dixon’s 
method combined with linear regression analysis to estimate the inhibitory constant (Ki) values; 
5.0 ± 0.2 µM (a), 36 ± 14 µM (b), 14.7 ± 1.3 µM (c), 217 ± 13 µM (d). A representative of one 
experiment, out of three independent measurements, is depicted.
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Discussion
This study reports a clear overview of Bcrp presence in several murine organs as well as 
its cellular localization in these tissues. In addition to adrenal gland, pancreas and testis, 
we show for the first time localization of Bcrp in ovary, pituitary gland and adipose tissues. 
Moreover, we report an efficient inhibitory effect of steroid hormones on BCRP function. 
Estradiol, testosterone, progesterone and androstenedione attenuated BCRP-mediated 
E1S transport in a non-competitive manner, which implies an allosteric inhibition of BCRP 
function by these steroids. 
Presence of BCRP in various tissues with a barrier function, including placenta, prostate, 
small intestine, brain, colon, liver, mammary gland and kidney has been shown previously.4,6-9 
Investigations on the presence of the efflux pump in endocrine organs received much less 
attention and localization of the protein has hardly been described. We assessed Bcrp on 
both mRNA level as well as protein presence in endocrine organs. In addition, endocrine 
organs from Bcrp-/- mice were used for comparison, allowing discrimination between 
background and Bcrp-specific staining. In accordance with the findings of Langmann et 
al.27, who quantified Bcrp mRNA in various human tissues, we found Bcrp mRNA in mouse 
kidney, testis and adrenal gland. While our results show highest mRNA levels in the kidney, 
Langmann et al. described highest mRNA levels in the testis. This could be attributed to 
interspecies differences. We described previously that Bcrp mRNA levels were much higher 
in mouse kidneys compared to rat and human kidneys.8 Additionally, our results revealed 
that for all organs tested, mRNA concentrations of Bcrp in male mice were significantly higher 
than in females, which is in agreement with previously published findings. Despite the clear 
gender differences in Bcrp mRNA levels, there were no differences in localization of the 
protein between male and female organs (data not shown). Tanaka et al.23 described male-
predominant Bcrp gene expression in rat kidney and mouse liver. Moreover, Merino et al.30 
found differences in the disposition of the BCRP substrate, nitrofurantoin, between male and 
female mice, with higher plasma levels in females. They also reported higher hepatic protein 
levels of human BCRP in men compared to women, determined by Western blot analysis 
using crude membrane fractions from human liver. The precise role of the efflux pump in 
males vs. females was beyond the scope of the present study, and further research should 
elucidate the consequences of this gender difference.
In accordance with previous findings8, immunohistochemical analysis revealed that Bcrp 
was prominently located in the brush borders of proximal tubule epithelium of the murine 
kidney. Furthermore, Bcrp was found to be present in adrenal gland, pituitary gland, testis 
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and ovary, where it was located predominantly in endothelial cells lining blood vessel walls. In 
agreement, Maliepaard et al.9 reported Bcrp localization in venous and capillary endothelial 
cells of almost all tissues. 
In addition to the arterioles in the adrenal gland cortex, Bcrp was found to be present in the 
cells lining the zona glomerulosa and zona reticularis, which secrete mineralocorticosteroids 
and androgens, respectively. The latter is in agreement with the findings of Fetsch et al.7. For 
the pituitary gland, we are the first to reveal Bcrp localization in the capillaries. Bcrp presence 
in blood vessels was also found in the pancreas, though, it was low as compared to the other 
organs studied. Presence of Bcrp in the pancreas was described previously, but mainly in 
pancreatic progenitor cells.31,32. In contrast to Fetsch et al., who reported Bcrp localization 
in the islet and acinar cells, we did not find Bcrp in the endocrine and exocrine cells of the 
pancreas.
In ovary, Bcrp was clearly present in capillaries and some larger blood vessels and in testis 
the capillaries showed positive staining as well. The fact that not all vessels in ovary tissue 
were Bcrp positive, might be characteristic for the dynamic environment of the estrous 
cycle, where there is a constant regeneration and degradation of capillaries. The degrading 
capillaries lose their endothelial function and thereby endothelial protein is decreased. 
Tanaka et al.23 reported Bcrp in ovary and testis of mice. In accordance with our results, they 
demonstrated that Bcrp protein levels were higher in testis than in ovary. Enokizono et al.33 
did not find evidence for Bcrp activity when evaluating genistein accumulation in the ovaries 
of wild-type and Bcrp-/- mice, but they did find Bcrp activity in murine testis. It was reported 
that the interstitial cells of Leydig7 and spermatogonial cells34 of the testis localized Bcrp. 
Conversely, our findings could not endorse these reports. Though, presence of Bcrp in the 
lumina of testicular blood vessels was evident.6
In both epididymal and abdominal fat pads, we found Bcrp to be present in mature adipocytes, 
which has as yet not been described. Adipocytes are metabolically active cells that play a key 
role in the control of the body’s energy balance by the secretion of resistin, adiponectin, and 
leptin. Moreover, adipocytes are involved in steroid hormone regulation since they highly 
express aromatase (CYP19A1), which is responsible for a key step in the biosynthesis of 
estrogens.35 Therefore, it will be interesting to unravel further the role of Bcrp in adipocytes. 
Another important endocrine organ, which we did not evaluated, is the mammary gland. 
Steroids highly influence the growth and function of the mammary gland. It is, therefore, 
interesting to study the presence and function Bcrp this organ. In 2005, Jonker et al.5 
published the localization of BCRP/Bcrp in breast tissue of mice, cows and humans. They 
clearly showed that the transporter was localized in mouse mammary gland epithelium 
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during late pregnancy and in lactating mice but presence of the protein was negligible in 
the mammary gland of nonpregnant and nonlactating mice. It would be interesting to study 
the mechanism by which Bcrp synthesis and function is influenced during pregnancy and 
lactation.
In all the organs we analysed, Bcrp was principally found in the endothelial layer of sinusoids, 
capillaries and veins. The fact that Bcrp was located in the canalicular membrane of the liver 
indicates that the efflux pump may be involved in excretion processes in the liver, similar to 
other ABC transporters, such as P-gp and MRP2.9 In the brain and in the testis, the endothelial 
cells form tight junctions, creating a blood-tissue barrier, preventing substances to freely 
enter the tissue. Here, efflux transporters, such as Bcrp, are thought to protect the brain and 
developing sperm cells against toxic agents. In other organs, normal endothelium consists of 
loosely connected endothelial cells and is known to be quite permeable for several substances. 
Nevertheless, the fact that Bcrp is so clearly present in these endothelial cells and it is able to 
transport substances against a concentration gradient indicates a contribution of the efflux 
pump to transport compounds across the endothelium. Although, the endocrine organs, 
obviously, have a significant secretory function, we did not find Bcrp localized in endocrine 
and exocrine cells, except for adipocytes and the adrenal gland. Hence, the efflux pump may 
contribute to the transport of steroids, or their derivates, into the blood stream.
Using Dixon’s method, we proved indirectly that estradiol, testosterone, progesterone and 
androstenedione are efficient inhibitors, but likely not transported by BCRP via the same 
binding site as E1S. The question whether steroids are substrates for BCRP has been discussed 
before and contradictory findings have been reported.18,25,26 Most studies support the 
conclusion that steroids interact but are not substrates for BCRP, which is in agreement with 
the present findings. Nevertheless, we cannot completely rule out the possibility of steroids 
being transported by BCRP. The idea that there is no need for steroids to be transported 
actively over the plasma membrane because of their high lipophilicity is outdated, since 
it has been described that steroids are substrates for other ABC transporters.36-39 Besides, 
steroids are derived from cholesterol, which itself is transported by other members of the 
ABCG subfamily.40,41 We have undertaken studies to measure steroid uptake in HEK293-BCRP 
membrane vesicles, but unreliable results were obtained due to the large passive permeability 
of these lipophilic compounds.
To exclude the possibility that the inhibitory effects of the steroids on BCRP activity were 
nonspecific, their effects on the activity of MRP3 was tested. None of the steroids inhibited 
MRP3-mediated E217βG uptake. Interestingly, however, testosterone and progesterone 
stimulated this uptake. Stimulation of MRP3 has been described before, although, the 
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mechanism explaining these complex stimulatory effects has not yet been elucidated.28,42,43. 
The fact that MRP3 function was not inhibited by the steroids indicates that the inhibition of 
BCRP activity by the steroids was a transporter-specific effect.
Estradiol, testosterone, progesterone and androstenedione inhibited BCRP activity for more 
than 70%. However, the concentrations needed to cause this inhibitory effect were rather 
high compared to plasma levels. These concentrations are indicative of the affinity of the 
steroids for BCRP compared to the affinity of the substrate (E1S) for BCRP, which is known 
to be very high. When the affinity of the steroids is much lower, then the concentrations 
needed to cause an effect are obviously much higher. Furthermore, the steroids themselves 
are very lipophilic and are therefore prone to stick to plastic tubes and/or wells, which might 
result in an over-estimation of the actual concentration. This problem was acknowledged 
earlier by Tanneberger et al.44 To predict the clinical relevance of the interaction between 
steroids and BCRP, knowledge on intracellular steroid concentrations is important. Plasma 
steroid levels are not relevant for predicting their effects on a membrane transporter that 
transports molecules from the inside to the outside of the cell. Intracellular levels are, so 
far, unknown and difficult to determine. One can imagine that intracellular concentrations in 
organs responsible for the production of hormones may be much higher than plasma levels 
and, thereby, could potentially influence BCRP function in vivo.
Not only BCRP function is altered by steroids, as shown in our results, also membranal 
localization of BCRP is highly influenced by sex steroids. Imai et al.22 found that estrogens 
post-transcriptionally downregulated BCRP in estrogen-responsive cancer cells. They found 
estradiol-mediated reduction in BCRP protein in MCF-7 cells, however, not on mRNA level. 
This downregulation was counteracted by gene silencing of estrogen receptor-α (ERα), 
indicating that ERα is necessary for the suppression of BCRP protein. In agreement, Hartz 
et al.21 described that estradiol signals through ERβ and ERα to initiate Bcrp internalization 
and acts via ERβ to stimulate proteosomal degradation of Bcrp in murine brain capillaries. 
In contrast, Ee et al.20 found that estradiol enhanced Bcrp mRNA levels in cells stably 
expressing ERα, at similar estradiol concentrations. Ovariectomy and castration of mice and 
rats, solely or in combination with sex steroid treatment, revealed regulation of Bcrp mRNA 
by estradiol and testosterone.23 In human placental BeWo cells, progesterone and estradiol 
significantly increased and decreased BCRP mRNA levels, respectively.45 Estradiol by itself 
likely downregulated BCRP through an estrogen receptor (ER), while progesterone alone 
upregulated BCRP via a mechanism other than progesterone receptor (PR). 
In conclusion, we found Bcrp to be present in numerous murine endocrine organs, including 
ovary, pituitary gland and adipose tissues. Furthermore, the efficient inhibition of BCRP-
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mediated transport by estradiol, testosterone, progesterone and androstenedione implies a 
clear interaction between the steroids and the efflux pump. Together, our results support the 
speculation that BCRP has a role in steroid hormone regulation. Further research will address 
this hypothesis.
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Abstract
Endocrine disrupting chemicals (EDCs) are considered to cause testicular toxicity primarily 
via interference with steroid hormone function. Alternatively, EDCs could possibly 
exert their effects by interaction with ATP-binding cassette (ABC) transporters that are 
expressed in the blood-testis barrier. Here, we investigated the effects of bisphenol A 
(BPA), tetrabromobisphenol A (TBBPA), bis(2-ethylhexyl) phthalate (DEHP), mono(2-
ethylhexyl) phthalate (MEHP), perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic 
acid (PFOS) on breast cancer resistance protein (BCRP), multidrug resistance protein 
1 and 4 (MRP1,4), and P-glycoprotein (P-gp) using membrane vesicles overexpressing 
these transporters. BPA solely inhibited BCRP activity whereas TBBPA, PFOA and PFOS 
inhibited all transporters tested. No effect was observed for the phthalates. Using 
transporter-overexpressing Madin-Darby canine kidney (MDCKII) cells, we show that BPA 
and PFOA, but not TBBPA, are transported by BCRP, whereas none of the compounds 
were transported by P-gp. To investigate the toxicological implications of these findings, 
testosterone secretion and expression of steroidogenic genes were determined in 
murine Leydig (MA-10) cells upon exposure to the selected EDCs. Only BPA and TBBPA 
concentration-dependently increased testosterone secretion by MA-10 cells to 6- and 
46-fold of control levels, respectively. Inhibition of the Mrp’s by MK-571 completely 
blocked testosterone secretion elicited by TBBPA, which could not be explained by 
coinciding changes in expression of steroidogenic genes. Therefore, we hypothesize that 
transporter-mediated efflux of testosterone precursors out of MA-10 cells is inhibited 
by TBBPA resulting in higher availability for testosterone production. Our data show the 
toxicological and clinical relevance of ABC transporters in EDC risk assessment related to 
testicular toxicity.
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Introduction
Male sub- and infertility is an increasing problem in Western society. Epidemiological trends 
show an increase in infertility and requests for assisted reproductive techniques. This 
increasing trend is observed not only as a consequence of lifestyle factors or side effect of 
therapeutic agents but is also suggested to be a consequence of environmental exposures. 
It is estimated that of all infertile couples, 20% of the cases can be attributed to male factors 
solely and that male factors are contributory in another 30-40%.1,2 Yet, male infertility is a 
complex problem of which possible causes are still poorly understood.
In adult males, spermatogenesis is driven by the gonadotropins luteinizing hormone (LH) 
that stimulates steroidogenesis in Leydig cells (LCs) and follicle-stimulating hormone (FSH) 
that acts on Sertoli cells. Local testicular steroidogenesis, i.e. production of androgens and 
estrogens, is essential in regulating spermatogenesis and involves multiple cytochrome P450 
(CYP) and hydroxysteroid dehydrogenase (HSD) enzymes. Maturation and differentiation 
of LCs coincides with decreased expression of genes related to adhesion and increased 
expression of steroidogenic enzymes (i.e. 3β-HSD).3 Moreover, the LH receptor (LHr), 
steroidogenic acute regulatory protein (StAR), cytochrome P450 cholesterol side-chain 
cleavage enzyme (CYP11A1), and 17α-hydroxylase/20-lyase (CYP17A1) expression are 
induced upon differentiation, resulting in adult LCs that primarily produce testosterone upon 
LH stimulation.
The testicular microenvironment is pivotal for mammalian steroidogenesis and spermato-
genesis. In the testis, the blood-testis barrier (BTB) physically divides the seminiferous 
epithelium into a basal and an apical compartment thereby playing a crucial role in the 
differentiation of spermatogonia into spermatocytes.4 In the active part of the BTB, like in 
various other tissues with a barrier function (i.e. blood-brain barrier, placenta), ATP-binding 
cassette (ABC) transporters are present that protect the organ from internal exposure to harmful 
substances and influence the disposition and metabolism of xenobiotics. These transporters 
are located at the cellular membranes of Leydig cells, Sertoli cells, and capillary endothelial 
cells. Efflux transporters are involved in the transport of a variety of molecules against steep 
concentration gradients at the expense of ATP. The most abundant efflux transporters in the 
BTB include breast cancer resistance protein (BCRP/ABCG2), P-glycoprotein (P-gp/ABCB1), 
and multidrug resistance proteins 1 and 4 (MRP1,4/ABCC1,4). Differential expression of these 
transporters can be observed throughout various parts of the BTB. In adult human testis, Leydig 
cells express P-gp, MRP1, and MRP4 but not BCRP.5,6 BCRP and P-gp are present at the luminal 
side of testis capillaries, whereas Sertoli cells mainly express P-gp, MRP1, and MRP4.7-9 The 
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positioning of the efflux transporters in the BTB suggests that their substrates are transported 
out of the seminiferous tubules to prevent entry and accumulation of xenobiotics in the testes 
and to protect the germ cells. Often, exposure to endocrine disrupting chemicals (EDCs), i.e. 
compounds that interfere with hormone biosynthesis, metabolism or action, is suggested to 
contribute to the increasing incidence of male sub- and infertility. Consequently, the possible 
risk of several high-volume chemicals that are used to enhance the usability and safety of 
consumer products, and which have shown endocrine activity, is under continuous debate. 
Examples of these chemicals include bisphenol A (BPA), tetrabromobisphenol A (TBBPA), 
bis(2-ethylhexyl) phthalate (DEHP), mono(2-ethylhexyl) phthalate (MEHP), perfluorooctanoic 
acid (PFOA), and perfluorooctanesulfonic acid (PFOS). People in developed countries are 
exposed daily to these chemicals and, as a result, continuous exposure occurs in blood, liver, 
kidneys, spleen, gall bladder, and also in testes.10-12 Several studies have shown that these 
EDCs can affect steroidogenesis in vitro and in vivo11,13-18 and, as such, may act as testicular 
toxicants. However, for risk assessment purposes it is extremely important to consider the 
toxicokinetics of these EDCs and to date it is unclear whether they can affect the activity of 
ABC transporters present in the BTB.
Here, we describe the interaction of six commonly suggested EDCs, i.e. BPA, TBBPA, DEHP, 
MEHP, PFOA, and PFOS, with the transport activity of the human efflux transporters BCRP, 
P-gp, MRP1 and MRP4 that can be found in the BTB, using a membrane vesicle interaction 
assay. Furthermore, Madin-Darby canine kidney (MDCKII) cells stably overexpressing BCRP 
or P-gp were used to study transport of BPA, TBBPA, and PFOA. Also, the effects of these 
EDCs and the role of the ABC transporters on testosterone secretion and steroidogenic gene 
expression were determined in P-gp-, Mrp1- and Mrp4-expressing MA-10 mouse Leydig cells.
Materials and methods
Chemicals 
Selected EDCs (supplementary figure 1), bisphenol A (BPA; >99%; CAS# 80-05-7), 
tetrabromobisphenol A (TBBPA; >97%; CAS# 79-94-7), perfluorooctanoic acid (PFOA; ≥98%; 
CAS# 335-67-1), and perfluorooctane sulfate (PFOS; ≥98%; CAS# 1763-23-1) were purchased 
from Sigma-Aldrich Co. (Zwijndrecht, the Netherlands). Diethylhexyl phthalate (DEHP; 
>98.0%; CAS# 117-81-7) was acquired from TCI Europe N.V. (Zwijndrecht, Belgium) and 
mono-ethylhexyl phthalate (MEHP; >97.5%; CAS# 4376-20-9) from Wako Chemicals GmbH 
(Neuss, Germany). [6,7-3H(N)]-estrone sulfate ([3H]-E1S; 54.3 Ci/mmol) and [6,7-
3H(N)]-
estradiol 17-β-d-glucuronide ([3H]-E217βG; 41.8 Ci/mmol) were obtained from Perkin 
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Elmer (Groningen, the Netherlands). [3H]-N-methylquinidine ([3H]-NMQ; 85 Ci/mmol) was 
purchased from Solvo Biotechnology (Szeged, Hungary), [3,5,7-3H(N)]-methotrexate ([3H]-
MTX; 25.3 Ci/mmol) from Moravek (Brea, CA, USA) and [3H(G)]-BPA (25 Ci/mmol) and [14C]-
PFOA (55 mCi/mmol) from American Radiolabeled Chemicals, Inc. (St. Louis, MO, USA). All 
radiochemicals were solved in ethanol.
Transduction of Human Embryonic Kidney (HEK293) cells and preparation of membrane 
vesicles
Overexpression of human BCRP, P-gp, MRP1, and MRP4 in HEK293 cells was established 
using baculoviruses, which were produced using the Bac-to-Bac system (Invitrogen, 
Breda, the Netherlands), as described previously.8,19,20 As a control, vesicles from HEK293 
cells overexpressing the enhanced yellow fluorescent protein (control) were used. Crude 
membranes were isolated, resuspended in TS buffer (10 mM Tris-HEPES and 250 mM 
sucrose, pH 7.4) and membrane vesicles were prepared according to the previously described 
method.19 Total protein content was determined by a Bio-Rad protein assay kit (Bio-Rad 
Laboratories, Veenendaal, the Netherlands). Crude membrane vesicles were dispensed in 
aliquots, snap frozen in liquid nitrogen, and stored at -80 °C until further use.
Transport interaction assay
The interaction of EDCs with transporter activity was assessed by adding a reaction mix 
consisting of TS buffer supplemented with 4 mM ATP/AMP, 10 mM MgCl2, radiolabelled 
substrates and various concentrations of EDCs to 7.5 µg of membrane vesicles. The following 
substrates were used; 250 nM [3H]-E1S for BCRP, 100 nM [
3H]-NMQ for P-gp, 133 nM [3H]-
E217βG for MRP1, and 200 nM [
3H]-MTX for MRP4. After an incubation of 60 sec (BCRP and 
P-gp) or 5 min (MRP1 and MRP4) at 37 ºC to enable ATP-dependent uptake, the reaction was 
stopped by placing the samples on ice and by addition of ice-cold TS buffer. Reaction mix was 
removed and the vesicles were washed by means of a rapid filtration technique using glass 
fiber filter plates (BCRP and P-gp) or PVDF filter plates (MRP1 and MRP4) (Millipore, Etten-Leur, 
the Netherlands). Scintillation fluid was added to the filters and the amount of radioactivity 
was determined using a scintillation counter (Tri-Carb® 2900TR; Perkin Elmer, Waltham, MA, 
USA). Reference samples were measured to calculate the amount of transported substrate. 
ATP-dependent transport was calculated by subtracting values measured in the presence of 
AMP from those measured in the presence of ATP. Net transporter-mediated transport was 
calculated by subtracting ATP-dependent uptake in control vesicles from that of transporter-
overexpressing vesicles.
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Accumulation assay in MDCKII cells
To determine transport of BPA, TBBPA, and PFOA, Madin-Darby canine kidney (MDCKII) 
cells stably overexpressing BCRP or P-gp were used, which were kindly provided by Dr. A. 
Schinkel (Netherlands Cancer Institute, Amsterdam, the Netherlands) and Dr. M. Gottesman 
(Laboratory of Cell Biology, National Cancer Institute, USA), respectively. Cells were seeded 
in 24-well plates and grown until confluency. For the accumulation assay, cells were washed 
with Hank’s balanced salt solution (HBSS), supplemented with 10 mM HEPES (pH 7.4), twice 
before 30 min preincubation with optiMEM (reduced serum medium; Invitrogen; Breda, the 
Netherlands) at 37 °C. Thereafter, cells were incubated with optiMEM containing 3H-BPA (40 
nM), unlabeled TBBPA (1 µM), or 14C-PFOA (1 µM) with or without the BCRP inhibitor Ko143 (1 
µM; Sigma-Aldrich Co., Zwijndrecht, the Netherlands) or the BCRP and P-gp inhibitor elacridar 
(2 µM; GF120918; Sequoia Research Products Limited, Pangbourne, United Kingdom). After 
one h at 37 °C, cells were washed twice with ice-cold HBSS/HEPES + 0.5% BSA and twice with 
ice-cold HBSS. For scintillation counting, cells were lysed with 1 M NaOH. Subsequently, HCl 
(1 M) was added and lysates were transferred into scintillation tubes containing scintillation 
fluid. Reference samples were measured to calculate the amount of transported substrate. 
For TBBPA measurements, cells were suspended after 30 min trypsin incubation and lysed by 
50% acetonitrile. TBBPA content was determined by LC-MS/MS analysis.
LC-MS/MS analysis of TBBPA
After the accumulation assay, rigorously pipetted samples were centrifuged for 10 min 
at 16,000 x g and subsequently injected into the LC-MS/MS system that consisted of an 
Accela HPLC system (Thermo scientific, Breda, the Netherlands) equipped with a C18 
UPLC column (Acquity UPLC HSS T3, 1.8 µm, 2.1 x 100 mm; Waters Corporation, Milford, 
Massachusetts, USA). Separation was performed at a flow rate of 200 µl/min with eluent A 
(50% acetonitrile/50% water) and eluent B (100% acetonitrile) under the following gradient 
conditions: 0 min, 0% eluent B, 5 min, 80% eluent B, 7 min, 80% eluent B, 8 min, 0% eluent 
B, 13 min, 0% eluent B. The eluate was directly passed into a TSQ Vantage tandem mass 
spectrometer (Thermo scientific) equipped with an electrospray ionization source. Negative 
electrospray ionization was achieved using a nitrogen sheath gas with ionization voltage 
at 2500 V. The capillary temperature was set at 350 °C. Detection of TBBPA was based on 
isolation of the deprotonated molecular ion, [M - H]+. Subsequently, MS/MS fragmentations 
and selected reaction monitoring were performed. The following SRM transitions were used: 
m/z 542,7 (parent ion) to m/z 447,8 and 419,9 (both product ions). A calibration curve of 
TBBPA was used to quantify the amount of transport. Acquired data were processed with 
Thermo Xcaliber software (Thermo scientific).
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MA-10 cell culture and exposure to EDCs and/or inhibitors
The MA-10 cell line, derived from mouse Leydig tumor cells, was kindly provided by Dr. 
Mario Ascoli (University of Iowa, Iowa City, Iowa, USA).21 Cells were cultured in 1:1 Dulbecco’s 
Modified Eagle Medium/F-12 nutrient mixture (Ham) with phenol red (DMEM/F-12 1:1, 
#11320; Gibco, Life Technologies Europe BV, Bleiswijk, the Netherlands) supplemented with 
15% HyClone (Thermo Fisher Scientific, Waltham, USA), 2% HEPES (1 M), and 1% penicillin/
streptomycin (Gibco). Cells were maintained at 37°C in a humidified atmosphere (95%) at 
5% CO2. Flasks and plates were coated at room temperature with 0.1% gelatin (Attachment 
Factor Protein; Gibco), 45 min before use.
For gene expression assessment, MA-10 cells were plated in gelatin pre-coated 12-wells 
plates (Greiner, the Netherlands) at a density of 6 x 105 cells per well. For testosterone 
secretion measurements, MA-10 cells were seeded at a density of 2 x 105 cells per well onto 
pre-coated 24-wells plates. After 24 h, the medium was replaced with medium containing the 
EDCs and/or inhibitors (at a maximum solvent concentration of 0.1% v/v). Gene expression 
was determined after a 6-hour exposure and testosterone levels were measured after 24 
hours.
Gene expression of ABC transporters and steroidogenic enzymes in MA-10 cells
After a 6-hour exposure of MA-10 cells, the effects of the EDCs on expression of transporter 
and steroidogenic genes with and without transporter inhibition were determined by 
quantitative polymerase chain reaction (qPCR). First, total RNA was isolated from MA-10 
cells by phenol-chloroform extraction using RNA InstaPure according to instructions provided 
by the manufacturer (Eurogentec, Liège, Belgium). Purity and concentration of the isolated 
RNA samples was determined at absorbance wavelengths of 230, 260, and 280 nm using 
a NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific Inc., Waltham, USA). RNA 
samples were diluted to a concentration of 66.7 µg/ml by addition of RNAse free water and 
stored at -80 °C until further use. cDNA was synthesized using the iScript cDNA synthesis 
kit (Bio-Rad Laboratories, Inc.) and diluted 10 times. qPCR was performed with reaction 
mixtures containing 12.5 µl iQ SYBR green supermix (Bio-Rad Laboratories, Inc.), 1 pmol 
forward primer, 1 pmol reversed primer, 0.5 µl RNAse free water, and 10 µl diluted cDNA. 
Supplementary table 1 describes the sequences of the primer pairs used including the 
reference gene β-actin. All primers span an exon-exon junction to ensure mRNA amplification 
only and were run through National Center for Biotechnology Information (NCBI) Blast 
(nucleotide non-redundant database) to confirm specificity. Also, efficiency was determined 
for all primer pairs. The mixtures were placed in the MyiQTM iCycler (Bio-Rad Laboratories, 
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Inc.) and heated to 95 °C for 3 min, following 40 cycles of denaturation at 95 °C for 15 s and 
annealing/extension at 60 °C for 45 s. To ensure exclusion of primer dimers and other non-
specific products formed, a melt curve was run afterwards.
Testosterone secretion
After a 24-h exposure of MA-10 cells to the EDCs, medium was removed and stored at 
-80 °C until analysis. Secretion of testosterone by MA-10 cells was measured in a 50 µl aliquot 
using a commercially available radioimmunoassay (RIA) kit (Beckman Coulter GmbH, Krefeld, 
Germany) according to manufacturer’s instructions.
Results
Effects of EDCs on BCRP, P-gp, MRP1, and MRP4 transport activity
To investigate the effects of the selected EDCs (supplementary figure 1) on activity of the 
ABC transporters, we performed an uptake assay using membrane vesicles overexpressing 
the specific transporters incubated with known substrates8,19,20 at concentrations of the EDCs 
ranging from 1 to 100 µM. Figure 1 shows the calculated net transporter-mediated substrate 
uptake depicted as percentage of maximum transport activity. BPA did not influence the activity 
of P-gp, MRP1, and MRP4. However, exposure to 100 µM of BPA resulted in a 77% reduction 
of BCRP-mediated E1S uptake (figure 1A). TBBPA inhibited the activity of all four transporters 
tested (figure 1B). At 10 µM, TBBPA inhibited BCRP and MRP4 activity with 39% and 25%, 
respectively. At 100 µM TBBPA the activity of all transporters was reduced with > 85%. For 
P-gp and MRP4, additional concentrations between 10 and 100 µM TBPPA were tested and 
a clear concentration-dependent decrease in transport activity was seen with corresponding 
IC50 values of 22.9 and 24.0 µM for P-gp and MRP4, respectively. Both phthalates DEHP and 
MEHP, did not interact with any of the transporters tested at concentrations up to 100 μM 
(figure 1C-D). PFOA and PFOS inhibited the activity of all transporters tested, mainly at 100 
μM (figure 1E-F). The strongest effect was observed on P-gp activity with an inhibition at 100 
μM of 71% and 84% by PFOA and PFOS, respectively.
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Figure 1. Transport activity of BCRP, P-gp, MRP1, and MRP4 upon exposure to various 
concentrations of (A) BPA; (B) TBBPA; (C) DEHP; (D) MEHP; (E) PFOA; and (F) PFOS. Membrane 
vesicles overexpressing the transporters were incubated with [3H]-labeled substrates and 
increasing concentrations of EDCs for 60 s (BCRP and P-gp) or 5 min (MRP1-4) at 37 °C in the 
presence of AMP or ATP. The following substrates were used; 250 nM [3H]-E1S for BCRP, 100 nM 
[3H]-NMQ for P-gp, 133 nM [3H]-E217βG for MRP1, and 200 nM [
3H]-MTX for MRP4. AMP values 
were subtracted from ATP values. Net transporter-mediated substrate uptake was calculated by 
subtraction of corresponding control values and expressed as percentage of maximum uptake. 
Bars represent means ± SEM of 3-4 independent experiments. Inhibition of transporter activity by 
the EDCs was assessed by means of a one-way ANOVA test followed by Dunnett’s post hoc test;  
(* P < 0.05, ** P < 0.01 and *** P < 0.001).
EDC accumulation in transporter-overexpressing MDCKII cells
An inhibition of transport by the EDCs does not necessarily imply that the compounds are 
substrates for the transporters. To investigate whether the EDCs tested acted as competing 
substrates, thereby inhibiting transporter activity, we determined the accumulation of BPA, 
TBBPA, and PFOA in MDCKII cells stably overexpressing BCRP or P-gp. Overexpression of 
BCRP significantly reduced the accumulation of BPA and PFOA to 20% and 52% of control 
cells, respectively (figure 2A and E). This inhibition was reversed by the BCRP inhibitor Ko143. 
TBBPA accumulated to similar levels in BCRP overexpressing cells as compared to control 
cells (figure 2C) indicating that this compound may not be a substrate for the transporter. 
Furthermore, in P-gp-overexpressing cells, no difference was found between BPA, TBBPA, or 
PFOA accumulation as compared to control cells (figure 2B, D, and F) indicating that these 
compounds are most likely not substrates for P-gp.
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Figure 2. Accumulation of BPA, TBBPA or PFOA in MDCKII cells with or without overexpression of 
BCRP (A, C, and E) or P-gp (B, D, and F). Cells were incubated with either 40 nM [3H]-BPA, 1 µM 
unlabeled TBBPA or 1 µM [14C]-PFOA in absence or presence of BCRP inhibitor Ko143 (1 µM; A,C,E 
black bars) or BCRP and P-gp inhibitor elacridar (2 µM; B,D,F black bars) for one h at 37 °C. BPA 
and PFOA accumulation were determined by scintillation counting and TBBPA accumulation was 
estimated by LC-MS/MS analysis. Bars represent means ± SEM of 3-4 independent experiments. 
Significance between control cells and inhibitor treated cells (*** P < 0.001) was assessed by 
means of a Student’s t-test.
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Effects of EDCs on testosterone secretion by MA-10 cells with and without transporter 
inhibition
Testosterone production by Leydig cells is prerequisite for proper spermatogenesis. To study 
the effect of EDCs on testosterone secretion and the role of ABC transporters in this process, 
we used the murine Leydig (MA-10) cell line. First, a qPCR was performed to confirm the 
presence of the ABC transporters in MA-10 cells. In table 1, the relative mRNA levels (ΔΔCt 
values transcript/β-actin) of Mrp1, Mrp4, and P-gp in MA-10 cells after a 24-hour exposure to 
vehicle (0.1% v/v DMSO) or 8-Bromoadenosine 3’,5’-cyclic monophosphate (8-Br-cAMP; 100 
μM) are shown. In accordance with previously described tissue distribution5, Bcrp expression 
was undetectable in the MA-10 cells (data not shown). To investigate the influence of the 
selected EDCs on testosterone secretion, MA-10 cells were exposed to the compounds 
for 24 hours, either alone or in combination with known ABC transporter inhibitors. Basal 
testosterone levels in MA-10 media were 6.6 ± 1.0 pg/ml. Complete inhibition of testosterone 
production was elicited by inhibiting Cyp17 activity using SU10603, indicating the presence 
of a de novo steroidogenic pathway in this cell line. Steroidogenesis could be induced by 
LH (not shown) and 8-Br-cAMP (figure 3A), which increased the testosterone concentration 
in the medium to 3.2 ± 0.4 ng/ml. Inhibiting Mrp or P-gp activity by MK-571 or PSC 833, 
respectively, did not affect basal nor 8-Br-cAMP-induced testosterone levels. Next, the effects 
of the selected EDCs on testosterone levels in the medium were determined. DEHP, MEHP, 
PFOA, and PFOS had no effect on testosterone levels at concentrations up to 30 µM (figure 
3B). In contrast, BPA and TBBPA concentration-dependently increased testosterone levels in 
the media up to 6- and 46-fold of control levels, respectively. Co-exposing the cells to BPA 
(10 µM) and PSC 833, but not MK-571, did increase testosterone concentrations even further 
(12-fold of DMSO control level; figure 3C). When MA-10 cells were co-exposed to TBBPA in 
combination with MK-571, testosterone levels did not increase above vehicle control levels 
and were statistically significantly lower than upon TBBPA-treatment alone (figure 3D). After 
co-exposure of cells to TBBPA and PSC 833, testosterone levels did not statistically significantly 
change compared to cells treated with TBBPA alone (figure 3D).
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Figure 3. Testosterone secretion by MA-10 cells after a 24-h exposure to (A) Cyp17 inhibitor 
SU10603 (2 µM), Mrp inhibitor MK-571 (100 μM), P-gp inhibitor PSC 833 (5 μM), 8-Br-cAMP 
(100 μM) or a combination; (B) various concentrations of EDCs; (C) various concentrations of BPA 
alone or in combination with MK-571 or PSC 833 and (D) various concentrations of TBBPA alone 
or in combination with MK-571 or PSC 833. Testosterone was measured using a commercially 
available RIA. Data are represented as means ± SEM of 3 independent experiments that were 
performed in triplicate. Significance was assessed using a Student’s t-test (A), a one-way ANOVA 
test followed by Dunnett’s post hoc test for individual curves (B), and a two-way ANOVA test 
followed by Bonferroni’s post hoc test for multiple curves (C-D). # Significantly different from 
vehicle-treated cells; * Significantly different from uninhibited BPA or TBPPA-treated cells at the 
same concentration; (# or * P < 0.05).
EDCs mediated ABC transporter and steroidogenic gene expression in MA-10 cells
Next, we investigated whether changes in testosterone levels of MA-10 cells were a result of 
altered steroidogenic gene expression upon EDC exposure. No changes in gene expression 
of Mrp1, Mrp4, and P-gp were observed upon exposure to 8-Br-cAMP (table 1), nor upon 
exposure to the Mrp inhibitor MK-571, the P-gp inhibitor PSC 833 or any of the EDCs at 
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10 µM (supplementary figure 2). Exposure of MA-10 cells to 8-Br-cAMP caused an increase 
in expression of the steroidogenic genes StAR (67-fold), Cyp11A1 (4-fold), Cyp17 (24-fold), 
and 5α-reductase type 1 (5αRed1; 2-fold) compared to vehicle-treated cells (figure 4A). 
This indicates that increased testosterone levels in media of 8-Br-cAMP-treated cells (figure 
3A) were a result of an increased testosterone production. Concurring with the effects on 
testosterone levels, DEHP, MEHP, PFOA and PFOS did not affect steroidogenic gene expression 
in MA-10 cells (supplementary figure 3). Interestingly, while exposure to BPA or TBBPA alone 
significantly increased testosterone levels in MA-10 media, the statistically significant effects 
on steroidogenic gene expression were only minor. BPA only slightly induced Cyp11A1 (1.5-
fold) expression and TBBPA moderately induced StAR (1.2-fold), Cyp11A1 (1.3 fold), and 
Cyp17 (1.3 fold) expression (figure 4B and 5C, respectively). This suggests that the changes 
in testosterone secretion by MA-10 cells after BPA or TBBPA exposure MA-10 cells are most 
likely not (solely) attributable to an increased production of testosterone as a result of 
upregulation of steroidogenic genes.
The next step was to determine whether gene expression in 8-Br-cAMP, BPA or TBBPA-
exposed MA-10 cells was affected during (P-gp or Mrp) transporter inhibition. Exposure to 
PSC 833 or MK-571 did not affect basal expression of the steroidogenic genes (supplementary 
figure 3). However, when cells were exposed to MK-571 in combination with 8-Br-cAMP, a 
2-fold increase in StAR gene expression was observed compared to 8-Br-cAMP alone, albeit 
non-statistically significantly different from cells exposed to 8-Br-cAMP alone (figure 4A). 
Furthermore, 8-Br-cAMP in combination with MK-571 showed a decrease in Cyp17 (2-fold) 
and 5αRed1 (2-fold) gene expression compared to 8-Br-cAMP treated cells (figure 4A). A 
significant increase in StAR gene expression (2-fold) was observed in MA-10 cells exposed to 
the combination of TBBPA with MK-571 compared to cells exposed to TBBPA alone (figure 4C). 
No effect of MK-571 on the expression of other steroidogenic genes studied in combination 
with 8-Br-cAMP, BPA or TBBPA was observed. PSC 833 did not significantly affect steroidogenic 
gene expression levels in 8-Br-cAMP, BPA or TBBPA-exposed MA-10 cells (figure 4A, B and C). 
Taken together, these data indicate that changes in testosterone levels in MA-10 cell media 
upon BPA or TBBPA exposure do not arise from concurrent changes in steroidogenic enzyme 
activity following altered gene expression.
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Figure 4. Expression of genes involved in steroidogenesis in MA-10 cells after a 24-h exposure 
to (A) 8-Br-cAMP (100 μM); (B) BPA (10 μM) or (C) TBBPA (10 μM) alone or in combination with 
MK-571 (100 μM) or PSC 833 (5 μM). Data are represented as means ± SEM of 3 independent 
experiments that were performed in triplicate. Significance was assessed by means of a Student’s 
t-test. # Significantly different from vehicle-treated cells; * Significantly different from 8-Br-cAMP, 
BPA or TBPPA-treated cells; (# or * P < 0.05). Dotted lines indicate the reference level of the DMSO 
control.
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Discussion
The present study shows for the first time differential inhibitory effects of BPA, TBBPA, 
PFOA and PFOS on BCRP, P-gp, MRP1, and MRP4 transport activities. Moreover, BPA and 
PFOA appear to be substrates for BCRP. Our data further indicate that exposure to BPA and 
TBBPA can affect testosterone secretion from murine Leydig cells, which appears to be only 
partly due to increased steroidogenic enzyme expression. Possibly, increased availability of 
precursors for testosterone production via decreased ABC transporter-facilitated excretion of 
testosterone precursors, plays a role in this process.
The BTB provides structural and protective support to developing germ cells. The BTB 
is constituted by coexisting tight junctions, testis-specific atypical adherens junctions, 
desmosomes, and gap junctions.22 The active part of the BTB consists of drug efflux 
transporters that are differentially expressed throughout various parts of the BTB. Drug efflux 
transporters are a major determinant of xenobiotic kinetics and, consequently, of testicular 
exposure to potentially harmful compounds. From this perspective, the interaction of EDCs 
with ABC transporters is of great toxicological relevance. Our study shows that BPA, TBBPA, 
PFOA and PFOS differentially inhibit the activity of BCRP, P-gp, MRP1 or MRP4. Interestingly, 
BPA specifically inhibits BCRP but not P-gp, MRP1 or MRP4 activity. Furthermore, we 
demonstrated that BPA is transported by BCRP and not by P-gp. In accordance, Mazur et al.23 
recently reported that BPA is a potential substrate for BCRP, but not for P-gp, based on an 
indirect ATP consumption assay. In contrast, the halogenated derivative of BPA, TBBPA, is not 
transported by BCRP or P-gp even though TBBPA is a potent inhibitor of all four transporters 
tested. Based on these data, TBBPA can be classified as a non-competitive transport inhibitor, 
yet detailed kinetic studies are needed to confirm this. PFOA also appeared to be a substrate 
for BCRP and, considering the structural similarity and inhibitory potency, it is likely that PFOS 
is also a BCRP substrate.
ABC transporters play an important role in the distribution of chemicals into several tissues, 
including the testis.24,25 Several single nucleotide polymorphisms (SNPs) have been reported 
that render transporters inactive causing substrates to accumulate in tissues.26-28 Moreover, 
drug-induced inhibition of ABC transporter activity can occur. For example, several commonly 
used drugs have been described to modulate BCRP function.29 BCRP, P-gp, MRP1 and MRP4 
transport a broad range of substrates, including endogenous molecules involved in cellular 
signaling and communication, such as folic acid, cyclic nucleotides, conjugated steroids, 
vitamin B2 and uric acid.26,27,30,31 Interestingly, a recent study has demonstrated impaired 
testicular testosterone production in Mrp4-deficient mice, suggesting a physiological role for 
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this transporter in spermatogenesis.6 Based on our findings that BPA, TBBPA, PFOA and PFOS 
are able to inhibit the activity of one or more ABC transporters, it can be expected that this 
potentially influences a myriad of cellular processes that are regulated by ABC transporters 
and disturbs cellular homeostasis and local sex steroidogenesis.
Mammalian male sexual differentiation and functioning is entirely androgen-dependent 
and therefore endocrine disrupting effects on the androgen-producing Leydig cells can have 
profound biological consequences. Testicular steroidogenesis is regulated by a negative 
feedback mechanism via the hypothalamus–pituitary–testis axis but also locally via cAMP-
mediated modulation of CYP17 activity.32 This latter mechanism was shown to be present in 
MA-10 cells that we used in this study. Mouse Leydig cells appear to resemble human Leydig 
cells with respect to interferences with local testicular steroidogenesis.33 Studies using fetal 
testis xenotransplants show that both human and mouse fetal testis, but not rat testis, are 
refractory to phthalate-induced inhibition of testosterone production.14,14,16,16,34 However, it 
is important to note that in men, a large portion of sex steroids and their precursor DHEA 
is produced in the adrenals. Circulating DHEA and its sulfate (DHEAS) provide a high level 
of substrates for androgen formation in peripheral tissues like the testis, which is reflected 
by extremely high expression levels and activity of human testicular 17β-HSD.35 This is in 
strong contrast with experimental animals, such as rat and mouse, where the secretion of sex 
steroids takes place exclusively in the gonads.36 These species-differences are mechanistically 
important and should be taken into account when translating effects of EDCs found in animal 
models for human risk assessment.
In vitro studies have demonstrated that exposure to estrogenic or anti-androgenic EDCs 
can affect sex steroidogenesis.13,17 For example, BPA and DEHP have been shown to induce 
CYP19 but not CYP17 activity in human adrenocortical H295R cells.17 TBBPA inhibited CYP17 
activity but had no effect on CYP19 activity.13 Here, we also demonstrate that BPA and TBBPA 
can affect testosterone secretion from MA-10 Leydig cells. In line with our findings, MEHP 
did not affect steroidogenesis in the H295R steroidogenesis assay nor altered testosterone 
production in MA-10 cells.17,37 In our study, 8-Br-cAMP increased testosterone secretion 
by MA-10 cells, which was accompanied by a marked increase in StAR and Cyp17 gene 
expression. Steroidogenesis is initiated by cholesterol transport into the inner mitochondrial 
membrane, which is mediated by the StAR protein.38 However, the changes in StAR and/
or Cyp17 gene expression did not concur with the changes in testosterone levels observed 
in media of MA-10 cells upon exposure to BPA or, even more profoundly, TBBPA. This 
indicates that other mechanisms are involved that can explain the concentration-dependent 
increase in testosterone levels upon BPA and TBBPA exposure. We also showed that TBBPA 
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potently inhibits P-gp transporter activity and inhibition of P-gp by the specific transporter 
inhibitor PSC 833 increased testosterone levels in MA-10 cells. This led us to hypothesize 
that transporter-mediated efflux of testosterone precursors, i.e. androstenedione or DHEA, 
from the MA-10 cells is inhibited by TBBPA and PSC 833 (graphically explained in figure 5). 
As a result, more precursors are available for testosterone production, which is reflected 
by increased testosterone levels measured. An in vivo study with rats showed that TBBPA 
exposure resulted in increased plasma testosterone levels, which correlated with an increase 
in testicular weight.18 In our study, the Mrp inhibitor MK-571 completely abolished TBBPA-
mediated increase in testosterone secretion in MA-10 cells, suggesting a decrease in active 
transport of testosterone out of the Leydig cells. The high rate of local testosterone production 
that is observed in vivo implies the need for local, intratesticular transport of testosterone 
from Leydig cells to specific target cells, i.e. Sertoli cells that nourish and support the 
developing sperm cells throughout the stages of spermatogenesis. Moreover, intratesticular 
testosterone levels are maintained at ∼100 times the level found in the systemic circulation in 
both humans and rodents39, stressing the importance of local, active transport of sex steroids 
within the testis. Possibly, ABC transporters play a role in this local transport.
In humans, plasma TBBPA levels are very low but maximum plasma concentrations of TBBPA-
glucuronide were found to be 16 nmol/l after a single oral dose of 0.1 mg/kg TBBPA given to 
healthy volunteers.40 In our studies, the concentrations of EDCs that affected ABC transporter 
activity and testosterone secretion were in the nanomolar to micromolar range. However, 
plasma EDC levels have limited relevance for predicting effects on a membrane protein that 
transports molecules from inside to outside the cell. To our knowledge no data on intracellular 
concentrations for the selected EDCs exist. Yet, the fact that people in industrialized countries 
are daily exposed to these chemicals 10-12 emphasizes the importance of our findings.
In conclusion, our results provide a novel insight in mechanisms of male testicular toxicity by 
EDCs that warrants further investigation. The results from this study demonstrate that the 
endocrine disrupting capacity of suggested EDCs should not only be sought in direct effects 
on steroidogenesis upon accumulation in the testis, but can also entail indirect effects via 
interaction with ABC transporters in the BTB. It is, therefore, of high toxicological and clinical 
relevance to take the interactions between EDCs and the ABC transporters into account when 
performing risk assessment related to testicular toxicity.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
73
EDCs differentially target ABC transporters in the BTB and affect Leydig cell testosterone secretion
3
Figure 5. Proposed effect of inhibition of P-gp and MRPs on testosterone production and secretion. 
In this study, we show that TBBPA potently inhibits P-gp. Also, TBBPA increases testosterone 
secretion by MA-10 Leydig cells, which suggests an increased conversion from testosterone (T-)
precursors into testosterone. Since steroidogenic genes were not markedly upregulated by TBBPA, 
this effect is probably caused by increased availability of T-precursors due to P-gp inhibition. The 
same effect was provoked by P-gp inhibitor PSC 833. Subsequent inhibition of Mrps by MK-571 
totally abolished TBBPA-mediated increase in testosterone secretion, indicating the potential role 
of Mrps to transport testosterone out of the cell.
Acknowledgements
The authors would like to thank A. Kulkarni and S.M. Nijmeijer for the technical assistance, 
J.J.M.W. van den Heuvel for preparing the bacoluviruses and P.H.H. van den Broek for the LC-
MS/MS measurements. The research performed at the Institute for Risk Assessment Sciences 
(IRAS; Utrecht University) was funded by the European Community’s Seventh Framework 
Program ([FP7/2010-2014]; GA244236), ChemScreen (http://www.bds.nl/chemscreen) and 
the Doerenkamp-Zbinden Foundation (http://www.doerenkamp.ch).
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
74
Chapter 3
References
1.  Sharlip ID, Jarow JP, Belker AM, Lipshultz LI, Sigman M, Thomas AJ, Schlegel PN, Howards SS et al. (2002) Best 
practice policies for male infertility. Fertil. Steril. 77(5):873-882 
2.  Makker K, Agarwal A, Sharma R (2009) Oxidative stress & male infertility. Indian J. Med. Res. 129(4):357-367 
3.  Ge RS, Dong Q, Sottas CM, Papadopoulos V, Zirkin BR, Hardy MP (2006) In search of rat stem Leydig cells: 
identification, isolation, and lineage-specific development. Proc. Natl. Acad. Sci. U. S. A 103(8):2719-2724 
4.  Su L, Mruk DD, Cheng CY (2011) Drug transporters, the blood-testis barrier, and spermatogenesis. 
J. Endocrinol. 208(3):207-223 
5.  Bart J, Hollema H, Groen HJ, de Vries EG, Hendrikse NH, Sleijfer DT, Wegman TD, Vaalburg W et al. (2004) 
The distribution of drug-efflux pumps, P-gp, BCRP, MRP1 and MRP2, in the normal blood-testis barrier and in 
primary testicular tumours. Eur. J. Cancer 40(14):2064-2070 
6.  Morgan JA, Cheepala SB, Wang Y, Neale G, Adachi M, Nachagari D, Leggas M, Zhao W et al. (2012) Deregulated 
hepatic metabolism exacerbates impaired testosterone production in Mrp4-deficient mice. J. Biol. Chem. 
287(18):14456-14466 
7.  Robillard KR, Hoque T, Bendayan R (2012) Expression of ATP-binding cassette membrane transporters in 
rodent and human sertoli cells: relevance to the permeability of antiretroviral therapy at the blood-testis 
barrier. J. Pharmacol. Exp. Ther. 340(1):96-108 
8.  Dankers AC, Sweep FC, Pertijs JC, Verweij V, van den Heuvel JJ, Koenderink JB, Russel FG, Masereeuw R (2012) 
Localization of breast cancer resistance protein (Bcrp) in endocrine organs and inhibition of its transport 
activity by steroid hormones. Cell Tissue Res. 349(2):551-563 
9.  Su L, Cheng CY, Mruk DD (2009) Drug transporter, P-glycoprotein (MDR1), is an integrated component of the 
mammalian blood-testis barrier. Int. J. Biochem. Cell Biol. 41(12):2578-2587 
10.  Jensen AA and Leffers H (2008) Emerging endocrine disrupters: perfluoroalkylated substances. Int. J. Androl 
31(2):161-169 
11.  Kitamura S, Suzuki T, Sanoh S, Kohta R, Jinno N, Sugihara K, Yoshihara S, Fujimoto N et al. (2005) Comparative 
study of the endocrine-disrupting activity of bisphenol A and 19 related compounds. Toxicol. Sci. 84(2):249-
259 
12.  Law RJ, Allchin CR, de BJ, Covaci A, Herzke D, Lepom P, Morris S, Tronczynski J et al. (2006) Levels and trends 
of brominated flame retardants in the European environment. Chemosphere 64(2):187-208 
13.  Canton RF, Sanderson JT, Letcher RJ, Bergman A, van den BM (2005) Inhibition and induction of aromatase 
(CYP19) activity by brominated flame retardants in H295R human adrenocortical carcinoma cells. Toxicol. Sci. 
88(2):447-455 
14.  Johnson KJ, Heger NE, Boekelheide K (2012) Of mice and men (and rats): phthalate-induced fetal testis 
endocrine disruption is species-dependent. Toxicol. Sci. 129(2):235-248 
15.  Kundakovic M, Gudsnuk K, Franks B, Madrid J, Miller RL, Perera FP, Champagne FA (2013) Sex-specific 
epigenetic disruption and behavioral changes following low-dose in utero bisphenol A exposure. Proc. Natl. 
Acad. Sci. U. S. A 110(24):9956-9961 
16.  Mitchell RT, Childs AJ, Anderson RA, van den DS, Saunders PT, McKinnell C, Wallace WH, Kelnar CJ et al. (2012) 
Do phthalates affect steroidogenesis by the human fetal testis? Exposure of human fetal testis xenografts to 
di-n-butyl phthalate. J. Clin. Endocrinol. Metab 97(3):E341-E348 
17.  Roelofs MJ, Piersma AH, van den Berg M, van Duursen MB (2013) The relevance of chemical interactions with 
CYP17 enzyme activity: Assessment using a novel in vitro assay. Toxicol. Appl. Pharmacol.
18.  Van der Ven LTM, Van de KT, Verhoef A, Verwer CM, Lilienthal H, Leonards PE, Schauer UM, Canton RF et 
al. (2008) Endocrine effects of tetrabromobisphenol-A (TBBPA) in Wistar rats as tested in a one-generation 
reproduction study and a subacute toxicity study. Toxicology 245(1-2):76-89 
19.  Wittgen HG, van den Heuvel JJ, van den Broek PH, Dinter-Heidorn H, Koenderink JB, Russel FG (2011) 
Cannabinoid type 1 receptor antagonists modulate transport activity of multidrug resistance-associated 
proteins MRP1, MRP2, MRP3, and MRP4. Drug Metab Dispos. 39(7):1294-1302 
20.  Wittgen HG, Greupink R, van den Heuvel JJ, van den Broek PH, nter-Heidorn H, Koenderink JB, Russel FG 
(2012) Exploiting transport activity of p-glycoprotein at the blood-brain barrier for the development of 
peripheral cannabinoid type 1 receptor antagonists. Mol. Pharm. 9(5):1351-1360 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
75
EDCs differentially target ABC transporters in the BTB and affect Leydig cell testosterone secretion
3
21.  Ascoli M (1981) Characterization of several clonal lines of cultured Leydig tumor cells: gonadotropin receptors 
and steroidogenic responses. Endocrinology 108(1):88-95 
22.  Cheng CY and Mruk DD (2012) The blood-testis barrier and its implications for male contraception. Pharmacol. 
Rev. 64(1):16-64 
23.  Mazur CS, Marchitti SA, Dimova M, Kenneke JF, Lumen A, Fisher J (2012) Human and rat ABC transporter efflux 
of bisphenol a and bisphenol a glucuronide: interspecies comparison and implications for pharmacokinetic 
assessment. Toxicol. Sci. 128(2):317-325 
24.  Enokizono J, Kusuhara H, Sugiyama Y (2007) Effect of breast cancer resistance protein (Bcrp/Abcg2) on the 
disposition of phytoestrogens. Mol. Pharmacol. 72(4):967-975 
25.  Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB (2000) Pharmacological inhibition 
of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug 
Metab Dispos. 28(6):655-660 
26.  Matsuo H, Takada T, Ichida K, Nakamura T, Nakayama A, Ikebuchi Y, Ito K, Kusanagi Y et al. (2009) Common 
defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese 
population. Sci. Transl. Med. 1(5):5ra11 
27.  Chen ZS, Robey RW, Belinsky MG, Shchaveleva I, Ren XQ, Sugimoto Y, Ross DD, Bates SE et al. (2003) Transport 
of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: 
effects of acquired mutations at R482 on methotrexate transport. Cancer Res. 63(14):4048-4054 
28.  Woodward OM, Kottgen A, Coresh J, Boerwinkle E, Guggino WB, Kottgen M (2009) Identification of a urate 
transporter, ABCG2, with a common functional polymorphism causing gout. Proc. Natl. Acad. Sci. U. S. A 
106(25):10338-10342 
29.  Robey RW, To KK, Polgar O, Dohse M, Fetsch P, Dean M, Bates SE (2009) ABCG2: a perspective. Adv. Drug Deliv. 
Rev. 61(1):3-13 
30.  Russel FG, Koenderink JB, Masereeuw R (2008) Multidrug resistance protein 4 (MRP4/ABCC4): a versatile 
efflux transporter for drugs and signalling molecules. Trends Pharmacol. Sci. 29(4):200-207 
31.  van Herwaarden AE, Wagenaar E, Merino G, Jonker JW, Rosing H, Beijnen JH, Schinkel AH (2007) Multidrug 
transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk. Mol. Cell Biol. 
27(4):1247-1253 
32.  Burgos-Trinidad M, Youngblood GL, Maroto MR, Scheller A, Robins DM, Payne AH (1997) Repression of cAMP-
induced expression of the mouse P450 17 alpha-hydroxylase/C17-20 lyase gene (Cyp17) by androgens. Mol. 
Endocrinol. 11(1):87-96 
33.  Trbovich AM, Martinelle N, O’Neill FH, Pearson EJ, Donahoe PK, Sluss PM, Teixeira J (2004) Steroidogenic 
activities in MA-10 Leydig cells are differentially altered by cAMP and Mullerian inhibiting substance. J. Steroid 
Biochem. Mol. Biol. 92(3):199-208 
34.  Heger NE, Hall SJ, Sandrof MA, McDonnell EV, Hensley JB, McDowell EN, Martin KA, Gaido KW et al. (2012) 
Human fetal testis xenografts are resistant to phthalate-induced endocrine disruption. Environ. Health 
Perspect. 120(8):1137-1143 
35.  Labrie F, Luu-The V, Lin SX, Labrie C, Simard J, Breton R, Belanger A (1997) The key role of 17 beta-
hydroxysteroid dehydrogenases in sex steroid biology. Steroids 62(1):148-158 
36.  Belanger B, Belanger A, Labrie F, Dupont A, Cusan L, Monfette G (1989) Comparison of residual C-19 
steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of 
extratesticular androgens in men. J. Steroid Biochem. 32(5):695-698 
37.  Clewell RA, Campbell JL, Ross SM, Gaido KW, Clewell HJ, III, Andersen ME (2010) Assessing the relevance of in 
vitro measures of phthalate inhibition of steroidogenesis for in vivo response. Toxicol. In Vitro 24(1):327-334 
38.  Devoto L, Kohen P, Vega M, Castro O, Gonzalez RR, Retamales I, Carvallo P, Christenson LK et al. (2002) Control 
of human luteal steroidogenesis. Mol. Cell Endocrinol. 186(2):137-141 
39.  Ochsenkuhn R and De Kretser DM (2003) The contributions of deficient androgen action in spermatogenic 
disorders. Int. J. Androl 26(4):195-201 
40.  Schauer UM, Volkel W, Dekant W (2006) Toxicokinetics of tetrabromobisphenol a in humans and rats after 
oral administration. Toxicol. Sci. 91(1):49-58 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
76
Chapter 3
Supplementary figure 1. Chemical structures of selected molecules prepared using the molecule 
editor ChemDraw (CambridgeSoft, Cambridge, MA, USA). These commonly suggested endocrine 
disruptors are widely used in the production of plastics (BPA, DEHP, and MEHP), as flame retardant 
(TBBPA), or surfactant (PFOA and PFOS).
Supplementary figure 2. Expression of genes of ABC transporters in MA-10 cells after a 24-h 
exposure to MK-571 (100 μM), PSC 833 (5 μM) or one of the EDCs (BPA, TBBPA; 10 μM). Data are 
represented as means ± SEM of 3 independent experiments that were performed in triplicate. 
Significance was assessed by means of a Student’s t-test. The dotted line indicate the reference 
level of the DMSO control.
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Supplementary figure 3. Expression of genes involved in steroidogenesis in MA-10 cells after a 
24-h exposure to MK-571 (100 μM), PSC 833 (5 μM) or one of the EDCs (DEHP, MEHP, PFOA, or 
PFOS; 10 μM). Data are represented as means ± SEM of 3 independent experiments that were 
performed in triplicate. Significance was assessed by means of a Student’s t-test. The dotted line 
indicate the reference level of the DMSO control.
Supplementary table 1. Sequences of primer pairs used in this study. All primers are designed for 
mouse genes as described in the Materials and methods section.
Gene Forward primer (5’-3’) Reverse primer (5’-3’)
β-actin ATGCTCCCCGGGCTGTAT CATAGGAGTCCTTCTGACCCATTC
Mrp1 AGGCTGGAGCTAAGGAGGAG CAGCCATGGAGTAGCCAAAT
Mrp4 GGTTGGAATTGTGGGCAGAA TCGTCCGTGTGCTCATTGAA
P-gp TCATTGCGATAGCTGGAGTG CAAACTTCTGCTCCCGAGTC
StAR AAAAGACACGGTCATCACTCA CCACCCCTTCAGGTCAATAC
Cyp11A1 GCACTTTGGAGTCAGTTTACATC AGGACGATTCGGTCTTTCTT
Cyp17 TCGCCTGGGTACCACAACTGC AGAGTCACCATCTGGGGCCGAC
3β-HSD TCAGCCACCACCATCTCAGACTTT AGCCGCTCAGTTCAGAATGTAGGA
17β-HSD ACTGTGCCAGCAAGTTTGCG AAGCGGTTCGTGGAGAAGTAG
5αRed1 CTGGAGGGTTTCCTGGCTTTC GTGAACAGCAGGGTGGGCTT
LHr CCAGAGTTGTCAGGGTCGCGC GGTGAGAGATAGTCGGGCGAGGC
Abbreviations: Mrp, multidrug resistance protein; P-gp, P-glycoprotein; StAR, steroidogenic 
acute regulatory protein; Cyp, cytochrome P450; HSD, hydroxysteroid dehydrogenase; 5αRed1, 
5α-reductase type 1; LHr, luteinizing hormone receptor.
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Abstract
Normal endocrine function is a prerequisite for proper development of the reproductive 
system and maintenance of function throughout adult life. The endocrine disruptor 
bisphenol A (BPA), widely used in the production of plastics, is thought to contribute to 
the increasing incidence of male subfertility because of its estrogenic properties. Recently 
we showed that the ABC transporter breast cancer resistance protein (BCRP), an efflux 
pump which is localized amongst others in the capillary endothelium of endocrine organs, 
transports BPA. In the present study, we aimed to determine the role of Bcrp in the 
disposition of BPA using wild type and Bcrp-/- mice. Mice were subcutaneously exposed 
to [3H]-BPA with or without elacridar, an inhibitor of Bcrp and another efflux pump, 
P-glycoprotein (P-gp), via a micro-osmotic pump. Maximum BPA plasma concentrations 
were reached after three to four days. After seven days, animals were sacrificed and total 
BPA levels were determined in plasma and several organs. In general, BPA accumulation 
in the testes, adrenal and pituitary glands, adipose tissue, brain, liver and kidneys of 
Bcrp-/- mice was not different as compared to wild type mice. Also, co-administration of 
elacridar did not affect BPA accumulation. Interestingly, the testis weight of unexposed 
Bcrp-/- mice was significantly higher as compared to wild type mice, but was not affected 
by BPA exposure with or without elacridar. Taken together, our results indicate that 
the disposition of the human BCRP substrate BPA is not altered in Bcrp-deficient mice, 
suggesting minor importance of the transporter in BPA handling in mice. 
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Introduction
Male infertility or subfertility is an increasing problem within our modern society. About 30-
40% of all infertile couples can be attributed to male factors.1,2 Normal endocrine function is a 
prerequisite for proper development of the reproductive system and maintenance of function 
throughout adult life. Endocrine disrupting chemicals (EDCs), compounds that interfere with 
hormone biosynthesis, metabolism or action, are thought to contribute to the increasing 
incidence of male subfertility. The effects of EDCs on male fertility are widely investigated, 
especially those of high-volume chemicals that are used in plastics and food-packaging such 
as bisphenol A (BPA). This compound is used in the manufacture of polycarbonate plastics 
and epoxy resins, and the widespread inclusion of BPA in consumer products has greatly 
enhanced the potential for human exposure. Of particular concern is the use of BPA in plastic 
food and beverage packaging and medical devices. BPA can leach from these products in 
appreciable amounts, resulting in nearly ubiquitous daily exposure to humans. Detectable 
levels of BPA have been found in the urine of 93% of the US population, as reported in 2008.3 
Health concerns regarding human exposures to BPA stem from its estrogenic properties. 
While BPA was initially considered to be a ‘weak’ estrogen based on a lower affinity for the 
nuclear estrogen receptor (ER) alpha relative to estradiol4, research showed that BPA is 
equipotent to estradiol in its ability to activate responses via estrogen receptors associated 
with the cell membrane.5,6 In addition, BPA has been described to antagonistically bind the 
androgen receptor.7,8 Exposures to BPA have been linked to reduced sperm counts in a rodent 
model and a human epidemiology study.9,10 Evidence has been reported that BPA can rapidly 
activate membrane-initiated ER signaling at doses found in human blood.11,12 Moreover, 
another study showed transplacental, multigenerational reproductive and carcinogenic 
effects by BPA in vivo at human relevant exposure levels.13 Understanding the kinetics and 
mechanism of toxicity of BPA is thus of key importance. 
The endocrine organs of the hypothalamic–pituitary–gonadal (HPG) axis are highly susceptible 
to BPA interference. Xi et al.14 described that the effects of BPA affects the feedback regulatory 
circuits in the HPG axis. At the hypothalamic-pituitary level, perinatal and postnatal BPA 
exposures resulted in an upregulation of the expression levels of kisspeptin (Kiss1), 
gonadotropin-releasing hormone (GnRH) and follicle-stimulating hormone (FSH) mRNA in 
male and female mice. At the gonadal level, BPA inhibited expression levels of testicular 
steroidogenic enzymes and the synthesis of testosterone in males. In accordance, another 
group also found that neonatal BPA exposure interferes with sex specific gene expression of 
estrogen receptor-α, -β and Kiss1 in rat anterior hypothalamus.15 Moreover, BPA triggered an 
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immediate inhibition of pituitary LH secretion in lambs, as reported by Collet et al.16 A way 
in which organs can protect themselves against compounds like BPA is extrusion via active 
transport. ATP binding cassette (ABC) transporters are involved in the efflux of a variety of 
molecules against steep concentration gradients at the expense of ATP. The transporters are 
present in various tissues, protecting the organs from harmful substances and influencing the 
disposition and metabolism of xenobiotics. We recently showed that BPA is a substrate for 
the ABC transporter breast cancer resistance protein (BCRP/ABCG2).17 Moreover, we showed 
that Bcrp is localized in capillary endothelium of murine pituitary and adrenal glands, adipose 
tissue and testes.18 These findings suggests that BCRP may be an important determinant in 
the distribution, disposition and, thereby, the toxicity of BPA. In the present study, we aimed 
at elucidating the role of Bcrp in the disposition and potential endocrine disrupting effects of 
BPA in mice.
Materials and methods
Chemicals
[3H(G)]-BPA (80 µM; 25 Ci/mmol) was purchased from American Radiolabeled Chemicals, Inc. 
(St. Louis, MO, USA). Prior to the in vivo experiment, [3H]-BPA was diluted in physiological 
salt solution to 8 µM (= 0.2 mCi/ml in 10% ethanol). [6,7-3H(N)]-Estrone sulfate ([3H]-E1S; 
54.26 Ci/mmol) was obtained from Perkin Elmer (Groningen, the Netherlands) and [3H]-N-
Methylquinidine ([3H]-NMQ; 85 Ci/mmol) from Solvo Biotechnology (Szeged, Hungary). The 
P-gp and BCRP/Bcrp inhibitor elacridar (GF120918) was purchased from Sequoia Research 
Products Limited (Pangbourne, United Kingdom) and dissolved in DMSO. BPA-glucuronide 
(BPA-G) was obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). 
Biodistribution of BPA in wild type and Bcrp-/- mice
Friend leukemia virus type-B (FVB) mice and FVB-Bcrp-/- mice were kindly provided by Dr. A. 
Schinkel (Netherlands Cancer Institute, Amsterdam, the Netherlands)19 and bred and housed 
at the Central Animal Laboratory of the Radboudumc. The Animal Experimental Committee 
of the Radboudumc approved all procedures involving the animal experiments in this study. 
Male mice (13-20 weeks old) were implanted with a micro-osmotic pump (model 1007D; 
Alzet®, Durect Corp, Cupertino, CA, USA), designed to release a steady exposure. The mice 
were anesthetized by inhalation of isoflurane for 5 min and the pumps were implanted 
subcutaneously at the back of the mice. After suturing the wound, Carprofen (Rimadyl®; 
1 µg/g body weight) was administered subcutaneously at day 1 and 2 for pain treatment 
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and the mice were individually caged. Prior to implantation, the pumps were filled with a 
physiological salt solution containing 20 µCi [3H]-BPA (10% ethanol) with or without the 
P-gp and BCRP/Bcrp inhibitor elacridar (1.68 µmol in 10% dimethylsulfoxide; DMSO) under 
sterile conditions and weighted to confirm the absence of air bubbles in the pumps. To the 
solutions without elacridar, 10% DMSO was added as solvent control. Leftovers of prepared 
solutions were taken for reference [3H]-BPA measurements. The pumps had a mean release 
rate of 0.5 µl/h, resulting in the following exposure; 100 µCi [3H]-BPA/kg/day and 8 µmol 
elacridar/kg/day. Six mice per group were used (N=3 for the Bcrp-/- mice exposed to both 
BPA and elacridar). Every day, 20 µl blood was withdrawn from the tail vein. After seven days, 
mice were sacrificed by a single, lethal intraperitoneal injection of 144 mg/kg pentobarbital 
(Nembutal®, 15 mg/ml) and blood was collected by a heart puncture. Diverse organs were 
isolated, weighed and homogenized using micropestles in Solvable® (Perkin Elmer, Waltham, 
MA, USA). Radioactivity was determined by scintillation counting (Tri-Carb® 2900TR; Perkin 
Elmer, Waltham, MA, USA) and total BPA content in blood and tissue samples was calculated 
based on reference samples. Accumulation in adrenal glands, kidneys and testes was 
determined in one organ per animal. 
Preparation of membrane vesicles and transport interaction assays
Overexpression of human BCRP and P-gp in HEK293 cells was established using baculoviruses, 
which were produced using the Bac-to-Bac system (Invitrogen, Breda, the Netherlands), as 
described previously.18,20,21 As a control, the enhanced yellow fluorescent protein (eYFP) was 
overexpressed using the same system. Crude membranes were isolated, resuspended in 
TS buffer (10 mM Tris-HEPES and 250 mM sucrose, pH 7.4) and membrane vesicles were 
prepared as described previously.20 Total protein content was determined by a Bio-Rad protein 
assay kit (Bio-Rad Laboratories, Veenendaal, the Netherlands). Crude membrane vesicles 
were dispensed in aliquots, snap frozen in liquid nitrogen, and stored at -80 °C until further 
use. The interaction of BPA’s primary metabolite BPA-G with transporter activity was assessed 
by adding a reaction mix consisting of TS buffer supplemented with 4 mM ATP or AMP, 10 
mM MgCl2, radiolabelled substrates (250 nM [
3H]-E1S for BCRP or 100 nM [
3H]-NMQ for P-gp) 
and various concentrations of BPA-G to 7.5 µg of membrane vesicles, based on total protein 
content. After an incubation of 60 sec at 37 ºC to enable ATP-dependent uptake, the reaction 
was stopped by placing the samples on ice and by addition of ice-cold TS buffer. Reaction mix 
was removed and the vesicles were washed by means of a rapid filtration technique using 
glass fiber filter plates (Millipore, Etten-Leur, the Netherlands). Scintillation fluid was added 
to the filters and the amount of radioactivity was determined using a scintillation counter. 
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Reference samples were measured to calculate the amount of transported substrate. ATP-
dependent transport was calculated by subtracting values measured in the presence of 
AMP from those measured in the presence of ATP. Net transporter-mediated transport was 
calculated by subtracting ATP-dependent uptake in eYFP vesicles from that of transporter-
overexpressing vesicles. 
Data analysis
Area under the curve (AUC) values were calculated from the plasma BPA concentration time 
curve. Differences in organ BPA accumulation were assessed by means of a one-way ANOVA 
test followed by Dunnett’s post hoc test. Membrane vesicle transport results were analyzed 
using a one-way ANOVA test followed by Dunnett’s post hoc test. All analyses were performed 
with GraphPad Prism software (version 5.02, GraphPad Software Inc., San Diego, CA, USA).
Results
Plasma BPA levels in wild type and Bcrp-/- mice
Kinetics of the BCRP-substrate BPA were studied in male wild type and Bcrp-/- mice, that were 
subcutaneously exposed to [3H]-BPA with or without elacridar via a micro-osmotic pump 
for seven days. Total plasma BPA levels were determined daily (figure 1). Maximum plasma 
concentrations were reached three to four days after implantation of the micro-osmotic 
pumps and plasma levels decreased thereafter. In Bcrp-/- mice, slightly lower plasma BPA levels 
were found compared to wild type mice, as supported by the calculated AUC values (figure 
1A), however, this difference was not statistically significant. No significant effect of elacridar 
was found on plasma BPA levels in wild type mice, however, the Bcrp and P-gp inhibitor 
seemed to reduce the decrease in plasma levels between day 4 and 7 slightly. The AUC in 
Bcrp-deficient mice treated with elacridar was significantly lower than elacridar-treated wild 
type mice (figure 1B). However, this difference could be due to low BPA measurements in this 
group at day 4, since BPA levels in the days thereafter were not lower than the other groups. 
Interestingly, plasma BPA levels kept rising after day 4 in inhibited Bcrp-/- mice while plasma 
levels of the other groups decreased after day 4. 
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Figure 1. Plasma BPA levels of wild type and Bcrp-/- mice after a seven day exposure to [3H]-BPA 
(100 µCi/kg/day) without (A) or with (B) BCRP and P-gp inhibitor elacridar (8 µmol/kg/day), 
subcutaneously via a micro-osmotic pump. Plasma levels of BPA were measured at indicated time 
points (mean ± SEM) and Area Under the Curve (AUC; mean ± SEM) per group was determined. 
N=6 (N=3 for Bcrp-/- exposed to BPA and elacridar). # P < 0.05 compared to inhibited wild type;  
*** P < 0.001 compared to all other groups.
No effects of BPA-G on transport activity of BCRP and P-gp
The concentration of [3H]-BPA in plasma reflects total levels of the compound, including 
its primary phase II metabolite BPA-G. It was shown previously that BPA is a substrate for 
human BCRP17 and possibly for rat Bcrp and P-glycoprotein22, however the handling of its 
major metabolite was less clear. We assessed the interaction of BPA-G on transport activity 
of BCRP and P-gp by incubating membrane vesicles overexpressing the transporters with the 
substrates [3H]-E1S (BCRP) and [
3H]-NMQ (P-gp) in the presence of increasing concentrations 
of BPA-G.18,21 Figure 2 depicts the calculated net transporter-mediated substrate uptake by 
membrane vesicles incubated with 1, 10 and 100 µM BPA-G, expressed as percentage of 
maximum. Neither of these concentrations influenced BCRP and P-gp activity. 
Accumulation of BPA in Bcrp-expressing organs
To investigate the role of the efflux pump in the disposition of BPA, the biodistribution of 
BPA was investigated in various Bcrp-expressing organs. After seven days of exposure, BPA 
accumulation was determined in plasma, testis, adrenal and pituitary glands, adipose tissue, 
brain, liver and kidney (figure 3 and 4A). Highest BPA levels per gram tissue were found in 
the testis and adrenal and pituitary gland and the lowest BPA concentrations were found in 
adipose tissue (figure 3 and 4A). Bcrp-deficiency did not lead to altered BPA concentrations 
in endocrine organs nor in the two main metabolizing organs, the liver and kidney. Co-
exposure to elacridar resulted only in increased liver BPA levels in Bcrp-/- mice in accordance 
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with inhibition of efflux. Yet, in the kidneys of wild type mice, elacridar-treatment resulted in 
increased BPA levels in wild type mice only. Interestingly, these levels were not reached by 
elacridar-treated Bcrp-/- mice. 
Figure 2. Effect of BPA-G on transport activity of BCRP (A) and P-gp (B). Membrane vesicles 
overexpressing the transporters or eYFP were incubated with [3H]-labeled substrates and increasing 
concentrations of BPA for 60 s at 37 °C in the presence of AMP or ATP. AMP values were subtracted 
from ATP values. Net transporter-mediated substrate uptake was calculated by subtraction of 
corresponding eYFP values and expressed as a percentage of maximum uptake. Graphs represents 
means + SEM of triplicate measurements in a representative experiment.
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Figure 3. BPA accumulation in organs of wild type and Bcrp-/- mice after a seven day exposure 
to [3H]-BPA (100 µCi/kg/day) with or without BCRP and P-gp inhibitor elacridar (8 µmol/kg/day), 
subcutaneously via a micro-osmotic pump. Accumulation of BPA (pmol/g tissue) in indicated organs 
was depicted as mean + SEM of N=6 (N=3 for Bcrp-/- exposed to BPA and elacridar). Chequered bar, 
exposed to BPA alone; Black bar, exposed to BPA in combination with elacridar. (** P < 0.01). 
BPA accumulation in the testis, the primary site of male steroidogenesis and thought to 
be highly susceptible for BPA-mediated endocrine disruption, is shown in figure 4. BPA 
accumulation expressed as pmol/g testis (figure 4A) is reduced in Bcrp-/- mice, however, 
absolute accumulation was not different between wild type and Bcrp-/- mice (figure 4B). The 
difference in relative accumulation can be explained by an increased testis weight of Bcrp-/- 
mice as compared to wild type mice (figure 4C). Exposure to BPA and elacridar did not affect 
the testicular weight. The weights of the adrenal glands, brains and kidneys, which were 
harvested as a whole, did not differ between the experimental groups. 
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Figure 4. BPA accumulation in the testis of wild type and Bcrp-/- mice after a seven day exposure 
to [3H]-BPA (100 µCi/kg/day) with or without BCRP and P-gp inhibitor elacridar (8 µmol/kg/day), 
subcutaneously via a micro-osmotic pump. BPA accumulation in the testis is expressed as pmol/g 
(A) and fmol/testis (B). Panel C shows the testicular weight. Both testis per mouse have been 
weighted and the testis of unexposed mice were weighed as negative controls. Bars show the 
mean + SEM of N=12 (N=6 for Bcrp-/- exposed to BPA and elacridar). (** P < 0.01; *** P < 0.001) 
All three Bcrp-/- groups in panel C were significantly different from their corresponding wild type 
group. 
Discussion
In this study, we investigated the biodistribution of BPA in male wild type versus Bcrp-/- mice 
to elucidate the role of Bcrp in the disposition and potential endocrine disrupting effects of 
BPA. Our results show that the disposition of human BCRP substrate BPA is not altered by 
murine Bcrp or P-gp. 
The role of efflux pumps in BPA disposition has recently gained interest of other investigators 
as well. Mazur et al. showed that BPA is a potential substrate for BCRP, based on an indirect 
ATPase activity assay.22 In accordance, we previously reported that BPA is indeed transported 
by BCRP but not by human P-glycoprotein.17 BPA is a lipophilic compound, which has been 
shown to accumulate in brain, adipose tissue and mammary glands of exposed rats.23 Since 
murine Bcrp is localized in the capillary endothelium of these organs (except in the mammary 
gland), as well as in the testes and pituitary and adrenal glands where it transports molecules 
towards the blood18, we hypothesized that the efflux pump influences the disposition of BPA. 
Accordingly, we expected BPA accumulation in these organs to be increased in Bcrp-deficient 
mice. Nevertheless, our results show that Bcrp does not influence the accumulation of BPA 
in mice. Knockout mouse models are useful to investigate the role of a specific transporter, 
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however, compensatory gene expression and protein synthesis may countervail the lack of 
the specific gene.24 To exclude the possibility that other, yet unknown, BPA-transporters were 
upregulated in Bcrp-deficient mice and counteracted the potential effects of Bcrp-deficiency, 
two additional groups were included, i.e. wild type and Bcrp-/- mice treated with the Bcrp and 
P-gp inhibitor elacridar.25 Except for the liver, elacridar inhibition did not significantly affect BPA 
accumulation in Bcrp-/- mice, therefore no effect of P-gp is suggested. The increasing effect of 
elacridar on BPA levels in the livers Bcrp-/- mice, would suggest an effect of P-gp, however, this 
was not found in wild type mice. Also, in the kidneys of wild type mice, elacridar-mediated 
increase in BPA levels could probably not be explained by P-gp-mediated efflux of BPA as this 
effect of elacridar was not found in the knockout mice. 
The mice were continuously exposed to BPA to ensure measurable tissue levels. BPA was 
administered subcutaneously via an osmotic pump to eliminate differences in absorption 
between the mouse strains that could occur after oral administration.25,26 It was reported by 
Doerge et al.27 that maximum BPA plasma levels in orally-treated neonatal rats were 34 times 
lower than from subcutaneous injections. These results reinforce the critical role of first-pass 
phase II metabolism of BPA in gut and liver. The same group examined the distribution of 
BPA and its primary phase II metabolite BPA-G in adult rats and showed that the fraction of 
total BPA present as the parent compound was >90% in adipose, muscle and brain tissues, 
three half-lives after intravenous injection.23 This indicates that BPA-G does not accumulate 
in tissues and is immediately excreted after formation. In our study, using radiolabelled BPA, 
total BPA levels were determined and, thus, we were not able to distinguish between BPA 
and its metabolites. However, based on the findings of Doerge et al., we assumed that the 
levels found in the tissues could be assigned to BPA itself. As BPA-G did not influence BCRP 
and P-gp activity in vitro, even at high concentrations (100 µM) and also Mazur et al.22 did 
not find an interaction between BPA-G and BCRP or P-gp, it can be assumed that the small 
fraction of BPA-G present in total BPA levels did not affect BPA accumulation in wild type and 
Bcrp-/- mice. 
Furthermore, we describe for the first time that the testicular weight of Bcrp-/- mice (either 
treated or not) was 40% higher than that of wild type mice. Generally, it is believed that 
testicular weight increases to compensate a decreased testicular function, i.e. steroidogenesis 
and spermatogenesis.28,29 BCRP/Bcrp have been correlated with steroid hormones before. 
Several steroids, including estradiol, testosterone, progesterone and androstenedione, 
can inhibit BCRP function.18 Besides, the localization of BCRP in the plasma membrane is 
shown to be sex specific, which is in males suggested to be due to the inductive effect of 
testosterone.30,31 N.B. We observed that Bcrp-/- mice exhibit reduced fertility with a reduced 
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number of pregnancies and smaller litter of pups as compared to wild type animals (7.2 
± 0.5 versus 9.5 ± 0.2 pups, respectively; N=10). The localization of the transporter in the 
plasma membrane is shown to be sex specific and the sex steroids estradiol, progesterone, 
and testosterone have been shown to impact BCRP gene expression.30-34 However, the role 
of BCRP/Bcrp in steroid hormone metabolism is far from elucidated. Our results suggest 
that Bcrp could be involved in proper testicular function. We, however, did not examine 
steroid production and germ cell count, hence, we cannot confirm that testicular function 
was impaired in Bcrp-deficient mice. Clearly, further research is required to elucidate why 
testicular weight is increased in Bcrp-deficient mice.
BPA was efficiently transported by human BCRP, as was shown in BCRP-overexpressing 
MDCKII cells loaded with 40 nM BPA with or without elacridar.17 Our current results argue 
that the murine orthologue Bcrp is probably not involved in the disposition of BPA. Significant 
interspecies differences between human and rodents in terms of BCRP/Bcrp mRNA and 
protein expression have long been recognized.35-37 However, delineating differences in 
substrate affinities between BCRP and Bcrp have been much less reported. Zhang et al.38 
described the interactions of the flavonoids chrysin and benzoflavone with human BCRP, 
which were not found with rat or mouse Bcrp. Moreover, Mazur et al.22 showed interspecies 
differences in the efflux transporter specificities for BPA between rat and human ABC 
transporters, including BCRP. BPA-mediated increase in ATPase activity was clearly found for 
human BCRP but not for rat Bcrp. Possibly, this species difference can explain the different 
outcomes in our experiments with human and mouse BCRP/Bcrp. No interaction of BPA with 
murine Bcrp has been described before. These differences between human and rodent ABC 
transporters need further confirmation, for example by studying BCRP/Bcrp from different 
species transfected in the same cell line. These results may have significant implications 
for interspecies extrapolation used in risk assessment. In humans, BCRP may be a potential 
determinant in BPA-mediated endocrine disruption, because increased BPA exposure of 
endocrine producing cells due to lack of BCRP activity can potentially increase the endocrine 
disrupting effects of BPA.
In summary, we show for the first time that Bcrp-/- mice display increased testicular weight, 
which could indicate a physiological role for Bcrp in testicular homeostasis and male fertility. 
Further, our results indicate that the disposition of BPA, a substrate for human BCRP, is not 
altered in Bcrp-deficient mice. Possibly, the EDC is not a substrate for the efflux transporter 
in mice. Although this interspecies difference needs further confirmation, it is an important 
phenomenon that should be taken into account when interpreting results obtained from 
rodent animal models, as the disposition and thus potentially the mechanism of toxicity may 
be different in humans as compared to rodents.
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Abstract 
Heme is the functional group of diverse hemoproteins and crucial for many cellular 
processes. However, heme is increasingly recognized as a culprit for a wide variety 
of pathologies, including sepsis, malaria, and kidney failure. Excess of free heme can 
be detrimental to tissues by mediating oxidative and inflammatory injury. Protective 
mechanisms against free heme are therefore pivotal for cellular survival. We postulated 
that overexpression of heme oxygenase-1 (HO-1) and breast cancer resistance protein 
(BCRP) would protect against heme-induced cytotoxicity. HO-1 is a heme-degrading 
enzyme generating carbon monoxide, iron, and biliverdin/bilirubin, while BCRP is a heme 
efflux transporter. Human embryonic kidney cells were transduced using a baculovirus 
system as a novel strategy to efficiently overexpress HO-1 and BCRP. Exposing cells to 
heme resulted in a dose-dependent increase in reactive oxygen species formation, DNA 
damage and cell death. Heme-induced cell death was significantly attenuated when cells 
overexpressed HO-1, BCRP, or both. The protective effects of HO-1-overexpression were 
most pronounced, while co-treatment with the HO-activity inhibitor tin mesoporphyrin 
reversed these protective effects. Also cells treated with the anti-oxidants N-acetylcysteine 
or HO-effector molecule bilirubin showed protection against heme insults, which may 
explain the increased protection by HO-1 compared to BCRP. In conclusion, both HO-1 
and BCRP protect against heme-induced toxicity and may thus form novel therapeutic 
targets for heme-mediated pathologies. 
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Introduction
Heme is a complex of free iron and a porphyrin ring and is synthesized in every nucleated 
cell.1 Heme possesses dual biological effects. It is crucial as the functional group of a variety 
of hemoproteins involved in oxygen transport and storage, electron transfer, and signal 
transduction. However, free heme catalyzes also the formation of reactive oxygen species 
(ROS) through the Fenton reaction resulting in tissue injury.2 Free heme not only promotes 
oxidative stress, but also possesses proinflammatory properties both in vitro and in vivo.2,3 
Heme induces vascular adhesion molecule expression, causes vascular permeability, and 
promotes leukocyte recruitment and the induction of inflammatory cytokines.2-5 Large 
amounts of free heme can be a major culprit in the etiology of a wide variety of pathological 
conditions and diseases.2,6-10 
Heme can also exacerbate disease processes10,11 as exemplified for malaria and sepsis. In 
an experimental setup in which mice infected with Plasmodium Berghei ANKA developed 
malaria but no experimental cerebral malaria. Administration of free heme to these mice 
promoted oxidative and inflammatory insults resulting in blood-brain barrier dysfunction.12,13 
This allowed the entrance of inflammatory mediators capable of exacerbating disease 
towards the brain.12 Similarly, in a murine model of sepsis, it was found that administration of 
heme severely aggravated sepsis by worsening organ injury.14 It is therefore pivotal to protect 
cells from heme-induced oxidative and inflammatory insults. Rhabdomyolysis, intravascular 
hemolysis and cell injury are characterized by the release of large amounts of heme.2,15 The 
heme- and hemoglobin (Hb)-scavengers hemopexin and haptoglobin act as a first line of 
defense against the injurious actions of heme.2,10,16 They have been demonstrated to protect 
against heme- and Hb-mediated insults such as vascular adhesion, lipid peroxidation, and 
organ failure.4,14,16 However, these heme-scavengers may be overwhelmed when exposed to 
large amounts of heme.2 Down-stream, several putative defense systems against intracellular 
heme are present, such as heme oxygenase-1 (HO-1) and the efflux pump breast cancer 
resistance protein (BCRP). 
Heme-mediated pathologies can be attenuated by activation of the heme oxygenase system 
(HO) system.2,10,12,17-20 HO breaks down heme into biliverdin, iron, and carbon monoxide. 
Biliverdin is then rapidly converted into the antioxidant bilirubin by biliverdin reductase, while 
iron is rendered inactive by co-induction of its scavenger ferritin.2 Two isoforms of HO have 
been identified in humans: HO-1 and HO-2. The inducible isoform, HO-1, shows low basal 
expression but can be highly induced by a variety of stimuli, including cytokines and oxidative 
stress21,22, while HO-2 is thought to be constitutively expressed. Another putative determinant 
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in heme-related toxicity is a member of the ATP-binding cassette (ABC) transporter family 
localized at the plasma membrane known as the breast cancer resistance protein (BCRP: 
ABCG2).23 This efflux pump modulates erythroid maturation by decreasing cellular heme 
levels24,25 and by protecting cells and tissues from heme accumulation following hypoxia.26 
The possible protection by BCRP against heme is further strengthened by the observation 
that heme accumulates in tissues of BCRP-knockout mice.26-28 
Since both HO and BCRP have the potential to clear heme from the cells, we postulated 
that the proteins BCRP and HO-1 protect against heme-induced toxicity. To test this, we 
overexpressed BCRP and HO-1, and combinations to investigate the possible protective roles 
of both proteins and their combination in heme-induced cytotoxicity in human embryonic 
kidney (HEK293) cells. 
Materials and methods
Culture of HEK293 cells
Human embryonic kidney (HEK293) cells were cultured in T75 flasks in Dulbecco’s modified 
Eagle’s medium (DMEM) with high glucose levels, containing 10% fetal calf serum (FCS) (MP 
Biomedicals, Uden, the Netherlands) at 37°C in a 5% CO2 atmosphere. Cells were passed (1:5) 
using Trypsin/EDTA when reaching approximately 90% of confluency.
Preparation of porphyrin and bilirubin solutions
Heme (FePP), the HO-activity blocker tin mesoporphyrin (SnMP) and the antioxidant bilirubin 
(all obtained from Frontier Scientific, Carnforth, UK) were freshly prepared as previously 
described.5 In short, the substances were dissolved together with Trizma base in a 0.1 M 
NaOH solution and diluted in H2O. The obtained solution (pH 11 to 12) was adjusted to pH 8 
with HCl. The solution was then filter-sterilized, protected from light and directly used. 
Measurement of reactive oxygen species (ROS)
The ROS-specific labeling dye 2’,7’-dichlorodihydrofluorescein diacetate (H2DCFDA) 
(Invitrogen, Breda, The Netherlands) was used to measure heme-induced ROS formation. 
HEK293 cells were seeded and grown till 70% confluency in DMEM without phenol red with 
10% FCS in collagen pre-coated 96-wells plates, suitable for fluorescence measurement 
(ThermoFischer Scientific, Vantaa, Finland) as described previously.29 Cells were washed once 
with Hanks’ Balanced Salt Solution (HBSS, Invitrogen) prior to labelling with 10 µM H2DCFDA 
in HBSS for 20 min at 37°C. Afterwards, cells were washed twice with HBSS and exposed to 
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heme (0-12.5 µM) for 90 min in the presence or absence of 6 mM N-acetylcysteine (NAC; 
glutathione precursor) or 30 µM bilirubin in DMEM without phenol red and 1% FCS. Unlabeled 
cells were used as negative control and H2O2-treated cells (200 µM) were used as positive 
control. Fluorescence, representing ROS formation, was determined using a Fluostar Galaxy 
fluorometer at excitation 485 nm and emission 520 nm (BMG Lab Technologies, Offenburg, 
Germany). 
Detection of DNA damage
The comet-assay (single cell gel electrophoresis) was used to detect DNA damage after 
heme-treatment. HEK293 cells were cultured until 40-50% confluency in 6-wells plates. 
Subsequently, cells were treated with 200 μM heme in presence or absence of 6 mM NAC or 
30 µM bilirubin for 48h. Cells were harvested and the amount of cells/mL was determined. In 
addition, 6000 cells were resuspended in 75 µL LM-Agarose (Trevigen, Gaithersburg, Germany) 
and immediately applied to the comet slides. Slides were allowed to solidify for 30 min at 
4°C and subsequently submerged in lysis buffer (Trevigen) for 60 min at 4°C. After cell lysis, 
the slides were placed on a horizontal electrophoresis system tray (Owl separation system) 
containing alkaline electrophoresis buffer (pH>13; 300 mM NaOH, 1 mM EDTA in H2O) and 
electrophoresis was performed at 25 V for 30 min to allow DNA unwinding. Slides were then 
neutralized by three times washing with neutralization buffer (0.4 M Tris-HCl pH 7.5), fixed 
in 100% ethanol during 10 min and air dried. After neutralization, samples were stained with 
50 μL ethidium bromide solution (1:75.000 in H2O) and enclosed with VectaShield (Vector 
Laboratories Inc, Burlingame, CA). All steps were performed at dimmed light conditions to 
avoid DNA damage by UV light. Slides were examined (40x magnification) using a LeicaDM 
fluorescent microscope with a TRITC-filter. The images of 20 randomly chosen nuclei per 
slide were blindly scored. Each nucleus was visually scored from undamaged DNA stage 0 to 
maximally damaged DNA stage 4.30 
Preparation of baculovirus constructs
To study the role of HO-1 and BCRP in the protection of heme-induced toxicity more 
extensively, we generated baculoviruses, suitable for transduction of human cells to 
overexpress the proteins, as described previously.31,32 In short, for BCRP-overexpression the 
pDONR-221-hBCRP clone (HsCD00044371; Harvard Institute of Proteomics, Harvard Medical 
School, Cambridge, MA, USA) was used and cloned into pFB-VSV-CMV-DEST. For HO-1-
overexpression the pFastBac-VSV-CMV-DEST hHO-1 WT construct was used. This construct 
was made as follows: the human HO-1 gene was amplified using the following primers: 
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forward primer 5’-ggggacaagtttgtacaaaaaagcaggcttcaacaccatggagcgtccgcaacccga and reverse 
primer 5’-ggggaccactttgtacaagaaagctgggtctcacatggcataaagcccta. Then hHO-1 was cloned 
into the entry vector pDONR201 (Invitrogen, Breda, the Netherlands) using the attB flanked 
PCR product by the BP clonase reaction. Subsequently, the hHO-1 gene was cloned into the 
destination vector pFB-VSV-CMV-DEST by the LR clonase reaction. DH10Bac competent cells 
were transformed with the destination vector and bacmide DNA was isolated. Baculoviruses 
were produced as described in the Bac-to-Bac manual. Enhanced yellow fluorescent protein 
(EYFP) cloned into pFB-VSV-CMV DEST was used as a control (Invitrogen). Sf9 insect cells were 
transfected with the recombinant bacmide DNA and viruses were harvested. P3 viruses were 
used for transduction.31
EYFP/EYFP, BCRP/EYFP, HO-1/EYFP and BCRP/HO-1 baculovirus-mediated double transductions
Human Embryonic Kidney (HEK293) cells were cultured in T75 flasks in Dulbecco’s modified 
Eagle’s medium (DMEM) with high glucose levels, containing 10% fetal calf serum (FCS) (MP 
Biomedicals, Uden, the Netherlands) at 37°C in a 5% CO2 atmosphere. Cells were passed 
(1:5) when reaching approximately 90% of confluency. Before double-transductions were 
performed, HEK293 cells were cultured in T75 flasks until 40% confluency. To overexpress 
BCRP and/or HO-1 proteins, the medium was replaced by equal volumes (650 µL baculovirus 
of each) and completed to 3.3 mL with medium. In all cases, double-transductions were 
performed to correct for the amount of virus. After 15-60 min of incubation at 37°C, medium 
was added to a final volume of 10 mL. Sodium butyrate (5 mM) was added 24 h after 
transduction to realize an up-regulation of protein expression.33 
Western blot analysis for HO-1 and BCRP protein expression 
To determine the HO-1- and BCRP-overexpression, cells were harvested, 48 h, 72 h and 
96 h after transduction, and pelleted by 5 min of centrifugation (500 g). For HO-1 protein 
determination, pellets were lysed for 10 min on ice using lysis buffer containing protease 
inhibitors (1 mM EDTA, 0.5% Triton-X-100, 25 μg/ml leupeptin, 25 μg/ml pepstatin, 100 
μM phenylmethanesulphonylfluoride, 3 μg/ml aprotinin in PBS, pH 7.2, all Sigma-Aldrich). 
Subsequently, cell lysates were centrifuged (20.000 g) for 2 min at 4˚C. For the determination 
of BCRP expression, membrane fractions were prepared. To this end, pellets of transduced 
cells were resuspended in PBS with added protease inhibitors (Roche, Mannheim, Germany). 
Afterwards, the lysates were snap-frozen in liquid nitrogen and defrosted at 37˚C three 
times. Samples were centrifuged (20.000 g) for 10 min. The pellet was resuspended in 40 
µL PBS. Samples were prepared for gel electrophoresis by incubation with Laemmli sample 
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buffer (consisting of 0.5 M tris-HCl pH 6.8, 8% sodium dodecyl sulfate (SDS), 40% glycerol 
(100%), H2O, 0.08% bromophenol blue and 0.4 M β-mercapto-ethanol) for 5 min at 95˚C. 
Proteins were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) using a 10% 
gel and blotted onto a nitrocellulose membrane using a BioRad wet blotting system.34 The 
membrane was blocked for 1 h at room RT using Odyssey Blocking Buffer (Westburg BV, 
Leusden, the Netherlands). The blot was incubated overnight at 4˚C with rabbit-anti-HO-1 Ab 
(rat) (SPA-895; 1:5.000; Stressgen/ITK, Uithoorn, The Netherlands) or mouse-anti-BCRP (BXP-
21, 1:200, Kamiya Biomedical Company, Seattle, USA). Mouse-anti-β-actin Ab (human) was 
simultaneously incubated as a protein loading control (1:100.000, Sigma-Aldrich). Afterwards, 
the membrane was rinsed three times with PBS followed by washing three times 10 min with 
PBS containing 0.1% Tween-20. Both the HO-1 blot and the BCRP blot were incubated with 
the secondary antibodies goat-anti-mouse IRDye 800 (1:20.000, Rockland, Heerhugowaard, 
the Netherlands) and goat-anti-rabbit Alexa Fluor 680 (1:20.000 Sigma-Aldrich) in Odyssey 
Blocking Buffer containing 0.1% Tween-20 and 0.01% SDS for 1 h at RT protected from light. 
After thorough washing, expression of β-actin and BCRP was assessed with the Odyssey 
Infrared Imaging System using channel 800 while HO-1 expression was determined using 
channel 700 (LI-COR Biosciences)29 Intensity of the bands was determined using the Odyssey 
application software. The ratios of HO-1/BCRP and β-actin intensities were calculated and 
protein levels were normalized to the expression in EYFP/EYFP transduced cells.
BCRP activity determination using flow cytometric analysis of Hoechst33342 accumulation in 
BCRP transduced HEK293 cells
Fumitremorgin C (FTC) is used as a BCRP-mediated transport inhibitor. To assess whether 
FTC actually inhibits the efflux pump in our BCRP-overexpressing HEK293 cells, the cells were 
incubated with 10 µM FTC or DMSO control, three days after transduction. After 20 min, the 
fluorescent BCRP substrate Hoechst33342 (10 µM) was added and incubated for 45 min at 
37°C. Subsequently, cells were washed with HBSS/Hepes (pH 7.4) and fixed with 4% PFA. 
Hoechst accumulation was assessed with a Beckman Coulter Altra flow cytometer, using a 
Coherent Enterprice II laser (621-CL). 
Determination of cell viability
The MTT-assay was used to determine cell survival after heme treatment. MTT 
(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) is reduced to the purple 
formazan in the mitochondria of living cells which was used as a measure for cell viability. 
HO-1 and BCRP transduced HEK293 cells were harvested (36 h after transduction), and 
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seeded on collagen pre-coated 96-wells plates at a density of 2.5*104 cells/well. After 12 
h, cells were treated for 48 h with increasing doses of heme (0-500 µM) in the presence 
or absence of 10 µM FTC, 10 µM SnMP, 6 mM NAC or 10 µM or 30 µM bilirubin in culture 
medium. A concentration of 500 µM heme was used as positive control for cytotoxicity. After 
heme treatment, medium was removed and 20 µL MTT solution (5 mg/mL in PBS; Sigma-
Aldrich, Zwijndrecht, The Netherlands) was added to the wells and incubated for 4 h at 37°C. 
Dimethyl sulfoxide (DMSO) was added to dissolve the water insoluble formazan. After 1 min 
of shaking, the absorbance of this colored solution was measured spectrophotometrically at 
a wavelength of 560 nm (Biorad, benchmark plus microplate spectrophotometer, UK). Cell 
viability of treated cells is expressed as a percentage compared to untreated cells. 
Data analysis
Data were analyzed by means of GraphPad Prism (version 5.01 for Windows; Graph Pad 
Software, San Diego, Ca, USA). The effect of heme treatment on cell survival was assessed 
by non-linear regression (sigmoidal dose response with variable slope). Results of ROS 
determination were statistically tested by use of a one-way ANOVA test followed by post hoc 
testing (Dunnett or Bonferroni). For the comet assay, a Kruskal-Wallis test was performed. 
The results of the FACS analysis were statistically evaluated using an unpaired T-test. Groups 
were considered to be significantly different when P<0.05.
Results
Heme induces cell death in HEK293 cells
To evaluate the toxicity of heme, HEK293 cell survival was determined using the MTT-assay 
after 48 h of heme treatment (0-500 µM). Figure 1 shows that concentrations higher than 10 
µM heme cause cell death in HEK293 cells. The concentration that resulted in 50% reduction 
in cell survival (IC50 value) was 143 ± 1 µM. No cell survival was observed at concentrations of 
250 µM heme or higher.
The effects on cell morphology of heme treatment, and the protective effect of the cellular 
antioxidant NAC, was visualized using light microscopy with 200x magnification (figure 1B). 
A 200 µM heme treatment resulted in rounding and detachment of the cells, while the cells 
were protected by NAC for this effect.
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5Figure 1. Assessment of cell survival in HEK293 cells after heme treatment. (A) Cells were treated for 48 h with heme (0-500 µM) and cell survival was determined using the MTT assay. Data are 
expressed as the mean ± SEM (N=6-8). Results were analyzed by non-linear regression (sigmoidal 
dose-response with variable slope). (B) Changes in cell morphology after 48 hours of heme (200 
µM) treatment and the protective effect of co-incubation with the cellular antioxidant NAC (6 mM) 
is visualized by light microscopy with 200x magnification.
Determination of heme-induced reactive oxygen species 
Exposing HEK293 cells to heme results in a dose-dependent ROS production (figure 2). After 
addition of the cellular antioxidant NAC, a significant decline in the amount of ROS produced 
by 3.0, 6.0, and 12.5 µM heme exposure was observed. Concentrations of heme above 12.5 
µM resulted in quenching of the ROS sensitive probe. By simultaneous addition of heme 
and the strong cellular antioxidant, bilirubin, a considerable attenuation in intracellular ROS 
production was observed at all heme concentrations. This indicates that bilirubin is a more 
powerful antioxidant than NAC.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
104
Chapter 5
Figure 2. Determination of intracellular ROS accumulation (after 30 min) in HEK293 cells directly 
after heme treatment. Cells were labeled with H2DCFDA prior to heme treatment (0-12.5 µM). 
200 µM H2O2 was used as a positive control to induce ROS production. ROS levels are presented 
as arbitrary fluorescence units. Data represent mean + SD of two independent replications, each 
condition was assayed in quadruplicate within an experiment. *** compared to medium (P<0.001); 
b compared to control within the same heme treatment group (P<0.01); c compared to control 
within the same heme treatment group (P<0.001).
Detection of oxidant-induced DNA damage
In view of the oxidative properties of heme, the comet assay was used to evaluate oxidative 
DNA damage in HEK293 cells (figure 3). Therefore, cells were treated for 48 h with heme 
(200 μM) in the absence or presence of NAC (6 mM) or bilirubin (30 μM). Figure 3B shows 
an induction of comet formation, indicating DNA damage, compared to the untreated group 
(P<0.05; Kruskal Wallis; n=20). The antioxidants NAC and bilirubin protected against heme-
induced DNA damage. Notably, however, the differences between the heme-treated group 
with and without NAC or bilirubin were rather small. This is in contradiction with results 
as presented in figure 2, where we observed that heme-induced ROS formation can be 
substantially reduced by NAC and bilirubin. 
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5Figure 3. Heme-induced DNA damage assessed by the comet-assay. HEK293 cells were treated for 
48 h with heme in the presence or absence of 6 mM NAC or 30 μM bilirubin. Cells were examined 
from undamaged DNA stage 0 to maximally damaged DNA stage 4. Panel A reflects representative 
comets for DNA damage stage 0-2 observed in this assay. Panel B represents individual DNA 
damage scores. * compared to control (P<0.05). 
Western blotting to assess expression of BCRP and HO-1 after baculovirus-mediated 
transductions
We examined the protein expression of HO-1 and BCRP in all baculovirus-mediated 
transduced HEK293 cells, 48 h, 72 h and 96 h after transduction. Treatment of HEK293 cells 
with baculovirus resulted in an induction of endogenous HO-1, independent of the type of 
baculovirus. This is shown in figure 4 were in EYFP/EYFP- and BCRP/EYFP-transduced cells 
the presence of HO-1 protein was detectable after 48 h. However, this figure also shows 
considerably higher HO-1 expression in the HO-1/EYFP- and BCRP/HO-1-transduced cells 
compared to the EYFP/EYFP- and BCRP/EYFP-transduced cells after 48 and 72 h. There is a 
substantial decrease in HO-1 expression over time in all groups to similar levels as the EYFP/
EYFP-transduced cells 96 h after transduction (figure 4A+B). Figure 5 shows the presence of 
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BCRP proteins in BCRP/EYFP- or BCRP/HO-1-transduced cells. Hardly no expression of BCRP 
was seen in EYFP/EYFP- and HO-1/EYFP-transduced cells. Baculovirus treatment resulted in 
a transient transduction of the cells with highest BCRP expression at 48 h after treatment, 
after which the expression decreased in time. After 96 h, the BCRP expression had decreased 
to approximately 50% of the level at 48 h, but was still high compared to EYFP/EYFP control 
(figure 5).
Figure 4. Effect of EYFP/EYFP, BCRP/EYFP, HO-1/EYFP and BCRP/HO-1 baculovirus transductions 
on the expression of HO-1 protein in HEK293 cells. (A) Whole cell lysates were obtained after 48, 
72 and 96 h of transduction to assess the protein expression of HO-1 and β-actin (housekeeping 
protein). One representative blot is shown for HO-1 and β-actin expression. (B) HO-1 expression 
was corrected for β-actin expression and compared to EYFP/EYFP. Data represent mean + SEM of 3 
(48 h) or 4 (72 and 96 h) independent experiments. 
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Figure 5. Effect of EYFP/EYFP, BCRP/EYFP, HO-1/EYFP and BCRP/HO-1 virus transductions on 
expression of BCRP proteins in HEK293 cells. (A) Total membrane fractions were harvested 
after 48, 72 and 96h of transduction to assess the protein expression of BCRP and β-actin. One 
representative blot is shown for BCRP and β-actin expression. (B) BCRP expression was corrected 
for β-actin expression expression and compared to EYFP/EYFP. Data represent the mean + SEM of 
2 (48 h) or 3 (72 and 96 h) independent experiments.
FTC increases the Hoechst33342 accumulation in BCRP-transduced HEK293 cells
To assess BCRP function in overexpressing HEK293 cells, the cells were incubated with 10 
µM of the fluorescent BCRP substrate Hoechst33342 in the presence or absence of the BCRP 
activity inhibitor FTC (10 µM). Subsequently, the Hoechst accumulation was assessed by flow 
cytometry. Figure 6A demonstrates the percentage of Hoechst negative cells, indicative of 
dye extrusion. When cells were incubated with FTC, 14.2 ± 1.9% of the cells were Hoechst 
negative (figure 6B), which is significantly less than cell samples that were not incubated with 
FTC (66.8 ± 2.8%). These results indicate that BCRP-mediated Hoechst33342 efflux could be 
largely inhibited by FTC.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
108
Chapter 5
Figure 6. Effect of FTC on Hoechst33342 accumulation of BCRP-transduced HEK293 cells analyzed by 
flow cytometry. Three days after transduction, the cells were incubated with 10 µM Hoechst33342 
for 45 min at 37°C. Prior to this, the cells were pre-incubated with the BCRP activity inhibitor 
FTC (10 µM) for 20 min. The percentage of Hoechst negative cells was determined as a measure 
of BCRP efflux activity. One representative experiment is shown in panel A; the experiment was 
performed in quadruplicate and depicted as the percentage of Hoechst negative cells + SD in panel 
B. An unpaired T-test was used for statistical testing; *** p<0.001.
Protective role of BCRP and HO-1 proteins in heme-induced cell death
The MTT-assay was used to assess whether an increased expression of BCRP, HO-1, or a 
combination of both influenced cell survival after exposure to heme. Cells were transduced 
with baculovirus and treated with heme (200 μM) for 48 h. Figure 7 demonstrates a 
significantly higher cell survival due to overexpression of BCRP, HO-1, or a combination 
of both proteins. Further, HO-1 shows to be more important in reducing heme-induced 
cytotoxicity than BCRP. Nevertheless, overexpression of both HO-1 and BCRP resulted in the 
highest protection against heme treatment, but there was only a slight difference (P<0.05) 
with HO-1-overexpression solely. 
After treating cells with a concentration range of heme (0-500 μM), the 50% reduction in cell 
survival (IC50 values) was determined by curve fitting, and is presented in Table 1. The IC50 
values confirm the protective role of BCRP and HO-1 against heme treatment. Fitted curves 
are presented in supplementary figure 1. 
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Figure 7. Assessment of cell survival in transduced HEK293 cells after heme treatment. EYFP/EYFP, 
BCRP/EYFP, HO-1/EYFP or BCRP/HO-1 proteins were overexpressed in HEK293 cells via baculovirus-
mediated transduction. 48 h after transduction, cells were treated with heme (200 μM) for 48 
h and cell survival was assessed using the MTT assay. Cell survival is expressed in percentages, 
relative to untreated cells. Data are presented as mean + SEM (N=3-4). # non-transduced cells 
compared to transduced cells (P<0.01); *** EYFP/EYFP transduced cells compared to all other 
transduced conditions (P<0.001). Comparisons between the specific combinations: * P<0.05; *** 
p<0.001 
Table 1. Assessment of cell survival in baculovirus-transduced HEK293 cells after treatment with 
hemea.
IC50 (µM)
No transduction 143 ± 1
EYFP/EYFP 165 ± 7
BCRP/EYFP 198 ± 10 **
HO-1/EYFP 234 ± 22 ***, ###
BCRP/HO-1 262 ± 52 ***, ###
aCells were transduced with EYFP/EYFP, BCRP/EYFP, HO-1/EYFP or BCRP/HO-1. 48 h after transduction, 
cells were treated with heme (0-500 μM) for 48 h and cell survival was assessed by using the MTT 
assay. The IC50 values (mean ± SEM, N=3-4) were calculated using non-linear regression analysis. 
ANOVA was used for statistical testing followed by Bonferroni’s multiple comparison: compared to 
no transduction ** (P<0.01), *** (P<0.001); compared to EYFP transduction ### (P<0.001). 
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Influence of BCRP and HO-1 activity inhibitors and the antioxidant NAC on heme-induced cell 
death
To test whether the protective effects of BCRP and HO-1 on heme-induced cytotoxicity could 
be diminished by specific inhibitors, FTC and SnMP were used to inhibit BCRP and HO-activity, 
respectively. Figure 8 shows the effect of the treatments on cell survival for each transduction 
group. SnMP or the combination of SnMP with FTC resulted in significantly lower cell survival 
rates in the cells transduced with BCRP/EYFP, HO-1/EYFP and BCRP/HO-1. Surprisingly, FTC 
alone did not reduce cell survival in the BCRP/EYFP and BCRP/HO-1 transduced cells. NAC co-
treatment demonstrated protection in all the baculovirus treatments.
Figure 8. At 48 h after transduction, cells were treated for another 48 h followed by cell survival 
assessment using the MTT assay. Effect of co-exposure to 10 µM FTC, 10 µM SnMP, 6 mM NAC or 
the combination of 10 µM FTC and 10 µM SnMP on survival of BCRP and/or HO-1-overexpressing 
HEK293 cells after treatment with 200 µM heme was measured. Cells were transduced with EYFP/
EYFP, BCRP/EYFP, HO-1/EYFP or BCRP/HO-1. Data represent mean + SEM (N=2-6). * P<0.05; ** 
P<0.01; *** P<0.001 compared to heme treatment solely. 
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Discussion
This study demonstrates that heme promotes ROS formation, DNA damage, and cell death 
in a dose-dependent manner in HEK293 cells. Heme-mediated toxic effects were attenuated 
when cells overexpressed the heme-degrading enzyme, HO-1, the heme efflux transporter, 
BCRP, or combinations thereof. The protective effect of HO-1 was most pronounced, and co-
treatment with an HO-activity inhibitor reversed this protective effect. In addition, exposure 
to antioxidants NAC or bilirubin protected cells from heme.
Heme has been found to be the causative and detrimental factor in the etiology of a wide 
variety of conditions, including hemolytic diseases35, hemoglobinopathies36,37, trauma, 
wound healing38,39, sepsis14, malaria12,13,40, pregnancy complications41, and renal failure19. 
The relatively high concentrations of heme used in the current study (0-500 µM) are within 
the range of those observed in an HO-1-deficient patient, with a reported serum heme 
concentration of 0.5 mM42, the concentrations in blood clots (0.4 mM)43, and in experimental 
models of heme overload4,5. Accumulating heme concentrations resulted in ROS formation 
and cellular injury, in agreement with previous investigations2,5,44, however, whether excessive 
heme also induces DNA damage is less well understood. Using the comet assay, we observed 
significant DNA damage after treatment of the cells with 200 μM heme. This is in agreement 
with an in vitro study that revealed nuclear damage after exposure to 50 μM heme in kidney 
cells.45 Furthermore, we showed that the antioxidants NAC and bilirubin attenuated this 
heme-induced DNA damage. 
Successful overexpression of BCRP, HO-1 or both was achieved using the baculovirus 
expression system, which is widely used for the functional expression of proteins in vitro, but 
its use in overexpressing HO-1 was not demonstrated earlier. Transduction of HEK293 cells 
resulted in a very high functional expression of HO-1 and BCRP, which was suitable to address 
our research questions. 
Since vital organs, such as the kidney, brain and liver, are highly sensitive to increased 
intracellular heme levels, it is important that the intracellular heme concentration is carefully 
regulated.2,4,6,27,36,39,46-48 Heme-binding proteins have been shown to lower intracellular free 
heme levels by scavenging heme with high affinity4,49, but the current study provides evidence 
for both BCRP and HO-1 as critical regulators of intracellular heme concentration. 
HO-1-overexpression protected against heme-induced cell death in HEK293 cells. We 
observed a significant increase in cell survival percentage in heme-treated HO-1/EYFP-
transduced HEK293 cells compared to heme-treated EYFP/EYFP-transduced (control) cells. 
Exposure to 200 μM heme increased the cell survival from approximately 25% (EYFP/EYFP-
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control) to 60% in HO-1-transduced HEK293 cells. Additionally, by inhibiting HO-activity using 
SnMP, this cell survival decreased significantly. This is in good agreement with other studies 
in which the protective role of HO-1 was demonstrated, such as in HO-1 knock-out mice and 
in a glycerol model in rats.18,19,50,51 In this glycerol model, rhabdomyolysis results in the release 
of a large amount of heme-proteins which accumulate in the kidney causing severe heme-
induced damage.20 
The present study shows for the first time the protective effects of overexpression of BCRP 
against the injurious actions of heme. BCRP is expressed in a variety of cells and tissues with 
a barrier function.52,53 Previously, we found BCRP expressed in the apical membrane of human 
kidney proximal tubules where it likely contributes to the urinary excretion of a diverse range 
of endogenous and exogenous xenobiotics and their metabolites.53,54 
Heme-induced cell death was significantly attenuated in BCRP/EYFP-transduced HEK293 cells 
compared to EYFP/EYFP (control)-transduced cells. After an exposure to 200 μM heme, cell 
survival increased from approximately 25% (EYFP/EYFP) to 50% in BCRP/EYFP-transduced 
cells. In addition, other studies demonstrated a role for BCRP in decreasing heme levels 
in erythroid maturation25 and decreasing heme accumulation under hypoxic conditions26. 
Surprisingly, FTC, which inhibits the activity of BCRP, did not affect cell survival, arguing against 
a prominent role for BCRP. However, when BCRP-mediated heme efflux may have hampered, 
BCRP could have functioned as a ‘heme-sink’ by shielding it and thereby rendering it inactive, 
similar to other heme-binding proteins.4,39 
Although the effect of transduction itself (EYFP/EYFP transduction-induced endogenous HO-
1) seemed small as judged from the IC50 values (165 ± 7 versus 143 ± 1; Table 1) and cell 
survival (figure 7), it may have larger effects in combination with other protective systems. 
In fact, figure 8 shows that BCRP and HO-1 can work together, since inhibition of HO-activity 
using SnMP in the setting with high BCRP levels demonstrates a significant decrease in cell 
rescue. Thus, under circumstances where baculovirus-induced endogenous HO-1 does not 
have to tackle the heme at its own, it is no longer overwhelmed by the high heme levels, but 
is able to significantly contribute to the BCRP-mediated protection against heme. 
Moreover, when HEK293 cells overexpressed both BCRP and HO-1 proteins we observed an 
additive effect of BCRP in protecting against heme-induced cell death compared to HO-1-
transduced cells alone. Again, suggesting a prominent role for both HO-1 and BCRP. But cell 
survival in the BCRP/HO-1-transduced cells was diminished by inhibition of HO-activity only 
and not by FTC treatment. In addition, in parallel experiments, we found that SnMP did not 
affect BCRP transport activity, indicating that the reduced cell survival after SnMP treatment 
of BCRP/HO-1 transduced cells is due to HO activity inhibition solely (data not shown). The 
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more dominant role for HO may be explained by its dual protection against heme-mediated 
damage. First, by the degradation of the pro-oxidant heme and secondly by the generation of 
the antioxidant bilirubin, the gasotransmitter carbon monoxide and the co-induction of the 
iron-scavenger ferritin.39 
Heme-induced ROS production, causes directly or indirectly (via the formation of DNA 
damage) cell death. When the redox balance in the cell is completely skewed by the ROS 
produced by the high levels of heme this will result in an environment where hardly survival 
is possible. Also mild induction of HO-1 levels is in that case not able to rescue (figure 8). 
However, when there are more players to restore the skewed redox balance than these 
cytoprotective proteins act together to fight the heme insult. 
The importance of restoring the redox balance is further underscored by a decrease in heme-
induced ROS formation by NAC. In baculovirus-transduced cells (EYFP/EYFP, BCRP/EYFP, HO-1/
EYFP and BCRP/HO-1), the addition of NAC resulted in significantly higher cell survival (figure 
8). Probably, cell survival increased due to attenuated ROS levels that were induced via heme-
mediated catalysis of the Fenton reaction. Additionally, simultaneous treatment of the cells 
with heme and NAC showed protection on the level of morphology and cell survival of HEK293 
cells. Furthermore, this protective effect of NAC could have clinical relevance in protecting 
against heme-induced cytotoxicity, although in vivo, NAC failed to protect against renal 
function impairment in the rat glycerol model.55 Interestingly, we recently demonstrated that 
experimentally-elevated bilirubin levels using atazanavir treatment caused both amelioration 
of vascular function and an improved redox status in type 2 diabetes mellitus patients56 
This suggests that bilirubin treatment may also protect against heme-induced toxicity and 
improve the redox status in a clinical setting.
In conclusion, both HO-1 and BCRP-overexpression protect cells from damage caused by 
heme, which may lead to novel therapeutic strategies for heme-mediated pathologies. 
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Supplemental figure 1. Assessment of cell survival in transduced HEK293 cells after heme 
treatment. Cells were transduced with EYFP/EYFP, BCRP/EYFP, HO-1/EYFP or BCRP/HO-1. 48 h after 
transduction, cells were treated with heme (0-500 μM) for 48 h and cell survival was assessed using 
the MTT assay. Results were analyzed by non-linear regression and IC50 values were calculated and 
are summarized in Table 1. Data are presented as mean ± SEM (N=3-4). 
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Abstract
Little is known about the transport of metabolites from the brain towards cerebrospinal 
fluid (CSF). We found the efflux transporter breast cancer resistance protein (BCRP) to 
be localized in the choroidal cell layer of the brain-CSF interface of murine brain. Next, 
we investigated the potential role of BCRP in regulating CSF composition. CSF of Bcrp-/- 
mice was compared to that of wild types by 1H-NMR analysis. Metabolites that differed 
in abundance were assessed for their effects on BCRP function. Furthermore, levels of 
the neuroactive compound kynurenic acid (KynA) was determined in plasma and brain 
homogenates and its effect on glucose uptake in malignant neuroblastoma (N2a) cells 
was determined. 1H-NMR analysis revealed that the concentration of glucose, glycine, 
creatine, alanine, and glutamine was altered in CSF in Bcrp-/- mice. Glucose was most 
discriminative and its concentration was significantly lower in the CSF compared to wild 
type mice. However, as neither glucose nor any of the other metabolites affected BCRP 
function, it seemed more likely that absence of the efflux transporter indirectly affected 
murine brain energy metabolism. KynA has been associated with energy metabolism 
disturbances and several neurological disorders. We identified KynA as a new BCRP 
substrate and elevated levels were found in plasma and brain homogenates of Bcrp-
deficient mice. Moreover, KynA was shown to increase glucose uptake into N2a cells in 
a concentration-dependent fashion. These findings provide evidence for a link between 
BCRP-mediated KynA transport and brain energy metabolism, suggesting that the efflux 
transporter could be a novel therapeutic target to modulate cerebral glucose and KynA 
levels.
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Introduction
Breast cancer resistance protein (BCRP/ACBG2) is a member of the ATP Binding Cassette (ABC) 
transporter superfamily and is involved in the active efflux of small molecules at the expense 
of ATP. BCRP is present in various tissues with a barrier function, including kidney, liver and 
brain, and is known to act as a transporter of several drugs and endogenous compounds, 
such as folate, riboflavin, urate and heme. In the brain, BCRP is localized in the blood-brain 
barrier (BBB) and in the choroid plexus (CP), the so-called blood-cerebrospinal fluid (CSF) 
barrier.1
Research on the role of BCRP in the brain has been predominantly focused on the restriction 
of drug penetration.1,2 Yet, little is known about the transport of substrates towards the 
CSF. The CSF provides a highly controlled and stable environment for the central nervous 
system and allows for homeostatic regulation by removal of metabolic waste, distribution 
of neuroendocrine factors and the exchange of fluids, electrolytes and nutrients between 
the CSF and brain interstitial fluid (ISF) at the ependymal interface.3 The subcommissural 
organ (SCO), one of the circumventricular tissues, represents the interface between the CSF 
and ISF. The SCO consists of choroidal cells that line part of the third ventricle and facilitates 
regulatory processes such as detection of monoamine and neuropeptide levels in the CSF. 
Moreover, the choroidal cells secrete glycoproteins into the CSF, which aggregate to form 
Reissner’s fibers and enable CSF flow.4 It is not known, as of yet, whether the SCO secretes 
other molecules into the CSF, nor has the presence of ABC transporters in the SCO been 
described. 
Transporters present at the blood-CSF and ISF-CSF barrier, may have a role either in the 
transport of nutrients from the blood into the CSF in order to provide the brain with its 
necessary fuel or in protecting the brain from waste products by transporting them from 
the ISF towards the CSF. So far, the role of Bcrp in the transport of endogenous substrates 
towards the CSF is yet unknown. In the present study, we assessed the localization of Bcrp 
at these barriers in murine brain slices. Furthermore, we aimed at investigating the potential 
role of BCRP in regulating CSF composition, which was explored by using CSF obtained from 
wild type and from a Bcrp-deficient mouse strain and comparative 1H-NMR analysis. Finally, 
murine neuroblastoma (N2a) cells were used to investigate the metabolic effects of the BCRP 
substrate KynA, which is potentially involved in brain energy metabolism disturbances. Our 
data suggest that BCRP may be a novel therapeutic target to modulate cerebral glucose and 
KynA levels.
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Materials and methods 
Immunohistochemistry
All procedures involving animals were approved by the Animal Experimental Committee of 
RUNMC. The wild type Friend leukemia virus B (FVB) and Bcrp-/- mice were kindly provided by Dr. 
A. Schinkel (Netherlands Cancer Institute, Amsterdam, the Netherlands) and bred and housed 
at the Central Animal Laboratory of RUNMC. Localization of Bcrp in the circumventricular 
organs was assessed by immunohistochemistry as previously described, as was the quality and 
specificity of the used antibody which was assessed using tissues from Bcrp-/- mice.5 In brief, 
perfusion-fixed, paraffin embedded brain-sections of male wild type mice were incubated 
with a primary antibody against mouse Bcrp (BXP-9). Diaminobenzidin was used to visualize 
Bcrp localization. The sections were prepared and structures were localized using the Mouse 
Brain Library.6 For P-glycoprotein (P-gp) staining, we used the mouse monoclonal antibody 
JSB-1 (Abcam ab3366; diluted 1:20). Sections were incubated for 1h at room temperature, 
followed by incubation with a biotin conjugated secondary antibody (rabbit anti-mouse IgG, 
Agrisera AS09 609; diluted 1:500) for 1h at room temperature. Detection was carried out 
with the streptavidin-biotin immunoperoxidase method and diaminobenzidin substrate for 
visualization. After counterstaining with hematoxylin, the slides were mounted. For negative 
control, the primary antibody was omitted. 
CSF sampling, sample preparation and data acquisition
The composition of the CSF from male wild type mice was compared to that of male Bcrp-/- 
mice by 1H-nuclear magnetic resonance (1H-NMR) spectroscopy. CSF samples were taken 
from the cisterna magna, using a method described elsewhere.7 The mice (N=8) were 
anesthesized with an intraperitoneal injection of 144 mg/kg pentobarbital (Nembutal®, 
15 mg/ml) and fixed in a stereotaxic instrument. After opening the skin, the subcutaneous 
tissue and muscles were separated. The dura mater was penetrated with a glass capillary 
and CSF was withdrawn. The mice were sacrificed by cervical dislocation and, subsequently, 
blood and relevant organs were collected, snap frozen in liquid nitrogen and stored at -80 °C. 
CSF samples were prepared for 1H-NMR measurement by addition of 3 µl 10 mM TSP-d4 
(sodium-3-(trimethylsilyl)propionate-2,2,3,3-d4) in heavy water (D2O) and 327 µl 100 mM 
potassium phosphate buffer (pH 7.4) in D2O. 250 µl was transferred into a 5 mm symmetrical 
microtube (Shigemi Inc.) susceptibility-matched to D2O. 
1H-NMR spectra were acquired at 
298K on an Avance-III spectrometer (Bruker BioSpin, Billerica, MA, USA) operating at 14.1 
T (599.76 MHz 1H Larmor frequency) equipped with a 5 mm CP-TCI probe with Z-gradient, 
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an automatic tuning-matching unit and sample changer. Samples were kept for 300 s inside 
the probe-head for temperature equilibration. One dimensional NOESY-presat (Bruker pulse 
sequence noesygppr1d), to suppress the solvent resonance, were recorded with 512 scans, 
10 ms mixing time and 4 s relaxation delay. The spectra were recorded using a 64K size FID 
and a spectral width of 12 ppm, resulting in an acquisition time of 4.6 s. Data was zero-filled 
and multiplied with an exponential window function prior to Fourier transformation. After 
data acquisition, the samples were stored at 4 °C until further analysis. 
Preprocessing of 1H-NMR spectra and data analysis
Sixteen spectra were pre-processed. Due to blood contamination four spectra were not 
suitable for data analysis, leaving N=6 per strain. Baseline-correction was performed by 
applying Asymmetric Least Squares method.8 Spectra were aligned by using Correlation 
Optimizing Warping (COW) method9 and binned to reduce the number of variables by adaptive 
intelligent binning10 in the chemical shift range δ 0.75 – 4.15. To facilitate the comparison 
between different samples, integral normalization and autoscaling were applied. In order to 
focus on the significant variables of the numerically complex NMR data, we applied the cross 
model validation (CMV) procedure.11,12 Principal Component Analysis (PCA) was then applied 
to the set of significant variables to extract and display the systematic variation in the data.13 
PCA converts the multidimensional data space into a low-dimensional model plane and 
expresses most of the variance within a dataset using a smaller number of factors, so called 
principal components (PCs). Each PC is orthogonal and therefore independent of other PCs.
Metabolite identification
Metabolites were identified using the 600 MHz library of metabolite spectra from the 
Chenomx NMR Suite 7.0, which is predicted based on a database of pure compound spectra 
acquired using particular pulse sequence and acquisition parameters.14 The software fits the 
spectral signatures of a compound from an internal database of reference spectra to the 
experimental spectrum. To avoid misidentification, the resonance assignments were further 
checked against literatures spectra15 and spectra in the Human Metabolome Database16.
Preparation of membrane vesicle, inhibition assays and KynA uptake experiments 
The methods for the overexpression of human BCRP in human embryonic kidney (HEK293) 
cells using baculoviruses (produced using the Bac-to-Bac system; Invitrogen, Breda, the 
Netherlands), the preparation of membrane vesicles and inhibition of BCRP-mediated 
3H-estrone sulfate (3H-E1S; 250 nM) uptake into vesicles were described earlier.
5 Uptake of 
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KynA into the membrane vesicles was determined by incubating membrane vesicles with 100 
µM KynA for 5 min at 37 0C in the presence of AMP or ATP. Vesicles were washed by means 
of a rapid filtration technique using 96-well polyvinylidene difluoride filter plates (Millipore, 
Etten-Leur, the Netherlands). KynA uptake into the vesicles was determined by LC-MS/MS.
KynA measurements by LC-MS/MS
After the completion of the vesicle uptake experiments, KynA was extracted from the filters 
in 3.3 % perchloric acid. Diluted CSF samples were used after 1H-NMR analysis and plasma 
samples were diluted in H2O (1:1) prior to LC-MS/MS measurements. The brains were cut 
longitudinally and one half was homogenized in H2O using a micropestle. All samples were 
deproteinized with perchloric acid (final concentration 3.3 %) and centrifuged at 12,000 x 
g for 3 min. Deuterated KynA was added as an internal standard for quantification. Clear 
supernatant was injected into the LC-MS/MS system and KynA measurements were 
performed as published earlier.17
Plasma glucose measurements
Plasma glucose levels were measured using a glucose oxidation method (Beckman Glucose 
Analyser II, Beckman Instruments, Fullerton, CA, USA).
Energy metabolism experiments
Murine neuro-2a (N2a) malignant neuroblastoma cells (ATCC #ccl-131, Manassas, VA, US) 
were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with high glucose containing 
10 % fetal calf serum (FCS; MP Biomedicals, Uden, the Netherlands). For experiments, cells 
were seeded at 50 % confluency in a 96-well plate. After 6 h, medium was replaced with 
low glucose (5 mM) DMEM, supplemented with 10 % dialyzed FCS and incubated overnight. 
Subsequently, cells were exposed to KynA (0-2000 µM) in low glucose DMEM. After 3 h, 
glucose concentrations in collected media were determined using the Amplex Red glucose 
oxidase assay kit (Invitrogen, Breda, the Netherlands). 
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Results 
Localization of Bcrp in murine brain
Immunohistochemistry on wild type brain sections was performed to reveal localization of 
Bcrp (figure 1). Figure 1a shows a frontal section of the brain with Bcrp positive staining of the 
CP, SCO and arachnoid barrier (the negative control for antibody specificity is shown in figure 
1g). In the CP, Bcrp is located at the ventricular side of ependymal cells facing the CSF (figure 
1b,d). The choroidal cells that face the CSF in murine brain SCO also showed clear staining 
associated with the apical membrane of the ependymal cell surface (figure 1c,e). Besides, 
there was staining associated with the basal and lateral membranes of these cells, which was 
clearly not observed in the CP (figure 1e). Other circumventricular organs, not containing an 
ependymal interface between brain and CSF (i.e. area postrema, pineal gland, subfornical 
organ, median eminence and organum vasculosum lamina terminalis) were negative for 
Bcrp staining (see supplementary figure 1). Besides, significant Bcrp staining was found in 
brain capillaries forming the BBB (figure 1b-c, depicted with arrows). As recently reported by 
Yasuda et al.18, the arachnoid barrier also showed clear Bcrp expression (figure 1f), as well 
as of the related ABC transporter P-glycoprotein (P-gp; ABCB1; figure 2). P-gp staining was 
further confirmed in CP (figure 2a versus 2b negative control) and BBB (figure 2d), but not in 
SCO (figure 2c). These data suggest that Bcrp could play a prominent role in CSF homeostasis.
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Figure 1. Bcrp expression in the murine brain. Immunochemical staining using an anti-Bcrp antibody 
shows expression in a frontal section of the murine brain (a) with Bcrp-positive staining in choroid 
plexus, SCO and arachnoid barriers. Bcrp is localized to the ventricular side of the ependymal cells 
of the CP (b, d) in the choroidal cells that face the CSF (*) of the SCO (c, e), and in arachnoid barrier 
cells (f). The corresponding negative control for Bcrp-specific SCO staining was obtained after 
incubating sections with the secondary antibody solely (e). Arrows show capillaries. Bars represent 
500 µm (a), 200 µm (b,c), 20 µm (d,e) or 100 µm (f,g). 
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Figure 2. P-gp expression in the murine brain. Immunochemical staining using an anti-P-gp 
antibody shows expression of P-gp in CP (a), BBB and arachnoid barrier (AB) (d), but not in SCO (c). 
The corresponding negative control for P-gp-specific CP staining (b) was obtained after incubating 
sections with the secondary antibody solely. Bars represent 20 µm (a, b, d) or 50 µm (c). 
Comparison of CSF composition between wild type and Bcrp-/- mice
To investigate the role of Bcrp in the transport of endogenous substrates towards the CSF, we 
compared CSF composition of wild type and Bcrp-/- mice. CSF samples were withdrawn from 
the cisterna magna (figure 3a), with a yield of 2-11 µl clear fluid per mouse, and analyzed by 
1H-NMR spectroscopy. The spectra obtained were divided into 237 bins, containing resonances 
of approximately 30 identified metabolites. A representative spectrum is shown in figure 3b. 
One metabolite can be represented by several resonances (peaks) in the spectrum. The most 
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informative variables corresponded to twenty-five NMR resonances. The resulting PCA biplot, 
defined by PC1 and PC2, shows each resonance as represented by a line drawn from the origin 
towards the corresponding PC1/PC2 level (figure 3c). Based on the position of the individual 
mice, we assessed whether the specific resonance was different between the two groups. 
The direction of the presented lines indicated whether the metabolites, represented by the 
specific resonances, were either decreased or increased in CSF of the wild type compared 
to Bcrp-/- mice. A clear separation between the two groups was found, mostly along PC1 
which explained 69.7 % of total variance in the data, indicating differences in concentrations 
of metabolites involved in cellular energy metabolism. The resonances pointing towards 
negative PC1 levels indicated lower peak intensities and, thus, lower concentrations of 
the metabolites in wild type compared to Bcrp-/- mice and correspond to glycine, creatine 
and alanine. The opposite applied for another set of resonances, corresponding to glucose 
and glutamine. A boxplot was established per metabolite, from either one (figure 3d,f,h) or 
multiple (figure 3e,g) corresponding resonances. Our data revealed that glucose was most 
discriminative between the two strains; its concentration was significantly lower in the CSF of 
Bcrp-/- mice, compared to wild types (P=0.007).
Effects of identified metabolites on BCRP activity
To verify the interaction between the metabolites identified by 1H-NMR analysis and BCRP 
transport function, we used a previously established method in which the uptake of BCRP 
substrate E1S in membrane vesicles overexpressing the transporter was measured (figure 4a). 
As shown in figure 4b, none of the metabolites tested inhibited BCRP-mediated E1S uptake, 
suggesting that these metabolites do not interact with the efflux transporter. These results 
indicate that Bcrp alters glucose levels in the brain potentially via an indirect mechanism 
involving other substrates. A likely candidate is KynA, an end product of tryptophan 
metabolism, which has been correlated with brain energy metabolism disturbances and 
recently shown to inhibit BCRP activity17.
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Figure 4. Effects of metabolites on BCRP transport activity. BCRP transport activity was assessed 
after incubating mock or BCRP-overexpressing membrane vesicles with 250 nM 3H-estrone sulfate 
(E1S) for 5 minutes in the presence of AMP or ATP (a). Indicated metabolites did not affect net 
BCRP-mediated E1S uptake, expressed as percentage of negative control (b). One-way ANOVA 
followed by Dunnett’s post hoc test was used for statistical analysis. Bars represent means + SEM 
of triplicate experiments.
KynA and brain glucose uptake
The decreased CSF glucose concentrations observed in the CSF of Bcrp-/- mice did not 
coincide with a difference in plasma glucose levels (figure 5a), suggesting that the difference 
in CSF glucose concentrations might originate from the brain. To determine a role for KynA in 
glucose metabolism, we first determined its levels in plasma and brain homogenates using 
LC-MS/MS analysis. KynA levels were significantly elevated in plasma of Bcrp-deficient mice, 
150 ± 20 nM versus 86 ± 12 in wild types (figure 5b). Elevated KynA levels were also observed 
in brain homogenates of Bcrp-/- mice (4.2 ± 0.6 versus 2.7 ± 0.2 in wild types; figure 5c). 
Unfortunately, we were not able to detect KynA in murine CSF samples because the diluted 
samples that were necessary for the 1H-NMR spectroscopy did not exceed the KynA detection 
limit of the LC-MS/MS analysis.
To assess whether KynA is a substrate for BCRP, membrane vesicles overexpressing the 
transporter were incubated with KynA and uptake was, subsequently, determined by LC-MS/
MS analysis. We clearly observed ATP-dependent transport for KynA, which was significantly 
different in vesicles incubated with KynA in presence of ATP from vesicles incubated in absence 
of ATP and from controls (mock transduced; figure 5d). Together, these data confirmed that 
KynA is an endogenous substrate for BCRP. 
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Next, we determined whether KynA could also influence brain glucose homeostastis. The 
effects of KynA on glucose uptake were assessed using malignant neuroblastoma (N2a) cells. 
After 3 h of exposure to KynA in low glucose medium, a clear increase in glucose uptake 
by these cells was observed (figure 5e). This effect was dependent on KynA concentration 
with 200 and 2000 µM causing a more than 100 % increase of glucose uptake compared to 
unexposed cells. Thus, increased Kyna levels in absence of Bcrp are a likely explanation for the 
disturbed glucose homeostasis in CSF of transporter-deficient mice.
Figure 5. Glucose and KynA parameters, BCRP-mediated KynA uptake and glucose uptake in N2a 
cells. Plasma glucose levels of wild type (N=11) and Bcrp-/- (N=7) mice were measured using a 
glucose oxidation method (a). KynA levels in plasma (b; N=13) and brain homogenates (c; N=5) 
were determined by LC-MS/MS analysis. BCRP-mediated KynA uptake (d) was assessed after 
incubating membrane vesicles with KynA in the presence of AMP or ATP. Malignant neuroblastoma 
(N2a) cells were exposed to KynA in low glucose (5 mM) medium and after 3h, glucose uptake was 
calculated by subtracting glucose levels from levels at t=0 (e). Bars represent means + SEM (a-c) 
of triplicate experiments (d) or a representative of three independent experiments (e). Statistical 
tests; two-tailed Student’s t-test (a-c), one-way ANOVA followed by Dunnett’s post hoc test (d,e).
Discussion 
We describe an important putative new role for the efflux transporter BCRP in the brain, i.e. 
regulating KynA levels and thereby influencing key neuronal processes. Moreover, we are 
the first to show specific Bcrp expression at the brain-CSF interface, in the SCO. Bcrp was 
mainly located at the ventricular side of ependymal cells facing the CSF, indicating a potential 
role for the transporter in the maintenance of a stable environment for the central nervous 
system. In the SCO, Bcrp was also expressed at the basolateral and lateral membranes of the 
choroidal cells. Therefore, Bcrp could potentially be responsible for a two-directional transport 
towards the CSF as well as towards the ISF, however, Bcrp expression at the basolateral and 
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lateral membranes was much lower than at the ventricular side. The presence of any ABC 
transporter in the SCO has never been described and we also did not observe P-gp-specific 
staining, suggesting a specific but yet unkown function for Bcrp. Circumventricular organs, 
such as the SCO, are located in the walls of the lateral 3th or 4th cerebral ventricles and are the 
most vascularized tissues in the brain that allow bidirectional movement of (polar) molecules 
between blood and CSF. Localization of Bcrp in the BBB and in the CP, representing the blood-
CSF barrier, has been demonstrated here and/or previously.5,19 Furthermore, the presence of 
Bcrp was recently shown at the arachnoid barrier (AB), another part of the blood-CSF barrier.18 
Interestingly, its direction of transport is different in both barriers. In the BBB, the luminally-
located Bcrp facilitates efflux of substrates into blood, while Bcrp transports substrates 
from blood towards CSF in the CP and AB cell layers.1,20 Considering its localization in the 
brain, Bcrp potentially influences the central nervous system’s homeostatic environment, 
however, nothing is known about its role in the transport of endogenous substrates towards 
CSF. Therefore, we compared the CSF of wild type and Bcrp-/- mice by 1H-NMR spectroscopy. 
This technique is very suitable to analyze and compare biological samples when there is 
no specific lead. We aimed to compare CSF samples based on a broad range of molecules, 
since Bcrp has a wide variety of substrates. The drawback of using murine CSF samples, 
obviously, is the limited volume obtained from one animal and, as a consequence, we were 
only able to detect molecules that were present in the µmolar range. Moreover, the high 
dilution of the CSF samples, needed to allow spectroscopy, may have been a limitation for 
some Bcrp substrates to be detected. Our results did reveal different concentrations of 
metabolites involved in cellular energy metabolism. Glucose was most discriminative and its 
concentration was significantly lower in CSF of Bcrp-/- mice. However, it is unlikely that glucose 
is a substrate based upon archetypical Bcrp-substrate-specific characteristics.21 Moreover, 
glucose is efficiently transported towards the ISF by the glucose transporter-1 (GLUT1), which 
is abundantly present in the BBB.3 Indeed, glucose did not inhibit vesicular BCRP transport 
activity nor did the other metabolites identified by 1H-NMR analysis, suggesting that these 
metabolites are not transported by the efflux transporter. Hence, we propose that Bcrp alters 
glucose levels in the brain via an indirect mechanism. 
Glucose is the principal energy source for the mammalian brain and a continuous supply 
is essential to maintain cerebral function and, therefore, it is dynamically exchanged 
between blood, CSF and ISF.22 The decreased CSF glucose concentrations observed in 
Bcrp-/- mice suggest increased glucose utilization by the brain since plasma glucose levels 
were not changed. A likely candidate, which has been correlated with energy metabolism 
disturbances23,24 and found to inhibit BCRP activity17, is KynA, an end product of tryptophan 
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metabolism. In the mammalian brain, astrocytes facilitate the conversion of kynurenine 
into KynA via kynurenine aminotransferase-II. Once synthesized, KynA is promptly released 
into the ISF where it affects its postsynaptic neuronal targets, therefore, KynA levels in brain 
homogenates mainly represent KynA levels in the ISF.25 We found significantly elevated KynA 
levels in plasma and brain homogenates of Bcrp-deficient mice. Using a well-established 
membrane vesicle uptake assay, we confirmed that KynA is a substrate for human BCRP. 
Consequently, the elevated KynA plasma levels observed in mice can be partially explained by 
the lack of Bcrp-mediated renal clearance26, however, the elevated levels of this metabolite 
in the brain must be due to the absence of Bcrp in this organ. Remarkably, no change in 
brain/plasma ratio was found between wild type and Bcrp-deficient mice, indicating that 
also other transporters are involved in the regulation of KynA distribution. A potential other 
KynA transporter is MRP4, for which an interaction with KynA has been described17,27 and 
which was found to be present in the BBB and CP28. Nevertheless, Bcrp is the major KynA 
efflux transporter described thus far and we demonstrated that it is capable of influencing 
KynA distribution in vivo, which makes it an interesting target in influencing several neuronal 
processes. As mentioned previously, KynA has been correlated with energy metabolism 
disturbances in heart mitochondria23,29 and rat cerebral cortex24. We evaluated whether KynA 
could affect glucose uptake using malignant neuroblastoma cells. After 3 h of exposure to 
KynA in low glucose medium, a clear concentration-dependent increase in glucose uptake 
was observed, indicating increased glucose utilization by these cells. In accordance, Schuck 
et al.24 reported increased glucose uptake after exposing rat cerebral cortex to KynA in vitro. 
They proposed that KynA interferes with the citric acid cycle, leading to increased glucose 
utilization (i.e. glycolysis) to compensate for the energy deficit, and our results support this 
hypothesis. On the other hand, Hodgkins et al.30 found a link between the decrease in KynA 
levels during hypoglycaemia and cellular energy metabolism in rat cortical tissue and showed 
that this decrease could be effectively reversed by lactate or pyruvate. Further investigation 
is needed to gain more insight into the mechanism by which KynA triggers glycolysis in the 
brain. 
Besides the effect on energy metabolism, multiple actions of KynA in the brain have been 
described, including interferences with cholinergic, glutamatergic and dopaminergic 
neurotransmission by antagonizing the α7-nicotinic-acetylcholine- (α7nAch-) and the 
N-methyl-d-aspartate- (NMDA-) receptor.31,32 KynA suppresses the presynap tic release of 
glutamate by binding to the α7nAch-receptor and it counteracts glutamate-mediated the 
NMDA-receptor activation.33 Neuronal disorders, as observed with Alzheimer’s disease and 
schizophrenia, are associated with increased KynA levels in the brain. In these cases, KynA 
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leads to a hypoglutamatergic state which induces many of the cardinal symptoms.34,35 Under 
physiological conditions, mammalian astrocytes facilitate the conversion of kynurenine 
into KynA via kynurenine aminotransferase-II (KATII). Elevation in brain KynA concentration 
can result in cognitive impairment34,36, however, under some pathological conditions, KynA 
has neuroprotective properties by counteracting glutamate excitotoxicity, for example in 
Huntington’s and Alzheimer’s disease. Because of the potent antiglutamatergic features 
of KynA, it has earned greater interest as an attractive pharmacological target to treat 
neurological disorders. In this respect, and because of its ability to influence brain energy 
metabolism, tight regulation of this metabolite is of key importance and our results indicate 
that BCRP/Bcrp could play a role in this. Bcrp-deficient mice are viable and besides sensitivity 
to the dietary chlorophyll-breakdown product phenophorbide a37, no severe abnormalities 
linked to developmental or neurological disorders have been described. Nevertheless, this 
does not imply that Bcrp-deficiency could not lead to subtle neurological effects, which, 
to our knowledge, have never been tested in these mice. Still, one should not neglect the 
complex consequences related to transporter deficiency in knockout animals. Besides, the 
link between brain glucose levels, KynA and Bcrp warrants further research to demonstrate 
a direct relation.
In conclusion, we describe a possible new role for BCRP/Bcrp in the brain, i.e. regulating 
KynA levels and thereby influencing key neuronal processes. We suggest that BCRP could be 
a potential novel therapeutic target to modulate KynA-mediated pathologies associated with 
cerebral glucose homeostasis.
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Supplementary figure 1. Circumventricular organs negative for Bcrp staining. These organs do not 
contain an ependymal interface between brain and CSF, and include the area postrema (a), pineal 
gland (b), median eminence (c), subfornical organ (d) and organum vasculosum lamina terminalis 
(e). Bars represent 100 µm (a) or 200 µm (b-e).

7
Hyperuricemia influences tryptophan metabolism via inhibition of 
multidrug resistance protein 4 and breast cancer resistance protein
Anita C.A. Dankers1*, Henricus A.M. Mutsaers1,2*, Henry B.P.M. Dijkman3, 
Lambertus P. van den Heuvel4,5, Joost G. Hoenderop2, Fred C.G.J. Sweep6, 
Frans G.M. Russel1, Rosalinde Masereeuw1
1 Department of Pharmacology and Toxicology, Radboudumc, Nijmegen, the Netherlands
2 Department of Physiology, Radboudumc, Nijmegen, the Netherlands
3 Department of Pathology, Radboudumc, Nijmegen, the Netherlands
4 Department of Pediatrics, Radboudumc, Nijmegen, the Netherlands
5 Department of Pediatrics, Catholic University Leuven, Leuven, Belgium
6 Department of Laboratory Medicine, Radboudumc, Nijmegen, the Netherlands
* These authors contributed equally
Biochim Biophys Acta. 2013 Oct;1832(10):1715-22.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
140
Chapter 7
Abstract
Hyperuricemia is related to a variety of pathologies, including chronic kidney disease 
(CKD). However, the pathophysiological mechanisms underlying disease development 
are not yet fully elucidated. Here, we studied the effect of hyperuricemia on tryptophan 
metabolism and the potential role herein of two important uric acid efflux transporters, 
multidrug resistance protein 4 (MRP4) and breast cancer resistance protein (BCRP). 
Hyperuricemia was induced in mice by treatment with the uricase inhibitor oxonic acid, 
confirmed by the presence of urate crystals in the urine of treated animals. A transport 
assay, using membrane vesicles of cells overexpressing the transporters, revealed that uric 
acid inhibited substrate-specific transport by BCRP at clinically relevant concentrations 
(calculated IC50 value: 365 ± 13 µM), as was previously reported for MRP4. Moreover, 
we identified kynurenic acid as a novel substrate for MRP4 and BCRP. This finding was 
corroborated by increased plasma levels of kynurenic acid observed in Mrp4-/- (107 ± 19 
nM; P=0.145) and Bcrp-/- mice (133 ± 10 nM; P=0.0007) compared to wild type animals 
(71 ± 11 nM). Hyperuricemia was associated with >1.5 fold increase in plasma kynurenine 
levels in all strains. Moreover, hyperuricemia led to elevated plasma kynurenic acid 
levels (128 ± 13 nM, P=0.005) in wild type mice but did not further increase kynurenic 
acid levels in knockout mice. Based on our results, we postulate that elevated uric acid 
levels hamper MRP4 and BCRP functioning, thereby promoting the retention of other 
potentially toxic substrates, including kynurenic acid, which could contribute to the 
development of CKD.
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Introduction
Uric acid is a weak organic acid and the end product of purine nucleotides degradation in 
humans. One of the enzymes involved in this process is xanthine oxidoreductase, which 
enables the oxidation of hypoxanthine to xanthine and can further catalyze the oxidation 
of xanthine to uric acid. During this reaction, reactive oxygen species are generated as by-
product.1,2 Therefore, uric acid is recognized as a marker for oxidative stress. However, the 
molecule itself has antioxidant properties and can act as a free radical scavenger and chelator 
of transitional metal ions which are converted into poorly reactive forms.3 Hyperuricemia, i.e. 
elevated plasma uric acid levels (≥ 360 µM)4, is related to a variety of pathologies, including 
gout, cardiovascular disease and chronic kidney disease (CKD). Gout is the most common form 
of inflammatory arthritis caused by sodium uric acid crystal precipitation, which is followed 
by phagocytosis of the crystals by neutrophils and macrophages and activation of acute 
inflammation and tissue injury.5 Epidemiological studies show that prevalence and incidence 
are still increasing.6,7 Formation of uric acid crystals is also the cause of nephrolithiasis, i.e. 
kidney stones, which is significantly more common among patients diagnosed with metabolic 
syndrome, obesity and type 2 diabetes.8 Hyperuricemia also correlates with the development 
and progression of cardiovascular diseases9-11, potentially via interfering with nitric oxide 
function. In animal models, it has been shown that mild hyperuricemia contributes to the 
development of hypertension as a result of endothelial dysfunction and reduction of nitric 
oxide levels.10,12,13 Recently, hyperuricemia has received attention as a possible risk factor for 
CKD4,14, which affects approximately 10% of the adult population in developed countries.15 
Hyperuricemia has been associated with a hazard ratio of 2.1 and 1.3 for men and women for 
developing CKD4, respectively. Several mechanisms were proposed via which uric acid could 
contribute to the development of CKD, including uric acid-induced glomerular hypertrophy 
and endothelial dysfunction.4,16 However, the pathophysiological mechanism has as of yet not 
been fully elucidated.
In healthy individuals, two-thirds of uric acid is excreted by the kidney and one-third by the 
intestine due to breakdown of urate by gut bacteria. Purine ingestion, endogenous synthesis 
of purines from nonpurine precursors and reutilization of preformed purine compounds 
are the sources of uric acid production, a process that, under steady-state conditions, is in 
balance with the uric acid disposal.17,18 Hyperuricemia can develop due to overproduction or 
a diminished excretion of uric acid. Maintaining uric acid homeostasis is highly dependent on 
kidney function and regulated by a number of transporters, including the urate transporter 
1 (URAT1: SLC22A12) - responsible for up to 99% of uric acid reabsorption after glomerular 
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filtration - the facilitated glucose transporter (solute carrier family 2 member 9 (SLC2A9)19, 
several organic anion transporters including OAT1 (SLC22A6) and OAT3 (SLC22A8)5, and the 
ATP-dependent urate efflux transporters multidrug resistance protein 4 (MRP4: ABCC4)20 and 
breast cancer resistance protein (BCRP: ABCG2)21-23. 
As uric acid is one of the important factors in a variety of pathologies, tight regulation of 
this metabolite is of key importance. The vital role of transporters in uric acid homeostasis 
can clearly be observed in patients suffering from hyperuricemia due to single nucleotide 
polymorphisms (SNPs) that render the transporters inactive, such as the common SNP C421A 
encoding the Q141K mutation of BCRP21,22,24 and several genetic variants for SLC2A919. Next 
to genetic factors, high plasma levels of uric acid might also result in a reduced transporter 
activity.20 Since these transporters are also involved in the excretion of a wide variety of 
other compounds, changes in transport efficacy could result in metabolic disturbances. 
This hypothesis is corroborated by two recent studies showing that high uric acid levels in 
patients with acute gout were associated with altered tryptophan concentrations in plasma 
and urine.25,26 Therefore, the aim of our study was to investigate the effect of hyperuricemia 
on tryptophan metabolism and the potential role herein of two important uric acid efflux 
transporters, MRP4 and BCRP. Both transporters are expressed in the apical membrane of 
renal proximal tubule cells, amongst other tissues, and are involved in the urinary excretion 
of a multitude of endogenous compounds and drugs.27 Using Mrp4-/- and Bcrp-/- mice, we 
show that hyperuricemia is associated with the accumulation of tryptophan and associated 
metabolites, most likely due to transporter dysfunction. 
Material and methods
Transduction of Human Embryonic Kidney cells and preparation of membrane vesicles
Overexpression of MRP4 and BCRP in human embryonic kidney cells (HEK293: American 
Type Culture Collection, Manassas, VA) was established using baculoviruses, which were 
produced using the Bac-to-Bac and the Gateway system (Invitrogen, the Netherlands), as 
described previously.28,29 As a control, the enhanced yellow fluorescent protein (eYFP) was 
introduced as mock protein into the baculovirus expression system. Crude membranes of 
HEK293-MRP4, -BCRP and -mock cells were isolated, resuspended in TS buffer (10 mM Tris-
HEPES and 250 mM sucrose, pH 7.4) and membrane vesicles were prepared according to a 
previously described method28 by means of ultracentrifugation. Crude membrane vesicles 
were dispensed in aliquots, snap frozen in liquid nitrogen, and stored at -80 °C until further 
use.
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Membrane vesicle inhibition and uptake assays
The effects of uric acid and oxonic acid on MRP4 and/or BCRP activity were assessed by a 
well-established assay in our laboratory.28-31 In brief, a reaction mix consisting of TS buffer 
supplemented with 4 mM ATP/AMP, 10 mM MgCl2 and 250 nM [
3H]-methotrexate (MTX for 
MRP4) or [3H]-estrone sulfate (E1S for BCRP) at pH 7.4 was added to 7.5 µg of membrane 
vesicles (based on total protein content). After incubation at 37 ºC to enable ATP-dependent 
uptake, the reaction was stopped by placing the samples on ice and by addition of ice-cold TS 
buffer. Reaction mix was removed and the vesicles were washed by means of a rapid filtration 
technique using filter plates (Millipore, Etten-Leur, the Netherlands). Scintillation fluid was 
added to the filters and the amount of radioactivity was determined using a scintillation 
counter (Tri-Carb® 2900TR: Perkin Elmer, Waltham, MA, USA). Reference samples were 
measured to calculate the amount of transported MTX and E1S. ATP-dependent transport was 
calculated by subtracting values measured in the presence of AMP from those measured in 
the presence of ATP. Net transporter-mediated substrate uptake was calculated by subtracting 
ATP-dependent uptake in HEK293-mock vesicles from that of HEK293-transporter vesicles. 
Uptake of kynurenic acid into MRP4-overexpressing membrane vesicles was established 
using the same assay. Vesicles were incubated with 0.1 mM kynurenic acid in the presence of 
AMP or ATP. After the described washing step, kynurenic acid was determined by LC-MS/MS. 
Oxonic acid-mediated induction of hyperuricemia in mice
All experiments were approved by the local Animal Welfare Committee of the Radboudumc 
(RU-DEC 2012-018), in accordance with the directive for animal experiments (2010/63/EU) 
of the European Parliament. The effects of hyperuricemia in vivo were examined in wild type 
Friend leukemia virus B (FVB) mice as well as Mrp4-/- and Bcrp-/- mice (both FVB background). 
The wild type FVB and Bcrp-/- mice were kindly provided by Dr. A. Schinkel (Netherlands 
Cancer Institute, Amsterdam, the Netherlands) and the Mrp4-/- mice by Dr. J. Schuetz (St. 
Jude Children’s Research Hospital, Memphis, TN, USA) and Dr. P. Borst (Netherlands Cancer 
Institute, Amsterdam, the Netherlands), all animals were bred and housed at the Central 
Animal Laboratory of the RUNMC. The animals (N=9) received the uricase inhibitor oxonic 
acid (2% w/v: pH 7) via their drinking water, ad libitum, to induce hyperuricemia.32 The animals 
were individually caged and housed under controlled conditions. Parallel control groups were 
also individually caged and received normal tap water at equal pH. After 14 days, mice were 
placed individually in metabolic cages (Techniplast, Germany GmbH) to collect 24 h urine 
samples, with access to water (with or without oxonic acid 2% w/v) and pulverized standard 
chow ad libitum. Next, blood was collected from the orbital sinus in lithium-heparin tubes via 
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a terminal procedure performed under isoflurane anesthesia and centrifuged for 15 min at 
3,000 x g to obtain plasma. Animals were sacrificed by cervical dislocation. Isolated kidneys, 
plasma and urine were immediately snap frozen in liquid nitrogen and stored at -80 °C until 
further analysis. Biochemical parameters were determined by routine clinical chemistry.
Energy-dispersive X-ray (EDX) microanalysis 
Transmission electron microscopy and EDX were performed for identification of the 
ultrastructure and composition of the insoluble crystals found in the urine samples of oxonic 
acid-treated mice. Urine samples were spotted onto copper grids (100 mesh) coated with 
a support film, air dried, negative stained with uranyl acetate and examined using a Jeol 
1200 EX II. For EDX measurements, the grids were examined using an Jeol 1200/STEM in 
combination with a Thermo Noran microanalysis six system. Accelerated voltage of 60 KeV 
was used for X-ray microanalysis. X-ray spectra for element distribution were acquired. In 
each sample, 3-5 measuring points were selected.
RNA isolation and quantitative PCR
Effects of hyperuricemia on kidney injury was evaluated by determining mRNA expression 
levels of early renal injury markers kidney injury molecule-1 (Kim-1) and neutrophil 
gelatinase-associated lipocalin (Ngal) in kidneys of treated and control mice. Frozen 
kidneys were homogenized using a Mikro-dismembrator U (Sartorius B. Braun Biotech Int., 
Melsungen, Germany). Subsequently, total RNA was isolated using a NucleoSpin® RNA II kit 
(Macherey-Nagel, Düren, Germany) according to manufacturer’s instructions. Immediately, 
a reverse transcriptase reaction was performed with 250 ng RNA using random primers 
(Invitrogen, Breda, the Netherlands) and an Omniscript® RT kit (Qiagen, Hilden, Germany), 
following manufacturer’s recommendations. Synthesized cDNA was used for quantitative 
PCR, performed in a StepOnePlus™ Real-Time PCR system by means of the TaqMan® 
protocol (Applied Biosystems, Warrington, UK). Kim-1 and Ngal mRNA concentrations 
were normalized to the mRNA concentration of the housekeeping gene glyceraldehyde-
3-phosphate dehydrogenase (Gapdh). The primer-probe sets were obtained from Applied 
Biosystems (Gapdh: Mm999999915_g1, Kim-1: havcr1 Mm00506686_m1, Ngal: lcn2 
Mm01324470_m1).
Tryptophan, kynurenine and kynurenic acid measurements by LC-MS/MS
After the vesicle uptake experiments, kynurenic acid was extracted from the filters in 3.3% 
perchloric acid. Plasma samples were diluted in H2O (1:1) prior to LC-MS/MS measurements 
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and deproteinized with perchloric acid (final concentration 3.3%). Samples were centrifuged 
at 12,000 x g for 3 min. Clear supernatant was injected into the LC-MS/MS system that 
consisted of an Accela HPLC system (Thermo scientific, Breda, the Netherlands) equipped 
with a C18 HPLC column (VisionHT C18 B 10062 mm, 1.5 mm: Grace). Tryptophan, kynurenine 
and kynurenic acid were measured in the same run. Deuterated kynurenic acid was added as 
an internal standard for quantification. Measurements were performed as published earlier.30 
Kinetic analysis and statistics
Statistics were performed using GraphPad Prism 5.02 via one-way analysis of variance 
(ANOVA) followed by the Dunnett’s Multiple Comparison Test to study differences between 
all groups as well as an unpaired Student’s t-test to study the impact of oxonic acid treatment 
within each strain. Differences between groups were considered to be statistically significant 
when p < 0.05. GraphPad Prism was also used to perform non-linear regression analysis. 
Results
Oxonic acid induces hyperuricemia 
To study the impact of hyperuricemia on murine physiology, wild type, Mrp4-/- and Bcrp-/- 
mice were treated with the uricase inhibitor oxonic acid as described before.32 Two weeks of 
oxonic acid treatment did neither affect overall weight of the mice, nor plasma levels of urea, 
sodium and calcium (table 1). Interestingly, water intake was strongly increased after oxonic 
acid treatment in all strains investigated, with an increase up to four times that of controls 
in Bcrp-deficient mice. This was accompanied by a two-fold increase in urine flow in treated 
wild type animals; whereas no significant changes were observed in knockout animals. Yet 
baseline urine flow of Bcrp-/- mice tended to be increased as compared to wild type animals. 
Following oxonic acid treatment, the urine collected from all animals was turbid due to 
presence of crystals (figure 1A-D). Energy-dispersive X-ray microanalysis (EDX) revealed 
that the major constituents of the urinary crystals were sodium, potassium, phosphorus 
and calcium; the copper signals arose from the sample grid used in the analysis (figure 1E). 
Two types of crystals could be distinguished: first, crystals that showed an archetypical peak 
pattern corresponding to uric acid crystals, which consisted primarily of sodium, calcium and 
phosphorus (figure 1F). Second, crystals that mainly contained calcium and potassium (figure 
1G), which was likely due to the treatment with oxonic acid potassium salt. These data are in 
accordance with the development of hyperuricemia in oxonic acid-treated mice. 
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Table 1. General characteristics and serum and urine biochemistry of experimental groups.
WT WT + 
oxonic acid
Mrp4-/- Mrp4-/- + 
oxonic acid
Bcrp-/- Brcp-/- + 
oxonic acid
General characteristics
Weight d.0 (g) 22.4 ± 0.8 25.3 ± 1.1 23.4 ± 1.4 25.0 ± 1.5 23.8 ± 1.1 25.7 ± 1.0
Weight d.14 (g) 24.6 ± 1.0 24.9 ± 1.2 23.5 ± 0.9 24.6 ± 0.9 24.5 ± 0.7 24.6 ± 0.6
Water intake (ml/24h) 1.6 ± 0.4 5.5 ± 0.8*** 2.9 ± 0.6 5.5 ± 1.0* 2.1 ± 0.7 8.5 ± 0.5***
Urine flow (ml/24h) 0.3 ± 0.1 0.6 ± 0.1* 0.3 ± 0.1 0.7 ± 0.3 0.7 ± 0.2 0.7 ± 0.1
Plasma
Urea (mM) 12.5 ± 0.8 11.8 ± 0.7 11.4 ± 0.4 10.5 ± 0.5 12.5 ± 0.5 11.7 ± 0.6
Sodium (mM) 149.7 ± 1.1 151.1 ± 1.4 147.6 ± 1.8 151.7 ± 0.8 149.4 ± 0.9 148.0 ± 1.0
Calcium (mM) 2.3 ± 0.02 2.4 ± 0.03 2.2 ± 0.02 2.3 ± 0.02 2.3 ± 0.01 2.3 ± 0.02
Urine
Creatinine (µmol/24h) 1.4 ± 0.6 1.6 ± 0.2 1.1 ± 0.2 1.5 ± 0.3 2.4 ± 0.8 1.3 ± 0.3
Sodium (µmol/24h) 139.7 ± 63.1 126.3 ± 14.1 93.4 ± 17.4 150.8 ± 42.7 196.0 ± 49.2 138.8 ± 21.4
Individually caged mice were treated with oxonic acid via their drinking water for 14 days. Mice 
were weighed before and after treatment period. Water intake, urine flow and urine content were 
determined after a 24h-period in metabolic cages at day 14. Plasma was collected at day 14. Data 
represent means ± SEM of 9 mice per group. *P<0.05 and ***P<0.001 compared to untreated 
mice from the same strain using a Student’s t-test. Differences between the strains were not 
significant (one-way ANOVA).
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Figure 1. Analysis of urine samples of wild type, Mrp4-/- and Bcrp-/- mice after 14 days of treatment 
with oxonic acid via their drinking water. A representative sample of clear urine of an untreated 
animal (A, left and B) and turbid, crystal-filled urine of an oxonic acid-treated animal (A, right and 
C) is shown by a photograph and micrographs (magnification 10x). The contents of the insoluble 
crystals were determined by energy dispersive X-ray microanalysis (EDX). In each sample, 3-5 
measuring points were selected (D). The components of all urinary crystals of three oxonic acid-
treated wild type mice were depicted as mean + SEM of twelve measurements (E). Mainly two 
types of crystals were found. A typical EDX spectrum of urate crystals, containing sodium, calcium 
and phosphorus, is depicted in panel F, while panel G represents an EDX spectrum of oxonic acid 
crystals consisting of calcium and potassium. 
Uric acid inhibits BCRP activity
Plasma urate levels are controlled by an interplay of transporters expressed in the kidney 
proximal tubules. MRP4 and BCRP have been associated with active urinary urate efflux, and 
MRP4 was also sensitive to inhibition by urate.20 We determined the inhibitory properties 
of uric acid on BCRP activity using membrane vesicles prepared from BCRP-overexpressing 
HEK293 cells. Uric acid dose-dependently inhibited BCRP-mediated uptake of the substrate 
E1S (figure 2A) with a calculated half maximal inhibitory concentration (IC50) value of 365 ± 
13 µM. Complete inhibition of BCRP activity was found at the highest uric acid concentration 
used (i.e. 1 mM). These findings indicate that uric acid can reduce transport activity of two 
important efflux pumps at concentrations demonstrated in patients with hyperuricemia (≥ 
360 µM). 
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MRP4-mediated transport of kynurenic acid
There is some evidence linking hyperuricemia to changes in tryptophan levels.25 In addition, 
we recently reported that kynurenic acid, a tryptophan derivative, can interact with MRP4 
and BCRP30, and we identified kynurenic acid as a BCRP substrate (Dankers et al., submitted 
for publication). Here, we investigated whether kynurenic acid is also a substrate for MRP4. 
Figure 2B shows that the ATP-dependent uptake of kynurenic acid in MRP4-overexpressing 
vesicles is 7-fold higher as compared to controls with an average rate of 21.6 pmol/mg*min-1. 
Furthermore, figure 2B demonstrates that non-specific, AMP-dependent, uptake is very low. 
These results indicate that kynurenic acid is indeed transported by MRP4.
Figure 2. Concentration-dependent inhibition of net BCRP-mediated [3H]-estrone sulfate (E1S) 
uptake by uric acid and MRP4-mediated kynurenic acid uptake into membrane vesicles. (A) 
Membrane vesicles were incubated with 250 nM E1S and increasing concentrations of uric acid in 
the presence of AMP or ATP, for 60 sec at 37 ºC. Net BCRP-mediated E1S uptake was calculated by 
subtraction of corresponding mock values. Curve fitting was performed by non-linear regression 
analysis using GraphPad Prism software (version 5.02, GraphPad Software Inc., San Diego, CA, 
USA). Graph represents means ± SEM of three independent experiments. (B) Kynurenic acid uptake 
was assessed by LC-MS/MS analysis after incubating membrane vesicles with 0.1 mM kynurenic 
acid in the presence of AMP or ATP, for five min at 37 ºC. Bars represent means + SEM of three 
independent experiments. ***P<0.001 compared to other bars by one-way ANOVA followed by 
Dunnett’s post hoc test. 
Retention of tryptophan and its metabolites during hyperuricemia
As uric acid can inhibit MRP4 and BCRP-mediated transport and kynurenic acid is a substrate 
for both pumps, we determined the effects of hyperuricemia on tryptophan metabolism and 
the role of the efflux pumps herein. Plasma tryptophan levels were similar in all untreated 
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groups, but oxonic acid treatment led to increased tryptophan levels in Mrp4-/- mice (125 µM) 
as compared to untreated animals (93 µM: figure 3). Baseline plasma levels of the intermediate 
tryptophan metabolite, kynurenine, were similar in knockout animals as compared to wild 
type animals. And oxonic acid treatment led to a >1.5 fold increase in kynurenine plasma 
levels in all three strains, without differences between strains. In contrast, baseline plasma 
kynurenic acid levels of knockout mice were elevated compared to wild type mice, which 
was significant for Bcrp-/- mice. Hyperuricemia did not further increase plasma kynurenic 
acid levels in knockout mice, but led to significantly elevated levels in wild type animals to 
the levels of untreated knockout mice. Furthermore, IDO activity, represented by the ratio 
between tryptophan and kynurenine, was similar in untreated strains, but significantly 
increased after oxonic acid treatment in Bcrp-/- mice (0.5 vs 0.7). Thus, hyperuricemia clearly 
affects tryptophan metabolism. 
Figure 3. Plasma tryptophan metabolism in wild type (WT), Mrp4-/- en Bcrp-/- mice. Plasma 
tryptophan, kynurenine and kynurenic acid levels and IDO activity of untreated (grey) and oxonic 
acid-treated (black) wild type, Mrp4-/- en Bcrp-/- mice after 14 days of treatment via drinking water, 
determined by LC-MS/MS analysis. IDO activity is expressed as the ratio between kynurenine 
and tryptophan * 100. Bars represent means + SEM of 9 mice per group. Statistical analysis was 
performed using both one-way ANOVA followed by the Dunnett’s Multiple Comparison Test and 
an unpaired Student’s t-test. *P<0.05 and **P<0.01 by Student’s t-test and #P<0.001 by one-way 
ANOVA. 
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Oxonic acid does not influence MRP4 and BCRP activity
To exclude the possibility that oxonic acid itself inhibited the efflux pumps resulting in 
metabolite retention, we investigated the effect of oxonic acid on MRP4 and BCRP transport 
activity. Membrane vesicle uptake studies revealed that oxonic acid itself did not affect MRP4-
mediated MTX uptake and BCRP-mediated E1S uptake with more than 15% in a concentration 
range of 1 µM to 1000 µM (figure 4).
Figure 4. Oxonic acid does not interfere with MRP4-mediated MTX uptake and BCRP-mediated 
E1S uptake. Membrane vesicles were incubated with 250 nM [
3H]-MTX or [3H]-E1S and indicated 
concentrations of oxonic acid for 5 min at 37 °C in the presence of AMP or ATP. AMP values were 
subtracted from ATP values. Net transporter-mediated uptake was expressed as means + SEM of 
triplicate measurements in a representative experiment. Results were analyzed by one-way ANOVA 
followed by Dunnett’s post hoc test. 
Hyperuricemia induces expression of the early kidney injury marker Ngal
Finally, we studied whether hyperuricemia and changes in tryptophan metabolism coincided 
with an amelioration of kidney function. Renal damage was evaluated by assessing mRNA 
expression of the early renal injury markers Kim-1 and Ngal in kidneys of treated and control 
mice. As shown in figure 5A, Kim-1 was not differentially expressed in oxonic acid-treated 
mice compared to untreated mice. In contrast, renal Ngal expression (figure 5B) was increased 
after oxonic acid-induced hyperuricemia. These increases were significant for both knockout 
strains, and in Mrp4-/- mice expression levels rose up to 2.3 times that of untreated mice. 
With regard to kidney function, no significant effect was observed on creatinine and sodium 
excretion (table 1), suggesting the absence of overt kidney damage which was confirmed by 
histology. Light microscopic evaluation of HE-stained kidney slices (figure 5C) revealed intact 
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brush borders and absence of casts or destroyed tubules in exposed animals. Taken together, 
these results indicate that two weeks of oxonic acid-induced hyperuricemia reveals, at most, 
early signs of kidney damage.
Figure 5. Expression of kidney injury markers and histology after oxonic acid treatment. Relative 
mRNA expression levels of kidney injury markers Kim-1 (A) and Ngal (B) in kidney tissue of 
untreated (grey) and oxonic acid-treated (black) mice obtained by qPCR. Animals were exposed 
to oxonic acid via their drinking water for 14 days. Cycle threshold (Ct) values were normalized 
for the endogenous reference gene Gapdh and expressed as mean fold difference from untreated 
animals + SEM (N=9). *P<0.05 by Student’s t-test. Both genes were not differentially expressed in 
untreated animals of the different strains. Panel C depicts a representative micrograph of a oxonic 
acid-treated wild type mice and shows that no kidney damage was observed in oxonic acid-treated 
mice (HE staining), which was comparable in treated knockout mice. 
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Discussion
This study reports for the first time that hyperuricemia is associated with disturbances in 
tryptophan metabolism, most likely due to uric acid-induced dysfunction of the renal efflux 
pumps MRP4 and BCRP. High levels of uric acid are associated with an increased risk for 
the development of various diseases and the common mode of action is the formation of 
crystals (e.g. gout and nephrolithiasis) or by negatively influencing the endothelium (e.g. 
hypertension). Here, we hypothesized that hyperuricemia could also contribute to disease 
development in an indirect manner by promoting the retention of other potentially toxic 
metabolites. Our results revealed that oxonic acid-induced hyperuricemia resulted in 
elevated plasma levels of tryptophan, kynurenine and kynurenic acid in vivo. The findings 
are in agreement with two recent studies by Liu et al.25,26, who reported that plasma levels 
of tryptophan were increased in patients with acute gout while their urinary concentrations 
were decreased. Hence, there appears to be a link between hyperuricemia and disturbances 
in tryptophan metabolism. 
The efflux transporters MRP4 and BCRP are important in regulating uric acid levels, but also 
essential for the clearance of many exogenous and endogenous waste products. Recently, 
we demonstrated that kynurenic acid could interact with MRP4 and BCRP activity in the 
membrane vesicle transport assay, suggesting that the metabolite is a possible substrate 
for both transporters.30 Using the same assay, we have shown that kynurenic acid is indeed 
transported by BCRP (Dankers et al., submitted for publication) and here we report that 
kynurenic acid is also a substrate for MRP4. These findings are in agreement with the observed 
increase in plasma kynurenic acid levels in Mrp4-/- and Bcrp-/- mice. Therefore, MRP4 and 
BCRP could be potential novel therapeutic targets for the regulation of kynurenic acid levels 
in a variety of diseases. 
Kynurenic acid is a widely studied antagonist of the N-methyl-D-aspartate-receptor and the 
α7-nicotinic acetylcholine receptors, and elevated levels of kynurenic acid are related to 
several neurological disorders.33 Another target of kynurenic acid is the orphan G-protein-
coupled receptor GPR35, of which kynurenic acid is one of the most potent endogenous 
agonists currently known. The receptor is highly expressed in the intestine and in several 
immune cells, including monocytes and T cells. Kynurenic acid also alters the release of 
multiple growth factors such as nerve growth factor and fibroblast growth factor-1.34 Thus, 
perturbations in kynurenic acid levels can result in marked effects on receptor activation 
and changes in growth factors. With regard to pathophysiological effects, classic experiments 
have demonstrated that kynurenic acid inhibited pro-insulin synthesis in isolated rat 
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pancreatic islets and increased the release of insulin in rats, suggesting a role in diabetes.35,36 
Furthermore, in CKD patients, kynurenic acid accumulates30 and increased levels correlate 
positively to multiple markers of endothelial dysfunction, namely von Willebrand factor, 
thrombomodulin and soluble adhesion molecules (sICAM-1, sVCAM-1).37,38 In addition, 
kynurenic acid is suggested to be an important early mediator of leukocyte recruitment.39 
Moreover, kynurenic acid reduces glucuronidation activity of UDP-glucuronosyltransferases, 
as shown in proximal tubule cells, thereby affecting the metabolic capacity of the kidney.40 
Hence, elevated levels of kynurenic acid induced by hyperuricemia, as observed in our study, 
might play a pivotal role in the pathophysiological effects currently attributed to uric acid.
Our results further demonstrated that kynurenine levels were similar in untreated wild 
type and knockout animals, suggesting that the levels of this metabolite are not influenced 
by MRP4 and BCRP activity. Following induction of hyperuricemia, kynurenine levels were 
markedly increased in all groups. The observed increase might be due to a reduced activity 
of a uric acid transporter other than MRP4 and BCRP, elevated tryptophan levels, as seen in 
Mrp4-/- mice, and/or increased activity of indoleamine 2,3-dioxygenase (IDO), as observed 
in Bcrp-/- mice. Interestingly, IDO is involved in immune regulation and enzyme activity is 
higher during chronic inflammation and in CKD patients.41 The exact interaction between 
hyperuricemia and IDO requires further investigation. For a long time, kynurenine was 
regarded as an intermediate of tryptophan metabolism with little biological activity. Yet 
Opitz et al.42 recently demonstrated that this metabolite is a ligand for the aryl hydrocarbon 
receptor (AHR) and can promote tumor cell survival and suppress antitumor immune 
responses. The AHR signaling pathway is involved in a myriad of cellular processes, including 
embryogenesis, inflammation and phase I and phase II metabolism. Fascinatingly, another 
tryptophan metabolite, indoxyl sulfate, is also reported to activate the AHR in primary human 
hepatocytes and human umbilical vein endothelial cells.43,44 Thus, by disturbing tryptophan 
metabolism, hyperuricemia could indirectly be involved in AHR activation and subsequent 
pathologies. 
Several polymorphisms in transporter genes are associated with elevated serum uric acid 
levels. For instance, Woodward et al.22, described that the common single nucleotide 
polymorphism (SNP) rs2231142 encoding the Q141K mutation of BCRP caused hyperuricemia-
based gout. Also in a Japanese population, Q141K was shown to be a common dysfunctional 
form of BCRP causing gout.21 Another transporter recently implicated in uric acid metabolism 
is SLC2A9. Using Xenopus oocytes, Vitart et al.19 demonstrated that SLC2A9-mediated 
uptake of uric acid was sevenfold higher in SLC2A9-expressing oocytes compared to URAT1-
expressing oocytes. These findings have been confirmed by others 10,45. Moreover, multiple 
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genome-wide association studies reported a relationship between uric acid levels and SNPs 
in several transporters including SLC17A3, SLC22A11 and SLC22A12.23,46,47 Taken together, 
when studying the link between uric acid and disease progression it is important to take 
into consideration the presence of possible polymorphisms in transporter genes as well as 
changes in metabolite levels of transporter-specific substrates.
Two weeks of hyperuricemia induced early signs of kidney damage, as observed by an 
increased mRNA expression of Ngal in knockout animals. In contrast, no signs of renal damage 
were seen in wild type animals. These findings suggest that knockout animals were more 
prone to the development of renal failure. Since, kynurenic acid levels were already elevated 
in Mrp4-/- and Bcrp-/- animals before the induction of hyperuricemia, one could argue that 
other tryptophan metabolites are responsible for induction of Ngal observed in knockout 
mice. To better understand the effect of hyperuricemia on the development of CKD, future 
studies should include longer treatment periods (> 2 wk) and also determine the levels of 
other intermediates and end products of tryptophan metabolism. 
In conclusion, our results showed that uric acid dose-dependently inhibited BCRP activity and 
inhibition occurred at physiologically relevant levels as was reported previously for MRP4.20 
Moreover, we demonstrated that Mrp4- and Bcrp-deficiency as well as hyperuricemia are 
associated with alterations in tryptophan metabolism and the retention of kynurenine 
and kynurenic acid, two metabolites with a broad array of biological activities. Therefore, 
we postulate that elevated uric acid levels hamper MRP4 and BCRP functioning, thereby 
promoting the retention of other potentially toxic substrates, including kynurenic acid, which 
could contribute to the development of CKD. These finding underline the complex relation 
between hyperuricemia and linked pathologies, which should be taken into account when 
interpreting results obtained using in vivo hyperuricemia models.
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Introduction
BCRP is a versatile efflux transporter with a myriad of xenobiotic as well as endogenous 
molecules as substrates. Besides its protective function against the toxic effects of xenobiotics, 
it becomes increasingly clear that the protein also has a physiological function. In this thesis, 
the role of BCRP in endocrine and metabolic processes was investigated. Different in vitro and 
in vivo techniques were used to elucidate the involvement of efflux pump in the transport 
of steroids, the protective function of BCRP on heme-induced cellular injury, and the role of 
BCRP in hyperuricemia and in endocrine disruption. In this chapter, the relevance of these 
results is being discussed. Furthermore, the effects of decreased BCRP function, the pitfalls 
which might be encountered while studying the role of BCRP or other efflux transporters, and 
the possibility to target BCRP for clinical applications are considered.
The role of BCRP in endocrine processes
The research described in chapters 2, 3 and 4 of this thesis was focused on the role of BCRP 
in endocrine processes. The presence of BCRP in various tissues, including placenta, prostate, 
small intestine, brain, colon, liver, mammary gland and kidney has been shown previously, 
however, investigations on BCRP expression in other endocrine organs received much less 
attention and localization of the protein in these organs has not been clearly described. We 
investigated the expression and possible role of BCRP in endocrine organs in chapter 2. In 
addition to adrenal gland, pancreas and testis, we show for the first time localization of Bcrp 
in murine ovary, pituitary gland and adipose tissues. Except in the adipose tissues, were it is 
expressed only in the plasma membrane, Bcrp was located mainly in the capillaries of both 
endocrine and in non-endocrine organs. Bcrp is most likely not involved in steroid hormone 
secretion as we did not find expression in most endocrine cells. The only steroid-secreting 
cells expressing Bcrp were found in the adrenal gland, i.e. cells lining the zona glomerulosa 
and zona reticularis, which secrete mineralocorticosteroids and androgens, respectively, and 
in adipose tissue, a major site for metabolism of sex steroids and glucocorticoids. Whether 
Bcrp/BCRP actually has a role in the excretion of the produced steroids and whether 
steroid hormones influence BCRP function, was investigated further. Also in chapter 2, it 
is shown that several steroid hormones, including estradiol, testosterone, progesterone 
and androstenedione, can inhibit BCRP function, however, at supraphysiological (plasma) 
concentrations. To predict the clinical relevance of the interaction between steroids and 
BCRP, knowledge on intracellular steroid concentrations is important, which so far appeared 
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to be difficult to determine. One can imagine that intracellular concentrations in organs 
responsible for the production of hormones may be much higher than plasma levels and, 
thereby, could potentially influence BCRP function. Besides, the actual steroid concentrations 
in the experiments were not determined and steroids are known to easily stick to plastic tubes 
and/or wells, so their effects on BCRP function could have been significantly underestimated. 
Moreover, high concentrations required to cause inhibitory effects do not necessarily mean 
that the molecules are not transported by BCRP. Nevertheless, we have undertaken studies to 
measure transport of steroids in HEK293-BCRP membrane vesicles and BCRP-overexpressing 
MDCKII cells, but we did not find clear evidence of BCRP involvement in the transport of 
steroid hormones in these models. The question whether steroids are substrates for BCRP 
has been addressed before and contradictory findings have been reported.1-3 In 2003, 
Janvilisri et al.3 demonstrated transport of estradiol in membrane vesicles from Lactococcus 
lactis containing functional human BCRP. However, this has not been repeated so far. Most 
studies support the conclusion that steroids interact but are not substrates of BCRP, which is 
in agreement with our findings.
Steroids, however, are clearly involved in the regulation of BCRP expression. The localization 
of BCRP/Bcrp in the plasma membrane is shown to be gender specific, as demonstrated in 
rodent liver, kidney and brain capillaries as well as in human breast, ovarian and placental 
cancer cell lines1,4-7 and as also confirmed in chapter 2. This gender-dependent BCRP/Bcrp 
expression is suggested to be due to the suppressive effect of estradiol and the inductive effect 
of testosterone4,5,8, as was demonstrated for example in ovariectomized or castrated mice 
and rats with or without sex steroid treatment.6 Also, progesterone has been demonstrated 
to regulate BCRP transcription, as was shown in cancer cell lines. In human placental BeWo 
cells, progesterone and estradiol significantly increased and decreased BCRP mRNA levels, 
respectively.7 Estradiol likely downregulates BCRP through an estrogen receptor (ER), while 
progesterone upregulates BCRP via a non-progesterone receptor-mediated mechanism.9 
Imai et al.5 found that estrogens post-transcriptionally downregulated BCRP in estrogen-
responsive cancer cells. This effect could be counteracted by gene silencing of estrogen 
receptor-α (ERα), indicating that ERα is necessary for the suppression of the BCRP protein. 
In agreement, Hartz et al.8 described that estradiol signals through ERβ and ERα to initiate 
Bcrp internalization and acts via ERβ to stimulate proteosomal degradation of Bcrp in murine 
brain capillaries. In contrast, Ee et al.4 found that estradiol enhanced Bcrp mRNA levels in cells 
stably expressing ERα at estradiol concentrations similar to those used by Hartz et al. 
By means of homology modelling, Mares-Sámano et al.10 generated a three-dimensional 
model of the nucleotide binding domain (NBD) of BCRP and its interaction with a series of 
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steroidal ligands were investigated using an in silico docking approach. All steroids, including 
progesterone, testosterone, estradiol and corticosterone, were predicted to bind in the 
vicinity of the P-Loop within the NBD of BCRP. By binding the NBD, ATP-binding is thought to 
be hindered, resulting in a decrease in BCRP activity. Eventually, decreased function might 
result in an increase in ABGC2 transcription and expression as a compensatory mechanism. 
This hypothesis might explain the inductive effect found for testosterone, but not the 
suppressive effect of estradiol. 
Besides the steroid-dependent regulation of BCRP expression, we found another relationship 
between BCRP and the endocrine system. In chapter 4, we describe that the testicular weight 
of Bcrp-/- mice was 40% higher than of wild type mice. Generally, it is believed that testicular 
weight increases to compensate a decreased testicular function.11,12 Our results indicate that 
Bcrp may be necessary for a proper testicular functioning in mice. However, since we did 
not examine steroid production and the number of Sertoli and total germ cells, we cannot 
conclude that testicular function was indeed impaired in Bcrp-deficient mice. Though, this 
interesting hypothesis requires further research to elucidate the underlying mechanism. 
This thesis also presents work performed with other efflux transporters expressed in the 
blood-testis barrier, like P-gp, MRP1 and MRP4, which were found to be present in a murine 
Leydig (MA-10) cell line. In chapter 3, one of the endocrine disruptors tested, TBBPA, increased 
Leydig cell testosterone secretion concentration-dependently without altering expression 
levels of androgen-producing enzymes. This led us to hypothesize that transporter-mediated 
(probably P-gp-mediated) efflux of testosterone precursors, e.g. androstenedione or DHEA, 
from the cells is inhibited by TBBPA. As a result, more precursors are available for testosterone 
production, which is reflected by increased testosterone levels. In addition, TBBPA-mediated 
increase in testosterone secretion was completely abolished by the Mrp inhibitor MK-571 
suggesting a decrease in active transport of testosterone out of the Leydig cells. Neither 
P-gp-mediated transport of testosterone precursors nor testosterone transport by MRPs/
Mrps have been described before, so further experimental support is needed to confirm this 
hypothesis. 
BCRP and metabolic processes
Besides steroids, other endogenous molecules, like heme, vitamin B2, folic acid and uric acid 
also interact with BCRP.13-19 In chapters 5, 6 and 7, we aimed to investigate further the role of 
BCRP in a number of metabolic processes in which these substrates are involved. We found 
that BCRP protects against the injurious actions of heme, next to the heme-degrading enzyme 
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heme oxygenase-1 (HO-1) (chapter 5). Heme is the functional group of various hemoproteins 
and crucial for many cellular processes.20,21 However, heme is increasingly recognized as a 
culprit for a wide variety of pathologies, including sepsis, malaria, and kidney failure.21-24 
Excess of free heme can be detrimental to tissues by mediating oxidative and inflammatory 
injury. Protective mechanisms against free heme, like BCRP and HO-1 expression, are 
therefore pivotal for cellular survival. Furthermore, the BCRP-substrate uric acid, the end 
product of purine nucleotide degradation, is related to a variety of pathologies, including 
gout, nephrolithiasis, cardiovascular disease and chronic kidney disease (CKD) (chapter 7).25-
27 The importance of BCRP in the regulation of uric acid levels is endorsed by several reports 
on the correlation of a common single nucleotide polymorphism (SNP) C421A, encoding 
the Q141K mutation of BCRP, with elevated serum uric acid levels (hyperuricemia).17,28,29 
Woodward et al.30 described that the Q141K mutation caused hyperuricemia-based gout, 
which was confirmed in a Japanese population.17 Several studies of SNPs in the ABCG2 gene 
have been published and over two dozen sequence variations of ABCG2 have been reported. 
Of these, the C421A nucleotide change, resulting in a glutamine to lysine substitution in the 
translated protein, has received the most attention. The SNP renders the transporter inactive, 
causing substrates to accumulate in tissues.13
Next to genetic factors, inhibitory effects can also result in reduced transporter activity. 
Nowadays, many inhibitors of BCRP are known. Some of them inhibit BCRP-mediated efflux 
by competition for the same substrate binding site, others are pure inhibitors without 
being transported themselves. Molecules that interact with BCRP include xenobiotics, such 
as chemotherapeutic agents, tyrosine kinase inhibitors, antivirals, HMG-CoA reductase 
inhibitors, statins and flavonoids, as well as endogenous molecules including steroids, BPA 
and uric acid (chapter 7). In addition, we showed that several steroid hormones are able 
to inhibit BCRP activity (chapter 2). Decreased BCRP functioning can promote the retention 
of other BCRP substrates. In chapter 7, we indeed show that uric acid-induced dysfunction 
of Bcrp caused disturbances in tryptophan metabolism in mice, including the retention of 
the novel identified substrate for the transporter, kynurenic acid. Elevated kynurenic acid 
levels were also found in plasma and brain homogenates of Bcrp-deficient mice (chapter 
6). Kynurenic acid is a widely studied antagonist of the N-methyl-D-aspartate-receptor and 
the α7-nicotinic acetylcholine receptor, and elevated levels of kynurenic acid are related to 
several neurological disorders.31 It may also alter the release of multiple growth factors such as 
nerve growth factor and fibroblast growth factor-1.32 Furthermore, in patients with disturbed 
kidney function, kynurenic acid accumulates33 and the increased levels correlate positively 
with multiple markers of endothelial dysfunction.34,35 These findings suggest that changes 
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in transport efficacy of molecules involved in cellular signaling and communication, caused 
by hampered BCRP function in which BCRP is impaired as well, might potentially influence 
a myriad of cellular processes that are regulated by BCRP and disturb cellular homeostasis.
Animal models and extrapolation to humans
When studying the role of ABC transporters, often transporter knockout animals are used. 
Authors that used Bcrp-knockout animals often state that the possibility of compensatory 
gene expression and protein synthesis of other transporters may countervail the lack of 
the Bcrp gene. In the kidneys of Bcrp-/- mice, mRNA expression of two sterol transporter 
genes, Abcg5 and Abcg8, was strongly increased, however, none of the Bcrp-substrates are 
known to be transported by either Abcg5 or Abcg8.36 Agarwal et al.37 studied compensatory 
changes in brain capillary endothelial cells of Bcrp knockout mice and found no significant 
differences in the expression of any of the measured proteins, including 12 ATP-binding 
cassette transporters, 10 solute carrier transporters, five transmembrane receptors, and 
two housekeeping proteins. Besides, Zamek-Gliszczynski et al.38 demonstrated very modest 
compensatory changes in Bcrp knockout rats, which do not preclude their general application 
to study for example transporter-mediated pharmacokinetics. Though, they did find significant 
upregulation of intestinal catechol-O-methyltransferase in these rats, which potentially 
influences the metabolism of compounds containing a free catechol group. Obviously, this 
only accounts for a small fraction of drugs and can be readily identified based on chemical 
structure. Yet, in the liver of Bcrp knockout mice, carboxylesterase enzymes appeared to be 
highly upregulated. This might have significant consequences for drugs hydrolyzed by these 
enzymes but, apparently, also for compounds that are not hydrolyzed, like the anticancer 
drug everolimus. Blood pharmacokinetics of this drug was altered in Bcrp-/- mice by increased 
binding to carboxylesterase enzymes.39
In general, a series of laboratory techniques is used to study the role of ABC transporters, 
including in vitro and in vivo models of animal or human material. Some studies present both 
laboratory animal and human data. However, one should take into account that expression 
levels and activity of ABC transporters are different between animal species compared to 
humans. For BCRP, Li et al.40 observed significant elimination of pheophorbide A (PhA), an 
exclusive BCRP/Bcrp substrate, by human and dog hepatocytes, while Bcrp-mediated PhA 
transport in monkey and rat hepatocytes was limited. In agreement, low Bcrp expression in 
rat hepatocytes has been reported before6,41, although this was determined on mRNA levels. 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
166
Chapter 8
Absolute rat Bcrp protein levels in liver tissue were slightly higher compared to human and 
monkey BCRP/Bcrp, as was determined by LC-MS/MS analysis. The highest Bcrp levels were 
found in dog livers.42 In the BBB, BCRP expression is lower in humans compared to rat, murine 
and bovine BBB.43 In rodent kidney, Bcrp mRNA levels were clearly higher as compared to 
human kidney, with highest expression in the mouse.36 Also for the placenta, differences in 
placental structure and transport to the fetus between species are described.44,45 Human, 
mouse and rat BCRP/Bcrp is located mainly in the apical membrane of syncytiotrophoblasts 
and also on the apical membrane of fetal capillary endothelium. Nevertheless, the number of 
cell layers between maternal and fetal circulations varies from one species to another, and, 
thus, the role of membrane-bound transporters may differ as well. Variances in BCRP/Bcrp 
expression levels between placentas of humans and laboratory animals are not yet known.45 
In addition, genes coding for receptors and metabolic enzymes are differentially expressed in 
animals compared to humans.46-48 
Species differences can also be a result of different specificity or affinity of a molecule for 
human transporters than for animal transporters. Although it was recently reported that 
substrate specificity of human and mouse BCRP is very similar49, Zhang et al.50 described the 
interaction of the flavonoids chrysin and benzoflavone with human BCRP. This interaction was 
not found with rat or mouse Bcrp. Moreover, Mazur et al.51 showed interspecies differences 
in the efflux transporter specificities for BPA between rat and human ABC transporters, 
including BCRP. BPA-mediated increase in ATPase activity was clearly found for human BCRP, 
but not for rat Bcrp. This might explain the different responses we found in chapter 4 in which 
we reported that BPA was well transported by human BCRP but in mice, Bcrp did not affect 
the disposition of BPA. Possibly, BPA is not a substrate for murine and/or rat Bcrp, though, we 
did not study this. 
Chapters 6 and 7 describe in vivo mouse studies on the role of Bcrp and Mrp4 in metabolic 
processes. Reasons to start these experiments originate from results obtained from in vitro 
studies using human transporter proteins. In chapter 6, we found Bcrp expression in the 
choroidal cell layer of the subcommissural organ (representing the brain-CSF interface) at the 
ventricular side of ependymal cells facing the CSF in the murine brain, which made us curious 
to investigate the role of Bcrp in regulating CSF composition. By comparing Bcrp-/- and wild 
type mice for several physiological parameters involved in energy or tryptophan metabolism, 
and studying murine neuroblastoma cells in vitro, we showed that Bcrp might influence 
brain energy metabolism by regulating kynurenic acid levels. Also in chapter 7, tryptophan 
metabolism was studied in mice, this time after inducing hyperuricemia. The results showed 
that elevated uric acid levels hamper MRP4 and BCRP functioning, thereby promoting the 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
167
General discussion
8
retention of other potentially toxic substrates, including kynurenic acid. Although the in vivo 
data implied that kynurenic acid is probably a substrate of murine Bcrp and Mrp4, again, we 
only confirmed transport of the molecule by human BCRP and MRP4. 
All together, these differences result in deviated kinetics and dynamics of molecules between 
humans and laboratory animals and, obviously, lead to difficulties in the extrapolation of 
animal results to humans. In the end, we want to clarify physiological processes in human. 
Since it is obviously difficult to study certain processes in human in vivo, probably the easiest 
way to add relevant data (at least regarding the research presented in this thesis) is to 
perform in vitro studies in both animal and human material. When human and murine in vitro 
data are similar, the extrapolation of the murine in vivo data to the human in vivo situation 
is somewhat more legitimate. Other possibilities to investigate human transporters are ex 
vivo human organ perfusion models or humanized animal models. The advantage of using 
organ and tissue material, e.g. placenta or liver tissue, to study transporter function is that 
they retain tissue structure and the polarized nature of endothelial cells, often expressing 
efflux transporters like BCRP.52-57 Also freshly isolated human brain capillaries have been 
successfully used to study transporter function and its dynamic regulation.58,59 Applications 
of these systems to date are limited by the availability of appropriate tissue samples and 
the complexity of the technique. Several humanized animals models exist. Chimeric mice 
are engrafted with human cells, e.g. bone marrow cells or hepatocytes. The advantage of 
humanized liver chimeric mice is that the entire liver is human, so the interplay between 
human transporters and metabolizing enzymes can be studied.60 Nevertheless, all other 
organs are murine. Consequently, circulating murine metabolites reach the humanized 
liver and bind the human proteins so the model does not fully reflect the human situation. 
Obviously, these are complex, laborious and costly models, which are mainly used to study 
metabolic pathways and drug-induced liver injury (e.g. in pharmaceutical development)60,61, 
and not often to study exclusively one specific transporter. To this end, mice models 
expressing specific human transporters have been generated. Once a stable genetic mouse 
model is generated, the mice can easily be bred and readily be used, whereas the chimeric 
mice have to be generated every experiment. Recently, van der Steeg et al.62,63 generated 
transgenic mouse models with specific expression of human OATP1B1, -1B3, or -1A2 in the 
liver and proved functionality by showing transport of the anti-cancer drugs methotrexate 
and paclitaxel. The only model expressing a human efflux transporter, as of yet, is the human 
MRP2 mouse model, generated by Scheer et al.64. This was achieved by a knock-in strategy 
allowing the expression of the human transporter under control of the corresponding mouse 
promoter. Therefore, the expression of human MRP2 was not restricted to one organ but the 
protein was ubiquitiously expressed. 
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In silico modeling and multiple BCRP binding sites
In numerous areas of molecular research, such as research focusing on the understanding of 
the mechanisms in physiology and diseases as well as drug development and environmental 
toxicology, efflux transporters are gaining momentum. Therefore, it is more and more 
important to understand which molecules interact with which transporters and to determine 
the kinetic characteristics of transport. Computational in silico modeling is a powerful cost-
effective tool often employed to predict structural requirements of transporter substrates and 
inhibitors prior to in vitro and in vivo studies.65 Many different in silico modeling techniques 
have been developed that describe the (quantitative) structure-activity-relationship (SAR/
QSAR) of compounds with BCRP.66,67 Besides, computational homology models of BCRP that 
can be used for docking calculations and interpretation of biochemical data, have recently 
been developed and await further experimental validation.68-70 Several SAR and QSAR 
studies indicate that lipophilicity and molecular polarizability of ligands are good predictors 
of BCRP inhibition67,71,72, nevertheless, other studies argue that these properties are not 
significant70,71,73,74. In general, high substrate prediction accuracy of the existing computational 
models has not yet been proven. Since they cannot give a decisive answer as to whether a 
compound is a substrate for BCRP, transport activity should be verified using experimental 
models. To date, many inhibitor datasets are available for BCRP modeling, while very few 
substrate datasets exist. The latter might be due to lack of a high resolution crystal structure 
of mammalian BCRP, which precludes direct examination of the substrate binding site.75
Evidence coming from both computational studies76 as well as from experimental studies77-81 
on for example BCRP mutants or inhibitory effects of different substrates, suggests that 
BCRP may have multiple binding sites. Different pharmacophore models, which describe the 
chemical properties of a compound that determine interaction with a binding site, should be 
developed for the different binding sites to predict the wide range of substrates. However, 
also evidence against the existence of more than one binding site has been raised.71 Caution 
is also warranted if the conclusion about the existence of multiple BCRP binding sites is solely 
based on experiments using different substrates. A compound can inhibit BCRP-mediated 
transport in several ways, for example by binding BCRP close to the substrate binding site, 
which might impede binding of some but not all substrates, or binding to the substrate 
itself, which hinders the substrate to bind to the transporter, and, thus, active transport. 
The existence of multiple binding sites on transport proteins could add to the complexity in 
identifying substrate and inhibitor molecules in in vitro assay systems, leading to incorrect 
interpretation of substrate-inhibitor interaction studies. 
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In chapter 2, we demonstrated the inhibitory effects of several steroid hormones on BCRP 
function. The mode of inhibition was determined using Dixon’s method combined with 
linear regression analysis, which revealed that estradiol, testosterone, progesterone and 
androstenedione non-competitively attenuated BCRP-mediated E1S transport. Based on the 
presence of a single BCRP binding site, non-competitive (allosteric) modulators are not likely to 
be substrates. However, the effect of steroid hormones on BCRP-mediated transport of other 
substrates is still to be determined. Similar inhibition studies, using E1S as a BCRP-substrate, 
were used in chapters 3, 6 and 7, however, the mode of inhibition was not determined. 
We used the assay as a positive selection for compounds that are able to interact with the 
transporter. For three of them (BPA, TBBPA and PFOA), we furthermore determined direct 
transport. For the negative compounds DEHP and MEHP, we cannot completely rule out 
the possibility that they are inhibitors of BCRP-mediated transport of other substrates or 
that they are transported by BCRP themselves. For uric acid (chapter 7), which was already 
known as a BCRP-substrate, we only determined the ability to inhibit transport of other 
substrates. We concluded that uric acid was able to inhibit BCRP function and that therefore 
hyperuricemia could promote the retention of other potentially toxic substrates. Strictly 
speaking, knowledge of the binding site of uric acid compared to the binding site of the 
particular (toxic) substrate is necessary to confirm this. So far, our in vivo results confirmed 
the effect of uric acid on the retention of kynurenic acid. 
Whether BCRP indeed exhibits multiple binding sites, as well as the exact locations of these 
putative sites and their interactions with the known substrates and inhibitors, still needs to 
be elucidated. Nevertheless, if BCRP contains multiple binding sites, then inhibitory effects 
should be determined using substrates that interact at different sites of the transporter before 
it can be concluded that a compound is only an inhibitor and not a substrate of BCRP. For 
example, rhodamine and daunomycin are described to interact at pharmacologically distinct 
sites on the protein28,78,82 as well as pheophorbide A and imatinib79. Also mitoxantrone and 
Hoechst33342 are thought to interact with another BCRP binding site than daunomycin.78 
Targeting BCRP for clinical applications
The presence of BCRP in many organs and tissues in the body and its role in clinical multidrug 
resistance makes the protein an interesting target for potential clinical applications. A strategy 
of BCRP inhibition could be employed to increase oral bioavailability of drugs, increase brain 
penetration, or overcome cancer cell resistance.83 Concerning oral bioavailability, a limited 
number of clinical trials have already demonstrated the feasibility of coadministering dual 
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BCRP/P-gp inhibitors with oral chemotherapy.84,85 This strategy is only useful for drugs that 
do not inhibit transporter activity at high concentrations. It has been shown that several 
orally administered drugs, i.e. gefitinib, nilotinib, and imatinib, are BCRP substrates at low 
concentrations and behave as inhibitors at higher concentrations.86,87 Concerns of high local 
substrate concentrations do not apply to the blood-brain barrier where very high endothelial 
BCRP levels have been observed. Inhibitors of BCRP alone or both BCRP and P-gp, such as 
elacridar, tariquidar and dofequidar, will increase brain penetration of drugs that need to act 
on the CNS. This has been described repeatedly in rodent models, however, unfortunately 
such proof in humans is lacking.83 A reason for this includes the lack of a validated probe for 
BCRP functioning in the human blood-brain barrier, which makes it difficult to interpret the 
results of clinical trials that combined a CNS-targeting drug with a BCRP inhibitor. 
The problem of accumulating potentially toxic substrates, in situations of undesirably 
hampered BCRP function, e.g. in the presence of the Q141K SNP or when BCRP is inhibited, 
is much more difficult to challenge. In the case of BCRP-inhibition, stimulating BCRP 
upregulation might be a good therapeutic approach. Several drugs have been described to 
upregulate the protein, such as mitoxantrone.88,89 However, it is probably not feasible to use 
mitoxantrone for BCRP upregulation in a clinical setting, considering the fact that mitoxantrone 
is metabolized relatively fast and has many other unwanted effects. The same holds true for 
testosterone. The dose of testosterone needed to cause an induction of BCRP expression 
will elicit too many side effects. Regulating BCRP expression levels at its transcriptional level 
is a theoretical goal for clinical applications. Expression of the ABCG2 gene is controlled by 
two functional cis elements in the ABCG2 promoter, the estrogen4 and hypoxia15 response 
elements, and a peroxisome proliferator-activated receptor-γ response element upstream of 
the ABCG2 gene.90,91 Besides, ABCG2 expression can be upregulated by the aryl hydrocarbon 
receptor (AhR)92,93. Some dietary flavonoids (i.e. quercetin, chrysin, and flavone), acting as 
AhR agonists, were shown to induce BCRP expression.92,94 Obviously, interfering with these 
transcription pathways affects many more processes than only ABCG2 expression and are 
therefore not feasible as pharmacological targets to increase BCRP function. To date, the 
ideal compound that is suitable for BCRP induction without affecting other receptors and 
disturbing physiological pathways, is not yet known.
Genotyping of BCRP in a clinical setting might become important in the near future for 
personalized medicine. As mentioned above, the common dysfunctional form of BCRP, 
Q141K, renders the transporter inactive. Besides, other polymorphisms of ABCG2 have 
been identified.68 Patients with reduced or no BCRP function may suffer from, for example, 
disturbed metabolic processes or accumulating uremic toxins because of lack of removal of 
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these molecules. Besides, the removal of drugs can be severely postponed in these patients, 
which could lead to toxicity if the dosage is not adjusted. Determining the genotype of ABCG2 
and other important transporters could contribute to the safety of drug-using patients and/
or make them aware of the risk factors of developing diseases like gout or chronic kidney 
disease. 
Conclusion
In this thesis, the role of the efflux transporter BCRP in endocrine and metabolic processes 
was investigated. Our data show clear inhibition of BCRP by steroid hormones, however, 
BCRP is not involved in the transport of steroids. Besides, we identified a role for BCRP in 
several metabolic processes, using both in vitro and animal models. Our results indicate that 
BCRP protects against heme-induced cellular injury and potentially also against BPA-, TBBPA-, 
PFOA-, and PFOS-induced endocrine disruption. Moreover, we found that hyperuricemia 
influences tryptophan metabolism via inhibition of BCRP. Furthermore, we state that caution 
is warranted when translating data obtained in laboratory animals to the human situation, 
since interspecies differences are associated with substantial differences in kinetics and 
dynamics of xenobiotics. 
Altogether, based on our results, we postulate that decreased BCRP function, either by 
transport inhibition or because of an inactive single nucleotide polymorphism, could 
promote the retention of potentially toxic substrates, including endocrine disruptors, heme 
and kynurenic acid. This influences a myriad of cellular processes that are regulated by BCRP 
and disturbs cellular homeostasis. Therefore, this protein could be an interesting target for 
potential clinical applications, such as its BCRP-induction to prevent accumulation of BCRP 
substrates. However, more research is needed to determine the feasibility of influencing 
BCRP in patients.
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Summary
Introduction
ATP-binding cassette (ABC) transporters are membrane-associated proteins that directly use 
ATP to transport a variety of molecules across the membrane against steep concentration 
gradients. Nearly all ABC proteins are efflux transporters, many of which have an important 
role in tissue defense through the removal of harmful molecules. The research described in 
this thesis was mainly focused on one of these ABC transporters, i.e. breast cancer resistance 
protein (BCRP), which is encoded by the ABCG2 gene. This gene was discovered in 1998 in a 
mitoxantrone-resisitant subline of breast cancer cells. BCRP is expressed in many organs and 
tissues in the body, including epithelia of intestine, liver and kidney, as well as tissues with 
a tight barrier function like the blood-brain barrier (BBB), the blood-placenta barrier and 
the choroid plexus as part of the blood-cerebrospinal fluid (CSF) barrier. BCRP is recognized 
as a xenobiotic transporter that plays a major role in multidrug resistance and a myriad 
of BCRP substrates have been described, among them a variety of xenobiotics including 
chemotherapeutic agents, tyrosine kinase inhibitors, antivirals, HMG-CoA reductase 
inhibitors, and flavonoids. Research on the role of BCRP in most organs has until now been 
predominantly focused on the restriction of drug penetration and its protective function 
against the toxic effects of exogenous compounds. Yet, accumulating evidence has shown that 
BCRP also transports various endogenous molecules, such as uric acid, folic acid, porphyrins, 
riboflavin (vitamin B2) and conjugated steroid hormones. Besides, steroid hormones have 
been associated with BCRP function, expression and degradation, however, the molecular 
bases of these protein-steroid interactions are not yet elucidated. The aim of this thesis was 
to study the role of BCRP in endocrine and metabolic processes. 
The role of BCRP in endocrine organs
The expression of BCRP in the plasma membrane is higher in males than in females. This 
is suggested to be due to the suppressive effect of estradiol and the inductive effect of 
testosterone. Moreover, involvement of BCRP in the transport of androgens and estradiol 
was suggested, indicating that the efflux pump might play a role in steroid action. Localization 
of BCRP was previously described in testis and adrenal gland, but for other organs involved 
in steroid hormone production or action BCRP, expression was not yet clear. In chapter 2, 
we investigated the presence and localization of Bcrp in endocrine organs of wild type mice. 
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Quantitative PCR revealed Bcrp mRNA in the pituitary and adrenal glands, pancreas, ovary, 
testis and adipose tissue and that mRNA levels of Bcrp in these tissues were slightly higher 
in male than in female mice. Immunohistochemistry was used to assess the localization of 
Bcrp in murine organs. Except for the fat pads, Bcrp was located mainly in the capillaries of 
both endocrine and in non-endocrine organs. Although endocrine organs have a significant 
secretory function, we did not find expression of Bcrp in most of the endocrine cells, indicating 
that the efflux pump is not involved in the excretion of steroids. The only steroid secreting 
cells expressing Bcrp were found in the adrenal gland, i.e. cells of the zona glomerulosa and 
zona reticularis which secrete mineralocorticosteroids and androgens, and in the plasma 
membrane of adipocytes, a major site for metabolism of sex steroids and glucocorticoids.
The interaction between BCRP and twelve steroid hormones was studied using membrane 
vesicles of BCRP-overexpressing HEK293 cells. Estradiol, testosterone, progesterone and 
androstenedione inhibited BCRP-mediated uptake of 3H-estrone sulfate (E1S) most potently. 
BCRP function was inhibited non-competitively, which implies an allosteric interaction of 
these steroids with BCRP-mediated E1S transport. We have undertaken studies to measure 
transport of steroids in HEK293-BCRP membrane vesicles and BCRP-overexpressing MDCKII 
cells, but we did not found clear evidence for the involvement of BCRP in steroid secretion. 
This is in line with previously reported findings, although conflicting data regarding this 
matter has been published as well.
Efflux transporters present in the blood-testis barrier are targeted by 
endocrine disruptors 
Epidemiological trends show an increase in male subfertility in Western society. This is 
not only a consequence of lifestyle factors or side effects of therapeutic agents, but is also 
suggested to be a result of environmental exposures. Endocrine disrupting chemicals (EDCs) 
are considered to cause testicular toxicity primarily via interference with steroid hormone 
function. The testicular microenvironment is pivotal for mammalian steroidogenesis 
and spermatogenesis. The blood-testis barrier (BTB) physically divides the seminiferous 
epithelium into a basal and an apical compartment, whereas, efflux transporters actively 
protect the organ from internal exposure to harmful substances. In addition to BCRP, the 
most abundant efflux transporters in the BTB include P-glycoprotein (P-gp) and multidrug 
resistance protein 1 and 4 (MRP1 and -4). Chapter 3 describes the interaction of six selected 
EDCs with the transport activity of these human efflux transporters, using the aforementioned 
vesicle transport assay. Bis(2-ethylhexyl) phthalate (DEHP) and mono(2-ethylhexyl) phthalate 
(MEHP) did not inhibit activity of the transporters studied. Bisphenol A (BPA) solely inhibited 
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BCRP activity, whereas tetrabromobisphenol A (TBBPA), perfluorooctanoic acid (PFOA) and 
perfluorooctanesulfonic acid (PFOS) inhibited all transporters tested. An accumulation assay 
using transporter-overexpressing MDCKII cells revealed that BPA and PFOA, but not TBBPA, 
are transported by BCRP, and none of these compounds were transported by P-gp. 
In adult males, interstitial cells of Leydig are responsible for steroidogenesis. Local testicular 
steroidogenesis, i.e. production of androgens and estrogens, is essential in regulating 
spermatogenesis and involves multiple cytochrome P450 (CYP) and hydroxysteroid 
dehydrogenase (HSD) enzymes. In chapter 3, we further investigated the toxicological 
implications of transporter inhibition by the EDCs in murine Leydig (MA-10) cells. This P-gp, 
Mrp1- and Mrp4-expressing cell line exhibits a de novo steroid synthesis pathway. Bcrp 
expression was undetectable in these cells. Only BPA and TBBPA concentration-dependently 
increased testosterone secretion by MA-10 cells to 6- and 46-fold of control levels, 
respectively. Inhibition of the Mrp’s by MK-571 completely blocked testosterone secretion 
elicited by TBBPA, which could not be explained by coinciding changes in expression of 
steroidogenic genes. This led us to hypothesize that transporter-mediated (probably P-gp-
mediated) efflux of testosterone precursors, e.g. androstenedione or DHEA, from the cells is 
inhibited by TBBPA. As a result, more precursors are available for testosterone production, 
which is reflected by increased testosterone levels. The data described in this chapter 
suggest that EDCs might affect male fertility by acting on ABC transporters present in the BTB 
and influence steroidogenesis, and endorse the toxicological and clinical relevance of ABC 
transporters in EDC risk assessment related to testicular toxicity.
BPA is widely used in the production of plastics and its widespread inclusion in consumer 
products has greatly enhanced the potential for human exposure. Detectable levels of BPA 
have been found in the urine of 93% of the US population, as reported in 2008. Health 
concerns regarding human exposures to BPA stem from its estrogenic properties. Since we 
showed that BPA is a substrate for BCRP, we hypothesized that BCRP may be an important 
determinant in the distribution, disposition and, thereby, the toxicity of BPA. In chapter 4, we 
aimed at elucidating the role of Bcrp in the disposition and potential endocrine disrupting 
effects of BPA in mice. Both wild type as well as homozygous Bcrp-knockout (Bcrp-/-) mice 
were subcutaneously exposed, via a micro-osmotic pump, to [3H]-BPA with or without 
elacridar, an inhibitor of Bcrp and P-gp. BPA accumulation in the testes, adrenal and pituitary 
glands, adipose tissue, brain, liver and kidneys of Bcrp-/- mice was not different as compared 
to wild type mice. Also, co-administration of elacridar did not affect BPA accumulation. 
Taken together, our results indicate that the disposition of the human BCRP substrate BPA 
is not altered in Bcrp-deficient mice, suggesting minor importance of the transporter in BPA 
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handling in mice. Possibly, BPA is not a substrate for murine Bcrp. Although this interspecies 
difference needs further confirmation, it is important to realize that the disposition and 
mechanism of toxicity of BPA or other xenobiotics may be different in humans as compared 
to rodents.
The role of BCRP in metabolic processes
The endogenous BCRP substrates heme, kynurenic acid and uric acid can negatively 
influence physiological processes at high concentrations. Heme is the functional group of 
hemoproteins and crucial for many cellular processes, such as oxygen transport and storage, 
electron transfer, and signal transduction. However, excess of free heme can be detrimental 
to tissues by mediating oxidative and inflammatory injury. Kynurenic acid is a widely studied 
antagonist of the N-methyl-D-aspartate receptor and the α7-nicotinic acetylcholine receptor, 
and elevated levels are related to several neurological disorders. In addition, elevated serum 
uric acid levels (hyperuricemia) are related to a variety of pathologies, including gout, 
nephrolithiasis, cardiovascular disease and chronic kidney disease. 
In chapter 5, we postulated that overexpression of heme oxygenase-1 (HO-1) and BCRP 
would protect against heme-induced cytotoxicity. To this end, HEK293 cells were transduced 
using a baculovirus system to efficiently overexpress HO-1 and/or BCRP. Exposing cells to 
heme resulted in a dose-dependent increase in reactive oxygen species formation, DNA 
damage and cell death. Heme-induced cell death was significantly attenuated when cells 
overexpressed HO-1, BCRP, or both, thus, their protective mechanisms against free heme are 
pivotal for cell survival.
Little is known about the transport of metabolites from brain towards cerebrospinal fluid 
(CSF). We found Bcrp to be localized in the choroidal cell layer of the murine brain-CSF 
interface, as described in chapter 6. We investigated the potential role of BCRP in regulating 
CSF composition by comparing CSF of Bcrp-/- mice to that of wild types by 1H-NMR analysis. 
The concentration of glucose, glycine, creatine, alanine, and glutamine was altered in CSF of 
Bcrp-/- mice. Glucose was most discriminative and its concentration was significantly lower 
in CSF of Bcrp-/- mice compared to that of wild type mice. However, as neither glucose nor 
any of the other metabolites, differentially present in CSF, affected BCRP function, it seemed 
more likely that absence of the efflux transporter indirectly affected murine brain energy 
metabolism. Kynurenic acid has been associated with energy metabolism disturbances and 
several neurological disorders. Using the membrane vesicle assay we identified kynurenic acid 
as a new BCRP substrate and elevated levels were found in plasma and brain homogenates 
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of Bcrp-deficient mice. Moreover, kynurenic acid increased glucose uptake into malignant 
neuroblastoma (N2a) cells in a concentration-dependent fashion. From this, we conclude 
that increased intracellular kynurenic acid concentrations as a result of a decreased kynurenic 
acid-efflux, may result in increased glucose uptake and, therefore, CSF may contain less 
glucose. 
Kynurenic acid was also studied in oxonic acid-mediated hyperuricemic mice. Hyperuricemia 
is related to a variety of pathologies, however, the pathophysiological mechanisms underlying 
disease development are not yet fully elucidated. In chapter 7, we studied the effect of 
hyperuricemia on tryptophan metabolism and the potential role herein of two important uric 
acid efflux transporters MRP4 and BCRP. Uric acid inhibited both MRP4 as well as BCRP activity. 
Besides, the membrane vesicle assay revealed that, next to BCRP, MRP4 also transports 
kynurenic acid Increased plasma levels of kynurenic acid observed in Mrp4-/- and Bcrp-/- mice 
corroborated this finding. Hyperuricemia was associated with elevated plasma kynurenic acid 
levels in wild type mice, but they did not further increase in Bcrp- or Mrp4-knockout mice. 
Based on these results, we postulate that elevated uric acid levels hamper MRP4 and BCRP 
functioning, thereby promoting the retention of other potentially toxic substrates, including 
kynurenic acid, which could contribute to the development of chronic kidney disease.
Conclusions and future perspectives
In this thesis, the role of the efflux transporter BCRP in endocrine and metabolic processes 
was investigated. Our data show clear inhibition of BCRP by steroid hormones, however, 
BCRP is not involved in the transport of steroids. Based on our results, we postulate that 
decreased BCRP function, either by transport inhibition or because of an inactive single 
nucleotide polymorphism, could promote the retention of potentially toxic substrates, 
including endocrine disruptors, heme and kynurenic acid. This influences a myriad of cellular 
processes that are regulated by BCRP and disturbs cellular homeostasis. Therefore, this 
protein could be an interesting target for potential clinical applications, such as its induction 
to prevent accumulation of BCRP substrates. However, more research is needed to determine 
the feasibility of influencing BCRP in patients. 
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Introductie
ATP-binding cassette (ABC) transporters zijn membraangebonden eiwitten die de energie 
die vrijkomt na hydrolyse van ATP gebruiken om verschillende moleculen tegen een 
concentratiegradiënt over de celmembraan te transporteren. Bijna alle ABC-transporters 
zijn effluxtransporters, waarvan vele een belangrijke rol spelen bij de verdediging van 
weefsels tegen schadelijke moleculen, door deze te verwijderen. Het in dit proefschrift 
beschreven onderzoek was vooral gericht op een van deze ABC-transporters, namelijk het 
borstkankerresistentie-eiwit (breast cancer resistance protein: BCRP) dat wordt gecodeerd 
door het ABCG2-gen. Het gen werd in 1998 ontdekt in een sublijn van borstkankercellen die 
resistent bleek voor het cytostaticum mitoxantrone. Sindsdien heeft men ontdekt dat BCRP 
tot expressie wordt gebracht in vele organen en weefsels in het lichaam, waaronder epitheel 
van de darm, lever en nieren, alsmede weefsels met een barrièrefunctie zoals de bloed-
hersenbarrière, bloed-placentabarrière en plexus choroideus, als onderdeel van de bloed-
hersenvochtbarrière. BCRP wordt gezien als een xenobioticatransporter die een belangrijke 
rol speelt bij resistentie tegen verschillende geneesmiddelen. Talloze BCRP-substraten zijn 
reeds beschreven, waaronder chemotherapeutische middelen, tyrosinekinaseremmers, 
antivirale middelen, HMG-CoA-reductaseremmers en flavonoïden. Onderzoek naar BCRP 
heeft zich tot nu toe voornamelijk gericht op haar beperkende rol in de opname van 
geneesmiddelen in bepaalde organen en de beschermende functie tegen schadelijke exogene 
stoffen. Er is in toenemende mate bewijs gevonden dat BCRP ook endogene moleculen, 
zoals urinezuur, foliumzuur, porfyrinen, riboflavine (vitamine B2) en geconjugeerde 
steroïdhormonen transporteert. Daarnaast worden steroïdhormonen in verband gebracht 
met BCRP-functie, -expressie en -afbraak. Echter, de moleculaire onderbouwing van deze 
BCRP-steroïdhormooninteracties is nog niet opgehelderd. Het doel van dit proefschrift was 
om de rol van BCRP in endocriene en metabole processen te bestuderen.
De rol van BCRP in endocriene organen
De plasmamembraanexpressie van BCRP is hoger bij mannen dan bij vrouwen. Er wordt 
gedacht dat dit komt door de remmende werking van estradiol en het stimulerende effect van 
testosteron. Bovendien is betrokkenheid van BCRP in het transport van androgenen en estradiol 
gesuggereerd, wat aangeeft dat de effluxpomp een rol zou kunnen spelen in het hormonale 
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systeem. De aanwezigheid van BCRP in de testis en de bijnier is reeds eerder beschreven, 
maar lokalisatie in andere organen die betrokken zijn bij de steroïdhormoonproductie of 
-werking is nog niet bekend. In hoofdstuk 2 onderzochten we de aanwezigheid en lokalisatie 
van Bcrp in endocriene organen van controlemuizen. Uit gen-analyse bleek dat Bcrp tot 
expressie komt in de hypofyse, bijnieren, alvleesklier, eierstokken, testes en vetweefsel. 
Daarnaast vonden we dat Bcrp-expressie in deze organen bij mannelijke muizen hoger was 
dan bij vrouwelijke muizen. De lokalisatie van Bcrp in de muizenorganen werd met behulp 
van immunohistochemie beoordeeld. Bcrp werd voornamelijk gevonden in de capillairen van 
zowel endocriene als niet-endocriene organen. Hoewel endocriene organen een belangrijke 
secretiefunctie hebben, hebben we in de meeste endocriene cellen geen Bcrp-expressie 
gevonden, wat aangeeft dat Bcrp niet betrokken is bij de uitscheiding van steroïdhormonen. 
De enige cellen die steroïdhormonen uitscheiden en Bcrp tot expressie brengen werden 
gevonden in de bijnier, namelijk cellen gelegen in de zona glomerulosa en zona reticularis 
die verantwoordelijk zijn voor de productie en uitscheiding van mineralocorticosteroïden en 
androgenen. Bcrp werd ook gelokaliseerd in de plasmamembraan van adipocyten (vetcellen), 
waar onder andere de omzetting van estrogenen en glucocorticoïden plaatsvindt.
De interactie tussen BCRP en twaalf steroïdhormonen werd bestudeerd met behulp van 
membraanblaasjes (vesikels), gemaakt van HEK293-cellen die BCRP tot overexpressie brengen. 
Estradiol, testosteron, progesteron en androsteendion remden de BCRP-gemedieerde 
opname van radioactief gelabeld [3H]-estronsulfaat het sterkst. Verder onderzoek wees uit 
dat er sprake was van non-competitieve remming, dus een allostere interactie tussen BCRP en 
de steroïdhormonen. We hebben het transport van steroïdhormonen in membraanvesikels 
en BCRP-overexpresserende MDCKII-cellen onderzocht maar hebben geen aanwijzingen 
gevonden voor een rol van BCRP bij de uitscheiding van steroïdhormonen. Deze conclusie 
wordt ondersteund door verschillende publicaties, hoewel eveneens tegenstrijdige resultaten 
beschreven staan in de literatuur. 
Effluxtransporters in de bloed-testisbarrière als doelwit voor 
hormoonverstorende stoffen
Epidemiologische trends laten een toename van subfertiliteit in de westerse samenleving zien. 
Dit is niet alleen het gevolg van leefstijlfactoren of een neveneffect van geneesmiddelgebruik, 
maar wordt waarschijnlijk ook veroorzaakt door een toenemende blootstelling aan 
milieuvervuilende stoffen. Er wordt verondersteld dat sommige van deze stoffen een 
hormoonverstorende werking hebben die bij mannen kan resulteren in verminderde 
steroïdogenese (de productie van androgenen en estrogenen) en/of spermatogenese (de 
productie van spermacellen) in de testis. 
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De bloed-testisbarrière (BTB) verdeelt de testis in een basaal compartiment en een apicaal 
compartiment, waarin de spermatogenese plaatsvindt. Transporters in de BTB beschermen 
het apicale compartiment tegen blootstelling aan schadelijke stoffen. De meest voorkomende 
transporters in de BTB zijn, naast BCRP, P-glycoproteïne (P-gp) en multidrugresistentie-eiwit1 
en -4 (MRP1 en -4). Hoofdstuk 3 beschrijft membraanvesikelexperimenten waarin de interactie 
van zes mogelijk hormoonverstorende stoffen met de bovengenoemde transporters is 
onderzocht. Bis(2-ethylhexyl)ftalaat (DEHP) en mono(2-ethylhexyl)ftalaat (MEHP) remden de 
activiteit van de transporters niet. Bisfenol A (BPA) remde uitsluitend BCRP-activiteit, terwijl 
tetrabroombisfenol A (TBBPA), perfluoroctaanzuur (PFOA) en perfluoroctaansulfonaat (PFOS) 
de activiteit van alle vier transporters remden. Vervolgens deden we een accumulatiestudie 
met BCRP- en P-gp-overexpresserende MDCKII-cellen waaruit bleek dat BPA en PFOA, maar 
niet TBBPA, worden getransporteerd door BCRP en dat geen van deze stoffen door P-gp werd 
getransporteerd. 
De interstitiële cellen van Leydig zijn bij volwassen mannen verantwoordelijk voor de 
steroïdogenese en zijn daarom essentieel voor spermatogenese. Verschillende cytochroom 
P450 (CYP)-enzymen en hydroxysteroïddehydrogenase (HSD)-enzymen zijn betrokken bij de 
lokale steroïdogenese. In hoofdstuk 3 hebben we de consequenties van transportremming 
door de hormoonverstorende stoffen verder onderzocht in de muizen-Leydigcellijn, MA-
10. In deze cellen komen P-gp, Mrp1 en Mrp4, maar niet Bcrp, tot expressie en de cellijn 
vertoont de novo-steroïdhormoonsynthese. De hoeveelheid testosteron die uitgescheiden 
werd door de MA-10-cellen werd concentratieafhankelijk verhoogd door BPA en TBBPA 
(respectievelijk 6- en 46-keer hoger dan controlewaarden). De TBBPA-gemedieerde 
verhoging van testosteronuitscheiding kon worden voorkomen door de Mrp’s te remmen. Uit 
genexpressieonderzoek (qPCR-analyse) bleek dat dit effect niet kan worden verklaard door 
een verandering in de expressie van enzymen die verantwoordelijk zijn voor de synthese van 
steroïdhormonen. Dit leidde tot de hypothese dat transportergemedieerde (waarschijnlijk 
P-gp-gemedieerde) uitscheiding van testosteronprecursors, bijvoorbeeld androsteendion 
of DHEA, uit de cellen wordt geremd door TBBPA. Daardoor zijn er intracellulair meer 
testosteronprecursors beschikbaar voor omzetting naar testosteron, hetgeen wordt 
weerspiegeld door een verhoogde testosteronuitscheiding. De resultaten die in dit hoofdstuk 
zijn beschreven suggereren dat hormoonverstorende stoffen de mannelijke fertiliteit kunnen 
beïnvloeden door aan te grijpen op de ABC-transporters in de BTB. Dit onderstreept de 
toxicologische en klinische relevantie van ABC-transporters in de risicobeoordeling van 
testistoxiciteit door hormoonverstorende stoffen.
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BPA wordt veel gebruikt in de productie van plastics zoals voedselverpakkingen en 
drinkflessen. Hierdoor is de blootstelling van de mens aan BPA vrij hoog. In een Amerikaans 
onderzoek uit 2008 werden meetbare hoeveelheden van BPA gevonden in de urine van 
93% van de proefpersonen. Bezorgdheid over de schadelijke effecten van BPA voor de 
volksgezondheid komt voort uit de kennis dat BPA estrogene eigenschappen bezit. Omdat 
we hadden aangetoond dat BPA een substraat is voor BCRP, veronderstelden we dat BCRP 
een belangrijke speler is in de blootstelling en dus ook de toxiciteit van BPA in het lichaam. 
In hoofdstuk 4 vergeleken we controlemuizen met homozygote Bcrp-knockout (Bcrp-/- -)-
muizen, die subcutaan via een micro-osmotische pomp werden blootgesteld aan [3H]-BPA 
met of zonder elacridar, een potente remmer van P-gp en Bcrp. BPA-accumulatie in de 
testes, bijnieren, hypofyse, vetweefsel, hersenen, lever en nieren van Bcrp-/--muizen was 
niet verschillend in vergelijking met controlemuizen. Ook toediening van elacridar had geen 
invloed op de BPA-accumulatie. Samenvattend tonen onze resultaten aan dat de verdeling 
van het humane BCRP-substraat BPA niet is veranderd in Bcrp-/--muizen. Dit suggereert dat 
Bcrp geen of een geringe rol speelt bij BPA-blootstelling van muizen. Mogelijk is BPA geen 
substraat voor het muizen-Bcrp. Hoewel dit interspeciesverschil verder onderzocht moet 
worden, is het belangrijk om te realiseren dat de verdeling en het mechanisme van toxiciteit 
van bepaalde stoffen anders zijn in dieren dan in mensen. 
De rol van BCRP in metabole processen
De endogene BCRP-substraten heem, kynureninezuur en urinezuur kunnen bij hoge 
concentraties fysiologische processen verstoren. Heem is de functionele groep van 
hemoproteïnen en is van cruciaal belang voor vele cellulaire processen, zoals zuurstoftransport 
en -opslag, elektronenoverdracht en signaaltransductie. Echter, grote hoeveelheden vrij 
heem kunnen schadelijk zijn via inductie van oxidatieve stress en ontstekingsmediatoren. 
Kynureninezuur is een antagonist van de N-methyl-D-aspartaatreceptor en α7-
nicotineacetylcholinereceptor en verhoogde kynureninezuurwaarden zijn gerelateerd aan 
verschillende neurologische aandoeningen. Daarnaast zijn verhoogde urinezuurspiegels in het 
bloed (hyperuricemie) gecorreleerd met het optreden van jicht, nierstenen, cardiovasculaire 
ziekten en chronische nierziekten.
In hoofdstuk 5 stelden we dat een overexpressie van heemoxygenase-1 (HO-1: het enzym dat 
heem afbreekt) en/of BCRP bescherming zou bieden tegen heemgemedieerde cytotoxiciteit. 
Om deze hypothese te testen hebben we HEK293-cellen met een overexpressie van één 
of beide eiwitten blootgesteld aan heem. Dit resulteerde in een concentratieafhankelijke 
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verhoging van de vorming van reactieve zuurstofdeeltjes en de daarmee gepaard gaande 
DNA-schade en celdood. Heemgemedieerde celdood was significant verminderd in cellen 
met overexpressie van één of beide eiwitten. Hiermee werd aangetoond dat beide eiwitten 
bescherming bieden tegen de schadelijke effecten van vrij heem.
Er is weinig bekend over het transport van metabolieten vanuit de hersenen richting het 
hersenvocht (cerebrospinal fluid: CSF). We ontdekten dat Bcrp gelokaliseerd is in de cellaag 
die zich bevindt in de hersen-CSF-interface van het brein van de muis, zoals beschreven in 
hoofdstuk 6. Vervolgens onderzochten we de mogelijke rol van BCRP in de regulatie van de 
CSF-samenstelling. Hiervoor vergeleken we de samenstelling van het CSF van Bcrp-/--muizen 
met die van controlemuizen met behulp van 1H-NMR-analyse. De concentraties van glucose, 
glycine, creatine, alanine en glutamine waren veranderd in het CSF van Bcrp-/--muizen. Het 
verschil in glucosewaarden was het grootst waarbij de glucoseconcentratie in het CSF van 
Bcrp-/--muizen was verlaagd ten opzichte van de controlemuizen. Echter, omdat we vonden 
dat glucose noch een van de andere metabolieten de activiteit van BCRP beïnvloedde, is het 
waarschijnlijk dat de afwezigheid van Bcrp een indirect effect op het energiemetabolisme van 
muizenhersenen had. Kynureninezuur was al eerder in verband gebracht met verstoringen 
in het energiemetabolisme en diverse neurologische aandoeningen. Door middel van de 
eerdergenoemde membraanvesikelopnamestudie konden we kynureninezuur identificeren 
als een nieuw BCRP-substraat en verhoogde waarden van deze stof werden gevonden in 
plasma en hersenhomogenaten van Bcrp-/--muizen. Bovendien zorgde blootstelling van 
maligne neuroblastoma (N2a)-cellen aan kynureninezuur voor een concentratieafhankelijke 
verhoging van de glucoseopname door de cellen. We concluderen hieruit dat de verhoogde 
intracellulaire kynureninezuurconcentraties, door verminderde kynureninezuuruitscheiding, 
een verhoogde glucoseopname in de hersenen tot gevolg kunnen hebben, waardoor het CSF 
minder glucose bevat. 
Kynureninezuur werd ook bestudeerd in hyperuricemische muizen. Hyperuricemie wordt 
gerelateerd aan een verscheidenheid van ziekten, echter, de pathofysiologische mechanismen 
die ten grondslag liggen aan de ontwikkeling van die ziekten zijn nog niet volledig opgehelderd. 
In hoofdstuk 7 onderzochten we het effect van hyperuricemie op tryptofaanmetabolisme en 
de mogelijke rol van twee belangrijke urinezuurtransporters MRP4 en BCRP hierbij. Urinezuur 
remt zowel de activiteit van MRP4 als van BCRP, zoals bleek uit membraanvesikelexperimenten. 
Daarnaast werd gevonden dat naast BCRP ook MRP4 kynureninezuur transporteert. Deze 
bevinding werd bevestigd door verhoogde plasmaspiegels van kynureninezuur in Mrp4-/-- 
en Bcrp-/--muizen in vergelijking met controle dieren. Hyperuricemie ging gepaard met 
verhoogde plasmakynureninezuurconcentraties in controlemuizen, maar deze stegen niet 
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verder in Mrp4-/-- of Bcrp-/--muizen. Op basis van deze resultaten stellen wij dat verhoogde 
urinezuurwaarden kunnen leiden tot een verminderde functie van MRP4 en BCRP, waardoor 
potentieel toxische substraten, zoals kynureninezuur, kunnen ophopen en zo bijdragen aan 
de ontwikkeling van ziekten, waaronder chronische nierziekte.
Conclusies en toekomstperspectieven
In dit proefschrift werd de rol van de effluxtransporter BCRP in endocriene en metabole 
processen onderzocht. Onze resultaten laten een duidelijke remming zien van BCRP functie 
door steroïdhormonen, echter, BCRP is niet betrokken bij het transport van deze hormonen. Op 
basis van onze resultaten stellen wij dat een verminderde BCRP-functie, hetzij door remming 
hetzij door de aanwezigheid van een inactiverend BCRP-polymorfisme, kan resulteren in 
ophoping van potentieel toxische BCRP-substraten, zoals hormoonverstorende stoffen, heem 
en kynureninezuur. Dit kan een verstorende invloed hebben op een groot aantal cellulaire 
processen die gereguleerd worden door BCRP. Daarom zou het transporteiwit een interessant 
aangrijpingspunt kunnen zijn in de ontwikkeling van nieuwe therapieën, zoals BCRP-inductie 
om ophoping van BCRP-substraten te voorkomen. Echter, er is meer onderzoek nodig om de 
haalbaarheid van het beïnvloeden van de BCRP-functie bij patiënten te bestuderen.
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List of abbreviations
1H-NMR    1H-nuclear magnetic resonance
5αRed1   5α-reductase type 1
8-Br-cAMP   8-Bromoadenosine 3’,5’-cyclic monophosphate
AB   arachnoid barrier
ABC transporter  ATP binding cassette transporter
ABC   avidin-biotin complex
ABCB1/P-gp  P-glycoprotein
ABCC/MRP  multidrug resistance-associated protein family
ABCC7/CFTR  cystic fibrosis transmembrane conductance regulator
ABCG2/BCRP  breast cancer resistance protein
AhR   aryl hydrocarbon receptor
AMP    adenosine 5’-monophosphate
ANOVA   analysis of variance 
APES   3-aminopropyltriethoxysilane
ATP    adenosine 5’-triphosphate
AUC   area under the curve
BBB   blood-brain barrier 
BPA   bisphenol A 
BPA-G   BPA-glucuronide
BSA    bovine serum albumine
BTB   blood-testis barrier 
Ci    Curie
CKD    chronic kidney disease
CMV   cross model validation
COW   correlation optimizing warping
CP   choroid plexus
CSF   cerebrospinal fluid
Ct value   cycle threshold value
CYP    cytochrome P450 enzyme
Cys   cysteine
DEHP   bis(2-ethylhexyl) phthalate 
DHEAS    dehydroepiandrosterone sulfate
DMEM    Dulbecco Eagle’s modified medium
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DMSO   dimethylsulfoxide
DNA   deoxyribonucleic acid
E1S    estrone sulfate 
E217βG    estradiol glucuronide
EDC   endocrine disrupting chemical
EDTA   ethylenediaminetetraacetic acid
EDX     energy-dispersive X-ray  
ERα    estrogen receptor-α
eYFP    enhanced yellow fluorescent protein
FCS    fetal calf serum
FePP   heme
FSH   follicle-stimulating hormone
FTC   fumitremorgin C (BCRP inhibitor)
FVB   Friend leukemia virus B mouse strain
Gapdh     glyceraldehyde-3-phosphate dehydrogenase  
GF120918   elacridar (mixed P-gp/BCRP inhibitor)
GLUT1   glucose transporter-1
GnRH    gonadotropin-releasing hormone 
H2DCFDA  2’,7’-dichlorodihydrofluorescein diacetate
Hb   hemoglobin
HBSS   Hank’s balanced salt solution
HE stain    hematoxylin and eosin stain  
HEK293   human embryonic kidney cell line 293
HO-1   heme oxygenase-1
HPG axis   hypothalamic–pituitary–gonadal axis
HPLC    high pressure liquid chromatography
HSD   hydroxysteroid dehydrogenase
IC50     half maximal inhibitory concentration  
IDO     indoleamine 2 3-dioxygenase  
ISF   brain interstitial fluid
KATII    kynurenine aminotransferase-II
Ki    equilibrium constant for inhibitory affinity
Kim-1     kidney injury molecule-1  
Kiss1    kisspeptin
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Km Michaelis constant: the substrate concentration at which an 
enzyme-catalyzed reaction proceeds at 50% of its maximum 
velocity
KynA    kynurenic acid
LC    Leydig cell 
LC-MS/MS   HPLC combined with tandem mass spectrometry
LH   luteinizing hormone
LHr   LH receptor 
MA-10   murine Leydig cell line
MDCKII    Madine Darby canine kidney cell line II
MEHP   mono(2-ethylhexyl) phthalate 
MTT   3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
MTX     methotrexate  
N2a   malignant neuroblastoma cell line
NAC   N-acetylcysteine
NBD   nucleotide binding domain
NCBI   National Center for Biotechnology Information
Ngal     neutrophil gelatinase-associated lipocalin  
NMDAR    N-methyl-d-aspartate-receptor
NMQ   N-methylquinidine
OAT     organic anion transporter  
PBS   phosphate buffered saline
PCA   principal component analysis
PCs   principal components
PFA   paraformaldehyde
PFOA    perfluorooctanoic acid 
PFOS    perfluorooctanesulfonic acid 
PR   progesterone receptor
qPCR   quantitative polymerase chain reaction
QSAR   quantitative structure-activity-relationship
RIA   radioimmunoassay
ROS   reactive oxygen species
SCO   subcommissural organ
SDS    sodium dodecyl sulfate
SDS-PAGE  SDS-polyacrylamide gel electrophoresis
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SEM   standard error of the mean
SLC     solute carrier family  
SnMP   tin mesoporphyrin
SNP   single nucleotide polymorphism
StAR    steroidogenic acute regulatory protein
TBBPA    tetrabromobisphenol A
TMD   transmembrane domain
TRITC   tetramethyl rhodamine iso-thiocyanate
TS buffer   Tris-sucrose buffer
TSP-d4    sodium-3-(trimethylsilyl)propionate-2,2,3,3-d4
UPLC    ultra performance liquid chromatography
URAT1     urate transporter 1
UV   ultraviolet 
Vmax    maximum velocity of an enzymatic reaction 
α7nAchR  α7-nicotinic-acetylcholine-receptor 
Note: of rodent genes and proteins, only the first character is capitalized 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
197
Curriculum vitae
9
Curriculum vitae
Anita Dankers volgde, na de middelbare school, de HBO-opleiding Medisch Beeldvormende 
en Radiotherapeutische Technieken (MBRT) aan de Fontys Hogeschool te Eindhoven 
waaraan ze in 2005 afstudeerde. Aansluitend begon ze aan de opleiding Biomedische 
Wetenschappen aan de Radboud Universiteit te Nijmegen. Tijdens de masterfase koos ze 
voor twee hoofdvakken: pathobiologie en toxicologie. Voor het hoofdvak pathobiologie liep 
ze stage bij de afdeling Mond-, Kaak- en Aangezichtschirurgie en de afdeling Biomaterialen 
(Radboudumc, Nijmegen) onder begeleiding van drs. R.E.C.M. Mooren en dr. X.F. Walboomers. 
Daar deed ze onderzoek naar de effecten van groeifactoren in platelet-rich plasma op 
botgenezing. Haar tweede masterstage (toxicologie) richtte zich op het onderzoek naar de 
toepassing van flowcytometrische analyse in de in vitro micronucleus test bij de afdeling 
Genetic & Exploratory Toxicology van Janssen Pharmaceutica (onderdeel van Johnson & 
Johnson, Beerse, België) onder begeleiding van dr. F. Van Goethem. Na het behalen van het 
doctoraaldiploma in 2008 is Anita begonnen met haar promotieonderzoek op de afdeling 
Farmacologie en Toxicologie van het Radboudumc bij het Radboud Institute for Molecular 
Life Sciences (RIMLS), in nauwe samenwerking met de afdeling Laboratoriumgeneeskunde 
(Radboudumc), onder begeleiding van dr. R. Masereeuw, prof. dr. C.G.J. Sweep en prof. 
dr. F.G.M. Russel, waarvan de resultaten in dit proefschrift staan beschreven. Ze voltooide 
tevens de postdoctorale opleiding tot toxicoloog en in 2011 organiseerde ze het congres 
voor AIO’s van de Nederlandse Vereniging voor Toxicologie. Tijdens haar promotieonderzoek 
heeft ze verschillende bachelor- en masterstudenten begeleid en haar werk op diverse (inter)
nationale congressen gepresenteerd. Ze won in 2011 de prijs voor beste posterpresentatie 
bij de jaarlijkse bijeenkomst van de Nederlandse Vereniging voor Toxicologie en in 2012 
won ze de Young Scientist Award voor beste presentatie tijdens de Invitrom bijeenkomst in 
Antwerpen. Sinds april 2013 is ze werkzaam als onderzoekster bij de afdeling Drug Metabolism 
& Pharmacokinetics, Janssen Pharmaceutica - Johnson & Johnson, Beerse, België. 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
198
Chapter 9
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
199
List of publications
9
List of publications
Dankers AC, Roelofs MJ, Piersma AH, Sweep FC, Russel FG, van den BM, van Duursen 
MB, Masereeuw R (2013) Endocrine disruptors differentially target ATP-binding cassette 
transporters in the blood-testis barrier and affect Leydig cell testosterone secretion in vitro. 
Toxicol. Sci. 136(2):382-391 
Dankers AC, Mutsaers HA, Dijkman HB, van den Heuvel LP, Hoenderop JG, Sweep FC, Russel 
FG, Masereeuw R (2013) Hyperuricemia influences tryptophan metabolism via inhibition of 
multidrug resistance protein 4 (MRP4) and breast cancer resistance protein (BCRP). Biochim. 
Biophys. Acta 1832(10):1715-1722 
Wagener FA, Dankers AC, van SF, Scharstuhl A, van den Heuvel JJ, Koenderink JB, Pennings 
SW, Russel FG et al. (2013) Heme Oxygenase-1 and breast cancer resistance protein protect 
against heme-induced toxicity. Curr. Pharm. Des 19(15):2698-2707 
Dankers AC, Sweep FC, Pertijs JC, Verweij V, van den Heuvel JJ, Koenderink JB, Russel FG, 
Masereeuw R (2012) Localization of breast cancer resistance protein (Bcrp) in endocrine 
organs and inhibition of its transport activity by steroid hormones. Cell Tissue Res. 349(2):551-
563 
Mutsaers HA, van den Heuvel LP, Ringens LH, Dankers AC, Russel FG, Wetzels JF, Hoenderop JG, 
Masereeuw R (2011) Uremic toxins inhibit transport by breast cancer resistance protein and 
multidrug resistance protein 4 at clinically relevant concentrations. PLoS. One. 6(4):e18438 
Mooren RE, Dankers AC, Merkx MA, Bronkhorst EM, Jansen JA, Stoelinga PJ (2010) The 
effect of platelet-rich plasma on early and late bone healing using a mixture of particulate 
autogenous cancellous bone and Bio-Oss: an experimental study in goats. Int. J. Oral 
Maxillofac. Surg. 39(4):371-378 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
200
Chapter 9
